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General introduction
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Prostate cancer
The prostate is a gland located between the male bladder and the pelvic floor, surround-
ing the urethra (figure 1). The Flemish anatomist Andreas Vesalius was the first to illustrate 
the prostate in 1538. The prostate secretes fluid that constitutes 30% of the semen volume, 
along with sperm cells from the testicles and fluid from the seminal vesicles located above 
the prostate gland. The presence of prostate cancer means that a single or multiple tumors 
have developed in the prostate gland due to abnormal growth and division of prostate 
epithelial cells, caused by the accumulation of mutations in their DNA (figure 1). The 
malignant cancer cells have the potential to spread to other parts of the body, usually the 
lymph nodes and bones at first, where they can cause metastatic tumors and eventually 
lead to death. Prostate cancer is the second most common cancer in men worldwide and, 
in general, affects men aged 50 years or older. In 2012 an estimated 1.1 million men were 
diagnosed with prostate cancer worldwide and 307.000 men died of their disease (1). In 
2015 a total of 10.469 men were diagnosed with prostate cancer in the Netherlands and 
2641 died of their disease (2). 
Figure 1: Male genitourinary system with cancer located in the prostate. Adapted from: http://en.isramedic.
co.il/index.php/oncologia/Prostate-cancer-treatment-in-Israel
Prostate cancer detection
Prostate-specific antigen (PSA) is a protein that is produced and excreted in the blood-
stream almost exclusively by prostate epithelial cells. The function of PSA is to liquefy 
the semen in order to improve the motility of sperm cells. In prostate cancer, the serum 
PSA level is often elevated due to increased PSA production by the tumor cells as well as 
increased leakage of PSA in the bloodstream. The elevation of the serum PSA level usually 
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precedes the occurrence of the first symptoms of the disease, which are often caused by 
metastases. Therefore, PSA can be used as a marker for early prostate cancer detection. 
However, PSA lacks specificity, meaning that it can also be elevated in a number of benign 
conditions such as benign prostatic hyperplasia (benign enlargement of the prostate) and 
prostatitis (inflammation of the prostate). 
The digital rectal examination plays an important role in the detection of prostate can-
cer next to PSA. The location of the prostate just anterior of the rectum allows for palpation 
with the index finger through the anus. Digital rectal examination can detect nodules in 
the posterior and lateral parts of the prostate, suggestive of the presence of a tumor. 
In case of a clinical suspicion of prostate cancer, based on an elevated PSA-level and/
or an abnormal digital rectal examination, a prostate biopsy is performed. A transrectal 
ultrasound, which can also detect lesions suspicious for cancer, is used to guide the 
prostate biopsy. A total of 8 – 12 biopsy cores are taken divided over the prostate gland 
in a systematic fashion. These biopsy cores are then examined under the microscope by 
a pathologist for the presence of prostate cancer cells. Although most men experience 
no or only minor complaints after a prostate biopsy such as pain, temporarily hematuria 
(blood in the urine) and hematospermia (blood in the semen), approximately 3% of men 
experience a prostate infection despite antibiotic prophylaxis (3).
Prostate cancer screening
The majority of men diagnosed with prostate cancer had (locally) advanced prostate 
cancer before the discovery of PSA as a biomarker and half of these men died of the 
disease (4, 5). After PSA was approved as a biomarker in 1986, it was widely adopted in 
opportunistic screening (outside of an organized screening program) in the early 1990s 
(6, 7). This led to a dramatic increase of the prostate cancer incidence (number of new 
prostate cancer diagnoses per 100.000 men per year) and, together with improvements in 
treatment modalities, led to a decrease of the prostate cancer-related mortality (number 
of prostate cancer deaths per 100.000 men per year) in the United States and Europe (8, 
9). The increase in prostate cancer incidence and decrease in mortality in the Netherlands 
since 1990 are shown in figure 2a and figure 2b, respectively. 
Next to widespread opportunistic screening, the rise of PSA as a biomarker led to the 
initiation of several prostate cancer screening studies investigating the effect of screening 
on mortality (10). The most substantial evidence on the effect of screening on prostate 
cancer mortality comes from the European Randomized study of Screening for Prostate 
Cancer (ERSPC).  This study, initiated in the early 1990’s, randomized close to 200.000 men 
aged 50 – 74 years in 8 European countries (the Netherlands, Belgium, Finland, France, 
Italy, Spain, Sweden and Switzerland) into a screening or control arm (11). Men in the 
screening arm received PSA testing with an interval of 2 – 4 years, followed by transrectal 
ultrasound-guided systematic biopsy in case of an elevated PSA. Men in the control arm 
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received standard of care. At a median follow-up of 13 years, the ERSPC study showed a 
21% relative reduction of the prostate cancer mortality and a 30% relative reduction of 
metastatic disease in the screening arm (12). For the individual, the through screening 
achieved mortality reduction can  be up to 50% when comparing a man not screened at 
all with a man fully compliant to the screening protocol (13).
Figure 2a: Prostate cancer incidence over time in the Netherlands standardized for the age distribution in 
Europe (European standardized rate). Adapted from: http://www.cijfersoverkanker.nl
Figure 2b: Prostate cancer mortality over time in the Netherlands standardized for the age distribution in 
Europe (European standardized rate). Adapted from: http://www.cijfersoverkanker.nl
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Unfortunately, there is also a significant downside of PSA-based prostate cancer screen-
ing. Many men receive unnecessary PSA testing and more importantly unnecessary biop-
sies, without experiencing benefit from screening. On top of that, the cancers detected 
by screening are often clinically insignificant, meaning that they have a low a potential of 
causing symptoms during a man’s lifetime. The detection of cancers that would have never 
been diagnosed had it not been for screening is referred to as overdiagnosis. The frac-
tion of screen-detected prostate cancers that are overdiagnosed is estimated to be up to 
50% (14, 15). Unfortunately, these overdiagnosed cancers are often treated by surgery or 
radiotherapy. These invasive treatments have potential side effects, such as incontinence 
and impotence, which can have a significant impact on the quality of life (16, 17).
Up to now, the harms of population-based prostate cancer screening are considered 
to outweigh the benefits. Therefore, an organized screening program on a national level, 
which has already been implemented for breast cancer, cervical cancer and colon cancer in 
the Netherlands, has not been initiated for prostate cancer. Nevertheless, as the individual 
can significantly benefit from screening, the (inter)national guidelines recommend the 
process of shared decision making in which the patient who is asking to be screened does 
have the right to be screened after being well informed by his doctor on the potential 
harms and benefits (10). Since the beginning of opportunistic PSA-based prostate cancer 
screening in the early 1990’s, we have been making progress on how to deal with the 
harms of screening. While risk-based patient selection for prostate biopsy using prediction 
models and/or magnetic resonance imaging is able to partly remediate the problem of 
unnecessary biopsies and overdiagnosis, active surveillance can counteract the problem 
of overtreatment.   
Grading of prostate cancer
Prostate cancer is graded by the pathologist after microscopic examination of the biopsy 
specimens using the Gleason score (18). This prognostic grading system gives a grade of 
cellular differentiation ranging from 3 to 5, where grade 3 is well differentiated and grade 
5 is poorly differentiated. The Gleason score is the sum of the primary (most common) 
Gleason grade pattern and the secondary (next most common) Gleason grade pattern in 
a biopsy core. Gleason score 3+3=6 prostate cancer is often classified as clinically insignifi-
cant disease, as Gleason grade 3 prostate cancer in the absence of a higher-grade tumor 
component (Gleason grade 4 or 5) virtually does not metastasize (19-21). Unfortunately, 
the absence of a higher-grade tumor component can only truly be ascertained after surgi-
cal removal of the prostate. Conversely, Gleason score ≥3+4=7 prostate cancer is often 
classified as significant disease due to its potential to cause metastases and prostate can-
cer death. Recently, it was discovered that certain growth patterns (e.g. cribriform growth) 
of grade 4 prostate cancer reflect more aggressive disease than others (22).
15
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Prediction models
Prediction models are statistical formulas that on the basis of many that already have 
undergone the intervention can predict the outcome of one man facing the decision 
to undergo the intervention. Several models have been developed for the prediction of 
prostate cancer in a transrectal ultrasound-guided systematic biopsy, the web-based ER-
SPC risk calculators being the best performing models (23, 24). The ERSPC risk calculators 
are constructed based on data of 3624 men attending in the first screening round and 
2896 men attending in the second screening round of the Rotterdam section of the ERSPC 
study (25). These risk calculators combine data on the PSA level, digital rectal examina-
tion, transrectal ultrasound, prostate volume and previous biopsy status of all these men 
to predict the risk of finding any prostate cancer and aggressive prostate cancer in the 
biopsy of a specific patient (figure 3). Patient-selection for prostate biopsy based on the 
ERSPC risk calculators has been shown to reduce the number of unnecessary biopsies by 
approximately 33% and to result in a more favorable significant-to-insignificant prostate 
cancer ratio in those men who receive a biopsy (25-30). 
Figure 3: Prostate cancer risk of an individual patient calculated with an ERSPC risk calculator. Adapted 
from: www.prostatecancer-riskcalculator.com
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Multiparametric MRI
Prostate cancer is often missed by random transrectal ultrasound-guided systematic bi-
opsy. Nowadays, multiparametric magnetic resonance imaging (MRI) is increasingly used 
in the early detection of prostate cancer, especially in case of a sustained suspicion of 
prostate cancer after a previous biopsy (31). The multiparametric MRI-scan combines the 
standard anatomical T2-weighted images with the functional diffusion weighted images 
and dynamic contrast enhanced images (32, 33). Diffusion weighted imaging reflects the 
diffusion of water molecules and thus the cell density in specific areas of the prostate. 
Naturally, a higher cell density is correlated with a higher likelihood of a tumor being pres-
ent in a specific area. In dynamic contrast enhanced imaging the patterns of inflow and 
washout of contrast in specific prostate areas are assessed. The multiparametric MRI has 
a high sensitivity and negative predictive value for aggressive prostate cancer, meaning 
that most aggressive prostate cancers are detected by MRI and that aggressive cancer is 
unlikely to be present if the MRI does not show a cancer-suspicious area (34-36). Individual 
lesions suspicious for cancer on MRI are graded according to the standardized Prostate 
Imaging: Reporting and Data System (PI-RADS) score (32, 33). Suspicious lesions can be 
targeted during biopsy in three ways: I) with the patient positioned in the MRI-scanner 
(In-bore targeted biopsy), II) after fusion of the MR images with the transrectal ultrasound 
visually (cognitive targeted biopsy) or III) software assisted (MRI-transrectal ultrasound 
fusion targeted biopsy). MRI-targeted biopsy tends to detect more aggressive cancers and 
less non-aggressive cancers than transrectal ultrasound-guided systematic biopsy (37, 38). 
Besides the additional costs, the current lack of widespread expertise of radiologists is a 
drawback of multiparametric prostate MRI. 
Active Surveillance
Traditionally, patients with localized prostate cancer (tumor confined to the prostate) were 
actively treated with curative intent. Radiation therapy and surgery (radical prostatectomy) 
can have a severe impact on urinary, bowel and sexual function and thus the patient qual-
ity of life (17). With the understanding that a considerable proportion of screen-detected 
prostate cancers are overdiagnosed came a strategy to monitor these so-called clinically 
insignificant cancers, as opposed to overtreating them. The aim of active surveillance is to 
delay or even completely avoid unnecessary invasive treatment. Patients on active surveil-
lance are in general monitored according to a strict follow-up schedule including repeated 
PSA measurements, digital rectal examinations and prostate biopsies. If disease reclas-
sification (signs of higher risk disease) occurs during follow-up, men should be able to 
switch to active treatment without losing the window of curability. Active surveillance has 
been shown to be safe at long-term follow-up with a 10-year and 15-year cancer-specific 
survival of respectively 98% and 94% in a Canadian cohort (39). A variety of protocols and 
guidelines on active surveillance are currently available (40). In 2006, the Prostate cancer 
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Research International: Active Surveillance (PRIAS) study was initiated at the Erasmus 
University Medical Center in Rotterdam (41). To date, PRIAS is the largest observational 
active surveillance study worldwide, including over 6.500 patients in over 20 countries. As 
in the Canadian cohort, the 10-year cancer-specific survival in the PRIAS study is excellent: 
>99% (42). On the other hand, approximately 50% of men in the PRIAS study have disease 
reclassification within 5 years of follow-up, indicating that difficulties remain up to now to 
determine which men are suitable for active surveillance  (42). 
Objectives of this thesis
The first objective is to determine how a reduction of the harms of prostate cancer screen-
ing (i.e. unnecessary biopsies and overdiagnosis of clinically insignificant cancer) can be 
established without affecting the benefit (i.e. reduction of metastatic disease and prostate 
cancer mortality). The second objective is to investigate how current protocols on active 
surveillance for clinically insignificant prostate cancer can be improved.
Outline of research questions addressed in this thesis
The first part of the thesis will focus on prostate cancer screening and is divided into four 
chapters. These four chapters will focus on the following research questions:
Can we reduce the harms of prostate cancer screening (i.e. unnecessary biopsies and overdi-
agnosis) without affecting the benefit of a reduction of metastatic disease and prostate cancer 
mortality?
•	 Can we select those men who may benefit from screening and refrain from screening 
in those who may not benefit? (Chapter 2 and 3)
•	 Can we select those men who need a biopsy using currently available prediction mod-
els, thereby avoiding unnecessary biopsies and overdiagnosis? (Chapter 3, 4 and 5)
•	 Can magnetic resonance imaging help to improve currently available prediction mod-
els? (Chapter 3 and 5)
The second part of the thesis will focus on active surveillance and is divided into three 
chapters addressing the following research questions:
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Can we improve current protocols on active surveillance for clinically insignificant prostate 
cancer? 
•	 Can we selectively identify those men who are suitable for surveillance based on mag-
netic resonance imaging and the prostate cancer growth pattern?  (Chapter 6 and 8)
•	 Do men on active surveillance comply with current strict follow-up protocols, includ-
ing repeated biopsies, and if not, what are the reasons for non-compliance?  (Chapter 
7) 
•	 Can we selectively identify those men who need a follow-up biopsy using magnetic 
resonance imaging, avoiding unnecessary biopsies in men at low risk of reclassifica-
tion? (Chapter 8)
19
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AbSTRACT
PSA-based prostate cancer screening remains a controversial topic. Up to now, there is 
worldwide consensus on the statement that the harms of population-based screening, 
mainly as a result of overdiagnosis (the detection of clinically insignificant tumors that 
would have never caused any symptoms), outweigh the benefits. However, worldwide 
opportunistic screening takes place on a wide scale. The European Randomized study of 
Screening for Prostate Cancer (ERSPC) showed a reduction in prostate cancer mortality 
through PSA-based screening. These population based data need to be individualized in 
order to avoid screening in those who cannot benefit and start screening in those who will. 
For now, lacking a more optimal screening approach, screening should only be started 
after the process of shared decision making. The focus of future research is the reduction 
of unnecessary testing and overdiagnosis by further research to better biomarkers and 
the value of the multi-parametric MRI (mpMRI), potentially combined in already existing 
PSA-based multivariate risk prediction models. 
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Increasing incidence of prostate cancer 
Prostate cancer (PCa) is the second most common cause of cancer and the sixth leading 
cause of cancer death among men worldwide (1). In 2008, an estimated 899.000 new pros-
tate cancer cases and 258.000 new deaths occurred worldwide (1). About one in six men in 
the United States will be diagnosed with prostate cancer, while one in 36 men will die from 
this disease (2). In Europe during the year 2012 416.732 new PCa cases were diagnosed, 
and 92,247 men died from the disease (3). The prostate cancer incidence in Asian countries 
such as Japan is substantially lower than in Europe and the United States, mostly due to 
the approximately 5 fold lower exposure rate to PSA-based screening (4). As a result of the 
low exposure rate to screening, the rates of metastases and death from prostate cancer in 
Asian countries are higher than in Western countries. 
Since prostate cancer is predominantly a disease of elderly men, it forms a major health 
problem in ‘developed’ countries where the life expectancy is relatively high (5). As the 
number of people aged over 60 years is expected to triple to 2 billion by 2050 (6), the 
prostate cancer incidence will inevitably increase in the future.
Prostate-specific antigen
Prostate-specific antigen (PSA) is a kallikrein-like serine protease. This enzyme is almost 
exclusively produced by the epithelial cells of the prostate, making it an organ-specific 
marker. However, PSA is not a cancer-specific marker. Benign prostate hyperplasia (BPH) 
and prostatitis can cause PSA elevation in the serum as well. Moreover, (clinically significant) 
PCa can be present in men without elevated PSA values (7, 8). In the pre PSA era, prostate 
cancer was mainly diagnosed by digital rectal examination (DRE). DRE has poor sensitivity, 
limited specificity and high inter-observer variability for the detection of prostate cancer 
(9-11). In 1987, PSA was introduced in the United States to evaluate treatment response 
after intended curative therapy. Soon after, PSA was widely used for opportunistic screen-
ing, causing a favorable stage shift at time of diagnosis and a subsequent increase of the 
disease incidence and a start of the decline of the mortality (12, 13). The wide adoption 
of PSA in opportunistic screening led to research on its potential role in reducing prostate 
cancer mortality, next to creating a favorable stage shift (14). Several PSA-based screening 
trials were conducted (table 1), often combining PSA with DRE, mainly to improve selec-
tion in men with low PSA levels (9). 
Rise of the PSA-based screening trials
In 1981, a non-randomized population-based study of prostate cancer screening was 
started in the Gunma prefecture of Japan (15). Men aged 50-79 years were screened using 
DRE and prostatic acid phosphatase (PAP) as screening modalities. Between 1992 and 
2000 men from Gunma were screened with PSA instead of PAP, and with additional tran-
srectal ultrasonography (TRUS).  A total of 13.021 men received a PSA test, of who 92.6% 
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had an initial PSA level of 4.0 ng/mL or less. Prostate cancer detection rates were 0.18%, 
1.0% and 3.6% at a PSA level of < 1.0 ng/ml, 1.0-1.9 ng/ml and 2.0-4.0 ng/ml respectively 
(16). Two early PSA-based screening trials were conducted in Sweden. The first study was 
initiated in Norrköping in 1987, where every sixth man (n=1494) aged 50-69 years was 
invited for screening with DRE and later on PSA every 3 years (17). The 7532 uninvited 
men acted as the control arm of the study. After 20 years of follow-up, the rate of prostate 
cancer mortality did not differ significantly between men in the screening arm and those 
in the control arm of the Norrköping  trial (18). The second Swedish study was conducted 
in Stockholm in 1988. A total of 1782 men aged 55-70 years were screened with PSA and 
TRUS, followed by prostate biopsies in the presence of a suspicious lesion or a PSA > 10 ng/
ml. An unscreened group of 27.204 men served as the control arm. Again, this study did 
not show an effect on the prostate cancer mortality at a follow-up of 15 years (19). 
In 1988, a PSA-based screening trial was conducted in Quebec, Canada. A total of 46.486 
men aged 45-80 years were randomized to a screening and control arm in a 2:1 ratio.  Of 
the 31.133 men in the screening arm, only 7348 men received actual screening. The PSA 
cut-off value to perform a TRUS was 3.0 ng/ml. Hypoechoic lesions were biopsied. The 
11-yr follow-up results of the Quebec trial were published in 2004 (20). The study analysis 
was performed on a ‘screening received’ rather than an intention-to-treat basis, and hence 
reporting a  present (RR = 0.38) instead of an absent (RR = 1.09) prostate cancer mortality 
reduction. This study was heavily criticized on its methodology.
Between October 1993 and September 1994, a non-randomized register study on 
PSA-based screening was conducted in the federal state of Tyrol, Austria (21). A screened 
population of 21.078 men aged 47-75 years was compared with the unscreened rest of 
Austria. Prostate biopsy criteria were based on age-specific reference PSA levels. 8% of the 
screened men had an elevated PSA, 48% of these men underwent biopsies. 25% of the bi-
opsied men had prostate cancer. With follow-up until 2008, this study showed a significant 
reduction in prostate cancer mortality (RR = 0.70) in screened men from Tyrol aged > 60 
Table 1. Overview of the PSA-based prostate cancer screening trials
Screening Trial Country number of 
Participants
Age group 
(years)
Randomized PCa mortality 
reduction
Gunma Study (16) Japan 13.021 50-79 no Unknown
norrköping Study (18) Sweden 9026 50-69 semi No
Stockholm Study (19) Sweden 1782 55-70 no No
Quebec Study (20) Canada 46.486 45-80 yes Yes (RR = 0.38)*
Tyrol Study (22) Austria 21.078 47-75 no Yes (RR = 0.70)
PLCO study (26) United States 76.685 55-74 yes No
Göteborg Study (23) Sweden 19.904 50-69 yes Yes (RR = 0.56)
ERSPC (29) 8 European countries 162.243 55-69 yes Yes (RR = 0.79)
*RR = 1.09 after analysis on an intention-to-treat basis
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years compared with the mortality rate from 1989 to 1993 (22).  It was concluded that the 
prostate cancer mortality reduction was probably due to the combination of a favorable 
stage shift and active treatment.
Two largest randomized screening trials
The two largest randomized PSA-based screening trials are the prostate arm of the Pros-
tate, Lung, Colorectal and Ovarian (PLCO) trial and the ongoing European Randomized 
Study of Screening for Prostate Cancer (ERSPC). The Göteborg screening trial has random-
ized 20.000 men between biannual PSA-based screening and a control group and forms 
part of the ERSPC (23). Both the PLCO trial and the ERSPC reported their outcomes on 
prostate cancer mortality reduction after a median follow-up of 9 years (24, 25) and 12 
years (26, 27), remarkably with contradictory results. The PLCO trial was conducted in 10 
centers across the United States from 1993 to 2001. A total of 76.693 men aged 55-74 years 
were randomized to a screening or control arm in a 1:1 ratio. Screened men were offered 
an annual PSA test for 6 years and DRE for 4 years. At a follow-up of 7 years, the prostate 
cancer incidence was 116 per 10.000 person-years in the screening arm and 95 per 10.000 
person-years in the control arm (25). There was no difference in prostate cancer mortality 
between the screening (50 deaths) and control arm (44 deaths). The outcome at a follow-
up of 10 years was similar. After 13 years of follow-up, the prostate cancer incidence was 
108 per 10.000 person-years in the screening arm and 97 per 10.000 person-years in the 
control arm (26). Again, there was no difference in prostate cancer mortality between the 
screening (158 deaths) and control arm (145) (RR = 1.09). 
Due to the excessive contamination rate in the control arm (53%), confirmed by the 
similar incidence figures in both arms, and the poor biopsy rate (≈ 40%) of men that were 
positive at screening the PLCO trial lacks sufficient power to demonstrate an effect on 
prostate cancer mortality (28).  The ERSPC was initiated in 1991 and is still ongoing. Men 
between 50-74 years, with a predefined core age group between 55-69 years, from eight 
different European countries were randomized between a screening (72.952) and control 
arm (89.435). Numbers reflect 7 centers since France joined too late to be part of currently 
reported mortality analyses. Men were screened with an interval of 2-4 years. Prostate 
biopsies were performed when PSA was > 3.0 ng/ml in most centers. The main outcome 
of the study was reported for the core age group of 55-69 years. After a median follow-up 
of 9 years, the cumulative prostate cancer incidence was 8.2% in the screening arm and 
4.8% in the control arm (24). A significant prostate cancer mortality reduction was seen 
in the screening arm (214 deaths) compared with the control arm (326 deaths) yielding a 
RR of 0.80 and thus a relative risk reduction of 20% of prostate cancer death. The absolute 
risk reduction was 0.71 deaths per 1000 men, yielding a NNI of 1410 and NND of 48. After 
a median follow-up of 11 years, the relative risk reduction of prostate cancer death was 
21% (p=0.001) and thus similar (27). The relative risk reduction adjusted for noncompli-
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ance was 29%. The absolute risk reduction increased however and was 1.07 deaths per 
1000 men, giving a NNI of 1055 and a NND of 37. The overall risk reduction of metastases, 
causing symptomatic disease that precedes death by 2 to 3 years, was 31% in favor of 
screening.  After a median follow-up of 13 years, the relative prostate cancer mortality re-
duction remained stable at 21%, with a relative risk reduction of 27% after adjustment for 
noncompliance (29). The absolute prostate cancer mortality reduction increased further 
to 1.28 deaths per 1000 men, translating into a NNI of 781 and NND of 27. These findings 
support the outcome of modeling studies which all predict much lower NNI (98) and NND 
(5) when looking at the effect of PSA-based screening over a life time (30, 31). Sub analysis 
of the Rotterdam section of the ERSPC showed a relative prostate cancer mortality reduc-
tion of no less than 51% after adjustment for non-participation and PSA contamination 
(32). This indirectly shows that the prostate cancer mortality reduction by population-
based screening could be substantially greater  in Asian countries, with a low exposure 
rate to opportunistic screening, compared to Western countries. The two largest prostate 
cancer screening trials are different in design and conduct. The ERSPC shows an effect 
on the prostate cancer mortality of systematic, strictly protocol, PSA-based screening as 
compared to little opportunistic screening. The PLCO did or could not show this effect on 
prostate cancer mortality; the biopsy protocol was less strict and large scale opportunistic 
screening took place in the control arm. Therefor the outcomes of both trials on prostate 
cancer mortality cannot be compared (33, 34). During the running period of the two trials, 
the prostate cancer mortality declined by 42% (1991 and 2005) (35). Modeling studies 
estimate that 45-70% of the observed decline in prostate cancer mortality in the United 
States is attributed to the stage shift at disease diagnosis, while advances in the primary 
treatment (22-33%) and other interventions play a less important role (30, 35). 
Meta-analyses on PSA-based screening
Despite the fundamental differences in performance of the ERSPC and PLCO trial, several 
meta-analyses have been conducted combining the main outcome (i.e. prostate cancer 
mortality) of both trials, along with the outcome of the smaller PSA-based screening 
trials (36-38). Djulbegovic et al. conducted a meta-analysis of six randomized controlled 
trials on prostate cancer screening, involving 387.286 men (36). This study showed an 
increase in prostate cancer detection by screening, but no significant reduction of the 
prostate cancer mortality (RR = 0.88,  p=0.25). Both the Cochrane meta-analyses of Ilic 
et al., conducted in 2011 (RR = 0.95, p=0.38) and 2013 (RR = 1.00, p=0.99), were not able 
to show a significant reduction of  the prostate cancer mortality by PSA-based screening 
(37, 38). However, these meta-analyses have been heavily criticized on their limitations, 
making the conclusions invalid (39). Methodological shortcomings of the individual trials 
included in the meta-analyses were bias during and after randomization, contamination 
of the unscreened arm and short duration of follow-up. 
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Harms associated with PSA-based screening
The potential benefit of prostate cancer mortality reduction by PSA-based screening must 
always be weighed against the potential harms for the screened individual or population. 
Both in the clinical setting and within a screening trial, an elevated PSA is followed by a 
prostate biopsy. This technical procedure normally holds a minor risk. Hematuria lasting 
more than 3 days (23%) and hematospermia (50%) are very common but benign (40) . 
Fever developed after a prostate biopsy  is relatively rare (3.5%), leading to a hospitaliza-
tion-requiring sepsis in 0.5% of all biopsied men (40, 41). In as many as 75% of men the 
result of the (unnecessary) biopsy is benign, but even a negative biopsy result can cause 
an elevated level of distress (42). Taking into account the nearly 1 million prostate biopsies 
that are performed annually in the United States alone, these physical and psychological 
discomforts form one of the important drawbacks of PSA-based screening. Another very 
important disadvantage of prostate cancer screening is overdiagnosis and subsequent 
overtreatment. Based on data of the Surveillance, Epidemiology and End Results (SEER) 
registry, it has been estimated that prostate cancer screening in the United States results 
in 28% of overdiagnosed cases (30). The rate of overdiagnosis within the ERSPC trial was 
estimated to be approximately 50% (43, 44). In a comprehensive overview of Loeb et al. 
the estimated overdiagnosis by PSA-based screening ranged widely, from 1.7% to 67%, 
depending on the method of assessment (45). Several strategies have been contemplated 
to reduce the rate of overdiagnosis, like higher PSA thresholds for biopsy in older men 
and larger screening intervals in men with low baseline PSA values (46, 47), however a 
solution is currently lacking. The diagnosis of a clinically insignificant tumor often leads 
to an unnecessary invasive treatment like radical prostatectomy or radiotherapy with the 
intent to ‘cure’ the patient. These treatments often cause side effects, like incontinence 
and impotence. Hence overtreatment of insignificant prostate cancer is a serious problem 
with a large impact on the quality of life. The nowadays increasingly used  strategy of 
Active Surveillance (48) with regular PSA and DRE check-ups and repeated prostate 
biopsies could solve part of the problem by reducing the rate of overtreatment with so 
far minimal risks of progression and prostate cancer death (49). Invasive treatment for 
potentially indolent prostate tumors is delayed or even prevented. However, the regular 
check-ups and repeated prostate biopsies are invasive on its own and might cause anxiety 
and distress. Thus, the ideal solution for the problem of overtreatment would still be to 
prevent overdiagnosis by the exclusive detection of clinically significant prostate cancers.
Prostate cancer screening guidelines
Mainly due to the problem of overdiagnosis, prostate cancer screening remains a highly 
controversial topic of an ongoing debate. The various positions on screening of associa-
tions worldwide are reflected in the number of different, often contradictory guidelines 
for clinical practice (Table 2) (50). 
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Table 2. Current guidelines on PSA-based prostate cancer screening
Guideline Group Year Screening Age Screening Interval
national 
Comprehensive 
Cancer network  
(60)
2014 •	 There should be a baseline 
DRE and PSA at 40y.
•	 > 50y annual screening.
•	 Repeat screening at 45y if PSA is <1.0 ng/
mL.
•	 >50y annual-biannual screening.
American Urological 
Association  (56)
2013 •	 <55y no routine screening if 
at average risk. 
•	 55-69y if at average risk
•	 ≥70y if life expectancy > 10-
15y
•	 At least biannual screening
•	 Individualized interval based on baseline 
PSA
European 
Association of 
Urology (52)
2013 •	 There should be a baseline 
PSA ≥40-45y.
•	 Individualized interval based on baseline 
PSA
•	 Interval of 8y if baseline PSA  <1.0 ng/mL.
•	 Once every 2-4y if baseline PSA > 1.0ng/
ml
•	 Stop screening >75y if baseline PSA  <3.0 
ng/mL
American College of 
Physicians  (57)
2013 •	 40 y if at highest risk*
•	 45 y if at high risk**
•	 55-69y if life expectancy > 
10-15y 
•	 Consider intervals > 1y
US Preventive 
Services Task Force 
(55)
2012 •	 Screening should not be 
offered
_
American Society of 
Clinical Oncology 
(58)
2012 •	 Men with life expectancy > 
10y
_
Canadian Urological 
Society (117)
2011 •	 Consider a baseline PSA 
between 40-49y
•	 ≥40y if at high risk
•	 ≥ 50y if at average risk and 
life expectancy ≥10y
•	 Consider intervals up to 4y
American Cancer 
Society (59)
2010 •	 40 y if at highest risk*
•	 45 y if at high risk**
•	 > 50 y if at average risk and  a 
life-expectancy >10 y.
•	 Annual screening if PSA ≥2.5 ng/ml
•	 Biannual screening if PSA < 2.5 ng/ml
Japanese Urological 
Association (61)
2010 •	 Recommends screening
•	 ≥50y if at average risk
•	 ≥40y and family history
•	 Once every 3y if PSA <1.0 ng/mL
•	 Annual screening if PSA > 1.0 ng/mL.
American College of 
Preventive Medicine 
(51)
2008 •	 No screening at any age
•	 Potential benefit if at high 
risk
_
*highest risk: several first-degree relatives diagnosed with PCa < 65 years
**high risk: African American men and/or a first-degree relative with PCa
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There is more or less consensus on the statement that there is currently insufficient 
evidence for routine population-based PSA screening (51, 52). This was again underlined 
in the Melbourne Consensus Statement on the early detection of prostate cancer, formed 
by a multidisciplinary panel of the world’s leading experts on this subject (53). However, 
population-based estimates of overdiagnosis, causing a negative benefit-harms ratio of 
population-based screening, are difficult to translate to the individual (54). Unlike the US 
Preventive Services Task Force, that strongly recommends against any form of prostate 
cancer screening (55), almost all associations recommend to individualize opportunistic 
screening with the process of shared decision making  (52, 53, 56-60). During this process, 
men are well informed on the currently existing pros and cons before they make a defi-
nite decision on ‘to screen or not to screen’. The recommended age group and screening 
interval differ between the various guidelines. There is level 1 evidence on prostate cancer 
mortality reduction by screening provided by the ERSPC in the core age group of 55-69 
years (24, 27, 29). Therefore, this is the recommended age group for men at average risk 
(i.e. without a first-degree relative with PCa and not of African descent) in the American 
Urological Association (AUA) guideline on prostate cancer screening (56). The American 
Cancer Society (ACS) guideline on the other hand, recommends screening motivated men 
from the age of 50 years on (59).  This guideline also recommends screening men above 
70 years with a life expectancy of more than 10 years, since these men may benefit from 
screening as well. The European Association of Urology (EAU) and the National Compre-
hensive Cancer Network (NCCN) recommend a baseline PSA at 40 years (52, 60), same 
as the Melbourne Consensus Statement (53). Several guidelines recommend to screen 
motivated men under the age of 50 years if there is an increased risk of prostate cancer 
(56, 59, 61). Recommendations on the screening interval vary from annual screening in 
men with a PSA of 2.5 ng/ml or above (59), to an interval of 8 years in men with a baseline 
PSA of less than 1.0 ng/ml (52).
new prostate cancer markers
To date, PSA has remains the single most predictive tumor marker for identifying men at 
increased risk of prostate cancer. However, as stated earlier, the suboptimal performance 
characteristics of PSA in prostate cancer detection leads to unnecessary testing, overdiag-
nosis and overtreatment. Numerous studies have been conducted to identify next gen-
eration prostate cancer biomarkers (-omics) in serum and urine (62), like prostate cancer 
antigen 3 (PCA3) and TMPRSS2-ERG.The genetic marker hypermethylated Glutathione 
S-transferase P1 (GSTP1) shows promise in reducing the number of unnecessary biopsies 
(63) and stratifying men with aggressive prostate cancer (64, 65). So far, no biomarker has 
the potential to replace PSA, although some can have a complementary role, modestly 
improving the performance of prostate cancer detection. The success of the PSA test led 
to studies on the performance of other kallikrein markers in prostate cancer detection. 
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The percentage free PSA turned out to be lower in men with prostate cancer compared 
with those without (66). A correlation of lower percentage free PSA with higher prob-
ability of a positive biopsy result was shown (67-70). However, the percentage free PSA 
was not widely implemented as a screening tool due to inconsistent performance in later 
studies (71, 72). The [-2] isoform of Proenzyme PSA (proPSA) is a promising biomarker in 
prostate cancer screening due to its correlation with prostate cancer rather than BPH and 
its accuracy in the detection of cancer (73, 74). The percentage [-2] proPSA particularly is 
a good predictor of cancer in men with a PSA of 2-10 ng/ml (75). In a small retrospective 
study, the AUC of percentage [-2] proPSA (0.73) was significantly greater than of total PSA 
(0.52) and percentage free PSA (0.53) (75). In a larger prospective study, percentage [-2] 
proPSA had an improved specificity of 44.9% compared with total PSA and percentage 
free PSA (30.8% and 34.6%, respectively) at an 80% sensitivity (76). In addition, this study 
showed that the percentage [-2] proPSA increases with increasing Gleason score, and is 
higher in aggressive cancers (76). The Beckman Coulter Prostate Health Index (PHI®) can be 
considered a ‘marker’ as well. This index is calculated by the following formula: PHI = ([-2] 
proPSA/freePSA) × √PSA. Both [-2] proPSA (AUC = 0.76) and PHI (AUC = 0.77) outperform 
total PSA and percentage free PSA in the PSA range of 2.5-10.0 ng/ml (77). More recent 
studies underline the superior predictive ability of PHI and percentage [-2] proPSA (78, 
79), with a significant improvement of the accuracy compared with standard PSA-based 
screening (+11% and +10%, respectively)(78). The performance characteristics of PSA can 
also be improved by combining the test in a panel of four kallikrein markers (i.e. total PSA, 
free PSA, intact PSA, and hK2). This kallikrein panel improves the AUC of standard PSA-
based screening from 0.63 to 0.78 in men with a PSA ≥ 3.0 ng/ml (80).The kallikrein panel 
could potentially reduce the unnecessary biopsy rates by nearly 50% (81, 82). It seems as 
if we are far from done with the PSA test. Part of the future of prostate cancer screening 
lies in improving the performance of PSA, either by using percentage [-2] proPSA/PHI or a 
kallikrein marker panel with hK2. 
Prediction tools to improve PSA-based screening
In addition to combining PSA with other kallikrein markers, the predictive capability can 
be improved by combining the PSA test with other pre-biopsy variables like the DRE, 
TRUS and prostate volume (83). Multivariate risk stratification in prostate cancer screen-
ing can be done by using various nomograms and prediction tools (84). Two of the most 
frequently used prediction tools in PSA-based screening are the risk calculators based on 
data from the Prostate Cancer Prevention Trial (PCPT) and the Rotterdam section of the 
ERSPC (85, 86). Both risk calculators are specifically of aid in reducing the number of un-
necessary prostate biopsies and the rate of overdiagnosis. The Rotterdam Prostate Cancer 
Risk Calculator (RPCRC, www.prostatecancer-riskcalculator.com) outperforms the PCPT 
risk calculator in external populations (accuracy of 0.71-0.80 vs. 0.57-0.74) (84). Unfortu-
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nately, despite various multicenter validation studies (87-89), the usage of the RPCRC is 
still insufficiently integrated in daily clinical practice. Part of the future of individualized 
PSA-based screening lies in the broad implementation of multivariate risk stratification 
with (improved) prediction tools like the RPCRC. 
Multi-parametric MRI of the prostate
Prostate cancer is the only solid malignancy that is often diagnosed by blind random biopsy 
of the organ, without visualization of the tumor. The transrectal ultrasound-guided random 
prostate biopsy was originally performed using the sextant method (90). Nowadays, addi-
tional biopsies cores are usually taken since an extended scheme increases the prostate 
cancer detection by a factor of 1.3 (91). Random prostate biopsy is poor at sampling tumors 
in the anterior, midline, and apex region of the prostate (92, 93), leading to the underdiagno-
sis of clinically significant disease. Furthermore, up to one in three low risk tumors on random 
biopsy are upgraded or upstaged based on the radical prostatectomy specimen (94). In 
contrast with transrectal ultrasound-guided random biopsy, transperineal template satura-
tion biopsy also samples the anterior prostate. Besides achieving higher detection rates, 
saturation biopsy also increases the rate of insignificant disease (95). Furthermore, saturation 
biopsy is more invasive, expensive, time-consuming and usually requires general anesthesia. 
The multi-parametric MRI (mpMRI) is increasingly used in PSA-based screening and could be 
the solution to the underdiagnosis of clinically significant disease by random prostate biopsy. 
The mpMRI has a high degree of accuracy in the detection of clinically significant prostate 
cancer confirmed by radical prostatectomy (96). The mpMRI detects greater than 90% of 
significant prostate cancers (97, 98). However, the mpMRI is less reliable at detecting small 
tumors (<0.5cc), low-grade disease (Gleason score 6) or tumors in the transitional zone (97). 
In mpMRI the anatomical T2-weighted images are combined with functional parameters: 
dynamic contrast enhancement (DCE), diffusion-weighted imaging (DWI) with apparent 
diffusion coefficient (ADC) mapping, and sometimes spectroscopy. Higher signal-to noise 
ratios provided by three-Tesla magnets further improve the accuracy of the mpMRI. Different 
scoring systems have been developed to address suspicious lesions on mpMRI. Suspicious 
lesions can be classified on a 3-point scale, ranging from low, moderate, to high suspicion, or 
on a 5-point scale (Likert or PI-RADS), ranging from 1 (no suspicion) to 5 (high suspicion) ac-
cording to the likelihood of significant prostate cancer being present (99-101). The PI-RADS 
(Prostate Imaging – Reporting and Data System) 5-point scale was developed by the Euro-
pean Society of Urogenital Radiology (ESUR) (101). Suspicious lesions on mpMRI can be used 
as targets for biopsy. MRI-targeted biopsy can be performed in the MRI scanner (in-bore). 
More commonly, target biopsy is performed under ultrasonographic guidance based on 
cognitive registration of the mpMRI images or after the process of MRI-Ultrasonography fu-
sion. In a recent study, the prostate cancer detection rate of cognitive target biopsy and fu-
sion biopsy was similar, while both techniques had performed better than random biopsy 
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(102). Several devices for MRI-Ultrasonography fusion have been approved by the US Food 
and Drug Administration (FDA) (103). Although MRI-Ultrasonography fusion biopsy is an in-
direct form of target biopsy, the average distance between desired and actual biopsy loca-
tion is minimal (1.7-2.4mm) and thus an acceptable margin of error that may be overcome 
by taking 2-3 cores (104, 105). Recently, a systematic review was conducted comparing the 
accuracy of MRI-targeted biopsy  with random biopsy for the detection of clinically signifi-
cant disease (106). Both target biopsy and random biopsy detected significant cancer in an 
equivalent number of men (43%). Missed significant cancers occurred in an equal amount of 
men using target biopsy and random biopsy. Since a third fewer men were biopsied using 
the MRI-targeted biopsy approach, target biopsy was more efficient. A mean of 3.8 target 
cores were taken compared with 12 random cores. MRI-targeted biopsy avoided the diagno-
sis of insignificant cancer in 10% of the presenting population. Thus it seems that a MRI-tar-
geted biopsy approach could reduce the number of men biopsied, the number of biopsies 
per men and the number of men diagnosed with insignificant disease, while the number of 
men diagnosed with significant disease remains the same. However, since 12-20% of signifi-
cant cancers are missed by MRI-targeted biopsy and are detected by random biopsy (107-
109), the target biopsy is currently still complementary and thus not replace the random bi-
opsy. The variability in methodology of the studies included in the systematic review limit 
the strength of outcomes. More recently, a systematic review and meta-analysis was con-
ducted comparing the accuracy of MRI-targeted biopsy with random biopsy in the same 
man (110). Only studies with patient data comprising individual MRI-targeted biopsy and 
random biopsy results for the same patient were selected for this study. In men with a suspi-
cious lesion on mpMRI, the overall prostate cancer detection rate was equal for target biopsy 
and random biopsy. However, in contrast with the results  of the previous systematic review, 
target biopsy had a higher detection rate of significant prostate cancer than random biopsy 
(sensitivity = 0.91 vs 0.76). Again, target biopsy had a lower detection rate of insignificant 
disease (sensitivity = 0.44 vs 0.83). Subgroup analysis revealed an improved detection rate of 
significant prostate cancer by target biopsy in men with previous negative random biopsy 
(relative sensitivity = 1.54), rather than in biopsy-naïve men (relative sensitivity = 1.10). There 
was significant heterogeneity in this meta-analysis, which limits the strengths of the conclu-
sions. Furthermore, the authors state that the comparison of target biopsy with random bi-
opsy needs to be regarded with caution, as a consequence of underlying methodological 
flaws of MRI-targeted biopsy. The EAU(111) and ESUR (112) guidelines state that the mpMRI 
and subsequent target biopsy may be used in men with high suspicion of prostate cancer 
after previous negative random biopsy. The meta-analysis of Schoots et al. underlines this 
recommendation (110). There is currently no indication for the usage of the mpMRI in clinical 
practice for screening of biopsy-naive men. The true value of the mpMRI and target biopsy 
and their place in prostate cancer screening has not yet been established. To allow better 
comparison, the reporting (of histological results) of individual studies on MRI-targeted bi-
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opsy should be more standardized. Recently, the STAndards of Reporting for MRI-Targeted 
biopsy studies (START) consensus panel recommended comparing the detection of signifi-
cant disease in random cores versus target cores in the same cohort of men (113). Studies 
should report histologic results of random and target cores separately using Gleason score 
and maximum cancer core length. A table comparing detection rates of significant and in-
significant disease by target and random biopsy should also be used. Target biopsy cores 
tend to show longer cancer core length and higher Gleason score than random biopsy cores 
(107) . Thus, target biopsy tends to classify the same disease more often as significant than 
random biopsy. Therefore, target biopsy might need a new definition of significant disease. 
In the future, if preliminary data are confirmed, mpMRI and MRI-targeted biopsy may provide 
a partial solution to the problem of overdiagnosis by PSA-based screening. Usage of the 
mpMRI could lead to lower rates of diagnosed insignificant cancer (106, 110).  Moreover, us-
age of the mpMRI could avoid 13-58% of unnecessary prostate biopsies (107-109, 114). Thus, 
the widely validation and implementation of the mpMRI could be the most important devel-
opment in PSA-based screening in the near future. Limitations for this development are not 
only the fact that current mpMRI data are preliminary, but also the lack of widespread exper-
tise on the mpMRI of radiologists. The interpretation of the mpMRI requires dedicated train-
ing and has a long learning curve (115, 116).
COnCLUSIOn
The ERSPC has provided level 1 evidence on prostate cancer mortality reduction by sys-
tematic, strictly protocol PSA-based screening. The wide scale introduction of PSA in an 
opportunistic prostate cancer screening setting has caused a staged shift at diagnosis and 
subsequent mortality reduction. Unfortunately, the suboptimal performance character-
istics of PSA lead to unnecessary testing, overdiagnosis and overtreatment. As a result, 
population-based prostate cancer screening purely based on the PSA test has a negative 
benefit-harms ratio. However, population-based estimates of effect and overdiagnosis are 
hard to translate to the individual. Therefore, most guidelines recommend applying the 
strategy of shared-decision making when it comes to opportunistic screening. In addition, 
a more individual approach is advised with less screening in men with low PSA values and 
men with a limited life expectancy. In the near future, further efforts should be made to 
reduce unnecessary testing and overdiagnosis. These goals could be accomplished by the 
wide scale validation and implementation of (new) prediction models, the mpMRI and the 
combination of PSA with other kallikrein markers. 
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AbSTRACT
Background: The harm of screening (unnecessary biopsies and overdiagnosis) generally 
outweighs the benefit of reducing PCa mortality in men aged ≥70 years. Patient-selection 
for biopsy using risk-stratification and MRI may improve this benefit-to-harm ratio.  
Objective: To assess the potential of a risk-based  strategy including MRI to selectively 
identify men aged ≥70 years with high-grade PCa.
Design, setting and participants: 337 men with PSA ≥3.0 ng/ml at 5th screening (71–75 
years) in the ERSPC Rotterdam were biopsied. 179 men received 6-core TRUS-Bx, while 158 
men received MRI, 12-core TRUS-Bx and fusion TBx in case of PI-RADS ≥3 lesions.
Outcome measurements and statistical analysis: Primary outcome was the overall, 
low-grade (Gleason score 3+3) and high-grade (Gleason score ≥3+4) PCa rate. Second-
ary outcome was the low- and high-grade PCa rate detected by 6-core TRUS-Bx, 12-core 
TRUS-Bx and MRI ± TBx. Tertiary outcome was the reduction of biopsies and low-grade PCa 
detection by upfront risk-stratification with the Rotterdam Prostate Cancer Risk Calculator 
4 (RPCRC4).
Results and limitations: 55% men were previously biopsied. The overall, low-grade and 
high-grade PCa rates in biopsy naïve men were 48%, 27% and 22%. In previously biopsied 
men these PCa rates were 25%, 20% and 5%. Sextant TRUS-Bx, 12-core TRUS-Bx and MRI 
± TBx had a similar high-grade PCa rate (11%, 12% and 11%) but a significantly different 
low-grade PCa rate (17%, 28% and 7%). RPCRC4-based stratification combined with 12-
core TRUS-Bx ± MRI-TBx would have avoided 65% of biopsies and 68% of low-grade PCa 
while detecting an equal percentage of high-grade PCa (83%) compared with a TRUS-Bx 
all men approach (79%).
Conclusions: After 4 repeated screens and ≥1 previous biopsies in half of men, still a signifi-
cant proportion of men aged ≥70 years harbor high-grade PCa. Upfront risk-stratification 
and the combination of MRI and TRUS-Bx would have avoided two-thirds of biopsies and 
low-grade PCa diagnoses in our cohort, while maintaining the high-grade PCa detection 
of a TRUS-Bx all men approach. Further studies are needed to verify these results.
Patient summary: Prostate cancer screening reduces mortality but is accompanied by un-
necessary biopsies and overdiagnosis of non-aggressive tumors, especially in repeatedly 
screened elderly men. To tackle these drawbacks screening should consist of an upfront 
risk-assessment followed by MRI and transrectal ultrasound-guided biopsy.
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InTROdUCTIOn
The European Randomized study of Screening for Prostate Cancer (ERSPC) showed a 21% 
prostate cancer (PCa) mortality reduction at 13 years follow-up (1). Correction for nonat-
tendance and contamination showed that the mortality reduction could be up to 51% for 
the individual (2). Unfortunately, screening using an algorithm with PSA and transrectal 
ultrasound-guided systematic biopsy (TRUS-Bx) is associated with unnecessary biopsies 
and overdiagnosis. Only ≈25% of men with PSA ≥3.0 ng/ml are diagnosed with PCa based 
on TRUS-Bx (3). The fraction of screen-detected PCa that are insignificant is estimated 
to be up to 50% (4). On the other hand, (high-grade) PCa are missed due to the use of 
a specific PSA cut-off for biopsy as well as undersampling by TRUS-Bx (5, 6). Finding an 
optimal harm-to-benefit ratio is challenging, especially men aged ≥70 years in whom the 
achieved mortality reduction generally does not outweigh the loss in quality-adjusted life 
years (7, 8). However, as the median life expectancy still increases and the incidence of 
poorly-differentiated PCa increases with age, some of these men may benefit from early 
detection (9-11). The drawbacks of screening at higher age could be tackled by improved 
patient-selection for biopsy using risk-stratification and MRI. Risk-stratification with the 
Rotterdam Prostate Cancer Risk Calculator (RPCRC) reduces the percentage of unneces-
sary TRUS-Bx by ≈33% (12-17). In a clinical setting, MRI and targeted biopsy (TBx) instead 
of TRUS-Bx detects significantly less low-grade PCa while detecting an at least equal 
percentage of high-grade PCa (18, 19). In the present study we investigate which men in 
the ERSPC Rotterdam 5th screening round (71 - 75 yrs) still harbor high-grade PCa. The low- 
and high-grade PCa detection rates of different biopsy strategies (6-core TRUS-Bx, 12-core 
TRUS-Bx and MRI ± TBx) are compared and the reduction of biopsies and overdiagnosis by 
upfront risk-stratification is assessed. 
MATERIAL And METHOdS
Study population  
All participants of the ERSPC Rotterdam 5th screening round (October 2010 – April 2016) 
were included. The study population and protocol of the ERSPC Rotterdam have been 
described previously (20). Starting in 1993, a total of 42.376 men aged 54 – 74 years were 
randomized to a screening or control arm. In the screening arm men were offered PSA 
testing with a 4-year interval until the age of 75 years. At each screening visit sextant TRUS-
Bx was offered in case of PSA ≥3.0 ng/ml. Within the 5th (last) screening round an MRI 
side study (MEC approval number: 138.741/1994/152) was initiated in January 2013. A side 
study information brochure with informed consent form was sent attached to the blood 
draw invitation. At the blood sampling visit additional information on the side study was 
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provided by a research nurse, if needed, before men decided on participation. Men with 
PSA ≥3.0 ng/ml who had a contraindication or were not willing to undergo MRI received 
sextant TRUS-Bx (group 1). Side study participants with PSA ≥3.0 ng/ml received an MRI 
and 12-core (instead of 6-core) TRUS-Bx ± TBx (Group 2). 
Multi-parametric MRI
According to the Prostate Imaging Reporting and Data System (PI-RADS) guidelines (21) 
the protocol consisted of T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) 
with apparent diffusion coefficient (ADC) reconstructions, and dynamic contrast en-
hanced (DCE) imaging, as described previously (22). Imaging was performed on a 3-Tesla 
MRI-scanner (Discovery MR750, General Electric Healthcare) using a 32-channel pelvic 
phased-array coil. The images were independently analyzed by 3 urogenital radiologists 
(IS, RD, JB), each experienced in reading prostate MRI. The PI-RADS score was used to grade 
all individual lesions. After independent review of the images, consensus on the PI-RADS 
score of each identified lesion was reached after open discussion lead by one radiologist 
(IS). MRI’s were classified as positive in the presence of ≥1 PI-RADS ≥3 lesions. 
TRUS-bx (fusion)
Men in group 1 with PSA ≥3.0 ng/ml received sextant TRUS-Bx. One additional core was 
taken from each hypoechoic lesion. Men in group 2 with PSA ≥3.0 ng/ml received 12-core 
TRUS-Bx blinded for MRI findings. One additional core was taken from each hypoechoic 
lesion. Subsequently, all PI-RADS ≥3 lesions were targeted with 2 cores per lesion using 
the UroStation™ (Koelis) for MRI-TRUS fusion. All biopsy procedures were performed by 
3 experienced operators (AA, LB, F-JD). The biopsy specimens were graded by one expert 
uro-pathologist (GL) according to the ISUP 2014 Gleason score (GS) (23). GS 3+3, regard-
less of the maximum cancer core length, was classified as low-grade PCa, while GS ≥3+4 
was classified as high-grade PCa. 
Outcome measurements
Primary outcome was the overall, low-grade and high-grade PCa rate in biopsy naïve and 
previously biopsied men. Secondary outcome was the low- and high-grade PCa rate as de-
tected by 6-core TRUS-Bx (group 1) and 12-core TRUS-Bx ± MRI-TBx (group 2). For in-depth 
analysis group 2 was divided into 12-core TRUS-Bx (group 2a) and MRI ± TBx (group 2b). 
Tertiary outcome was the reduction of biopsies and low-grade PCa diagnoses by upfront 
risk-stratification with the RPCRC4 (12).
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Statistical analysis
The Mann-Whitney U test was used to test for significant differences in continuous patient 
characteristics between men who received sextant TRUS-Bx (group 1) and men in the MRI 
side study (group 2). The χ2 test was used to test for significant differences in categorical 
patient characteristics and PCa detection rates between men in group 1 and 2. Cross tabu-
lation was performed of 12-core TRUS-Bx (group 2a) vs MRI ± TBx (group 2b) outcomes 
in men in group 2 (supplementary tables 1 – 3).The McNemar’s test was used to test for 
differences in PCa rates between group 2a and 2b. Targeted biopsy cores of hypoechoic 
lesions were analyzed as part of the TRUS-Bx. The risk of a biopsy positive for (high-grade) 
PCa was retrospectively assessed in all men using the RPCRC4, a prediction model based 
on data of 2896 men who were screened for the 2nd time 4 years after initial screening in 
the ERSPC Rotterdam (12). Men were stratified based on the RPCRC4 risk cut-off values 
to perform a biopsy: a risk of any PCa ≥20% and/or a risk of high-grade (GS ≥3+4) and/
or locally advanced (T-stage ≥2C) PCa >3% (12). The potential reduction of MRI’s, biopsies 
and overdiagnosis of low-grade PCa by upfront risk-stratification was assessed. Statistical 
tests were two sided with the criterion of significance set at p <0.05. Statistical analyses 
were performed with SPSS for Windows (Version 21.0. Armonk, NY:IBM Corp.).
RESULTS
Patient characteristics
A total of 1734 invited men attended for PSA testing (figure 1). A total of 23% (406/1734) 
attendees were eligible for biopsy based on PSA ≥3.0 ng/ml and 83% (337/406) of these 
men were biopsied, all of whom were MRI naïve. A total of 16% (65/406) men refused a 
biopsy based on anticipated burden or presence of comorbidities, while the biopsy failed 
in 2 men due to anal sphincter tension and was omitted in 2 men in whom MRI revealed a 
bladder tumor. A 6-core TRUS-Bx was performed in 179 men (group 1), of whom 62 men 
received TRUS-Bx after initiation of the side study: 5% (10/220) men biopsied after side 
study initiation had a contraindication for MRI (8 with magnetic prosthetic material, 1 with 
a pacemaker and 1 with GFR <30 mL/min) while 24% (52/220) men were not willing to 
undergo MRI, most frequently due to the extra (MRI-)visit additional to the biopsy visit and 
claustrophobia. A total of 158 men received MRI and 12-core TRUS-Bx ± TBx (group 2). The 
median age and PSA were 73 years (IQR 72 – 74) and 4.3 ng/ml (IQR 3.4 – 5.7) respectively 
(table 1). A total of 55% (184/337) men had received ≥1 TRUS-Bx at previous screening 
rounds. There were no significant differences in patient characteristics between men in 
group 1 and 2. 
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Prostate cancer detection at fifth screening (primary outcome)
A total of 36% (120/337) biopsied men were diagnosed with PCa. The low-grade PCa rate 
was 23% (77/337) and the high-grade PCa rate was 13% (43/337) (table 2). In biopsy naïve 
men the overall, low-grade and high-grade PCa rates were 48% (74/153), 27% (41/153) 
and 22% (33/153), respectively. The overall, low-grade and high-grade PCa rates in previ-
ously biopsied men were 25% (46/184), 20% (36/184) and 5% (10/184), respectively. 
Prostate cancer detection of different biopsy strategies (secondary outcome)
The median number of biopsy cores in group 1, 2, 2a and 2b was respectively 6 (IQR 6 – 6), 
12 (IQR 12 – 14), 12 (IQR 12 – 12) and 2 (IQR 2 – 3). A total of 30% (48/158) men in group 
2 had a positive MRI and received MRI-TBx (table 3). The high-grade PCa rate was not sig-
nificantly different between group 1 and 2 (11% vs 15%, p = 0.21). Sextant TRUS-Bx (group 
1), 12-core TRUS-Bx (group 2a) and MRI ± TBx (group 2b) had a similar high-grade PCa 
rate of respectively 11%, 12% and 11% (table 3). The low-grade PCa rate was significantly 
5th screening round attendees 
1734  
PSA < 3.0 ng/ml 
1328  
PSA ≥ 3.0 ng/ml 
406  
No biopsy 
60  
Sextant TRUS-Bx 
179  
12-core TRUS-Bx ± TBx  
158  
Multiparametric MRI 
167  
No biopsy 
9 
Sextant TRUS-Bx outcomes 
• No PCa: 130 (73%) 
• GS 3+3 PCa: 30 (17%) 
• GS ≥3+4 PCa: 19 (11%)  
12-core TRUS-Bx outcomes 
• No PCa: 94 (59%) 
• GS 3+3 PCa: 45 (28%) 
• GS ≥3+4 PCa: 19 (12%) 
TBx outcomes 
• No TBx: 110 (70%) 
• No PCa: 20 (13%) 
• GS 3+3 PCa: 11 (7%) 
• GS ≥3+4 PCa: 17 (11%) 
12-core TRUS-Bx ± TBx outcomes 
• No PCa: 87 (55%) 
• GS 3+3 PCa: 47 (30%) 
• GS ≥3+4 PCa: 24 (15%) 
Figure 1. Flowchart of all attendees in the 5th screening round of the ERSPC Rotterdam PSA = prostate-
specific antigen, MRI = Magnetic Resonance Imaging, TRUS-Bx = transrectal ultrasound-guided systematic bi-
opsy, TBx = targeted biopsy, PCa = prostate cancer, GS = Gleason score
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Table 2. Prostate cancer detection rates at 5th screening stratified for previous biopsy status
Prostate cancer detection rates at 5th screening in the ERSPC Rotterdam
Sextant TRUS-Bx
(Group 1)
12-core TRUS-Bx with 
MRI ± TBx (Group 2)
All men
(Group 1 + 2)
Number % Number % p-value Number %
biopsy naïve men
GS 3+3 PCa
GS ≥3+4 PCa
All
18
14
79
23
18
100
23
19
74
31
26
100
0.25
0.23
41
33
153
27
22
100
Previously biopsied men
GS 3+3 PCa
GS ≥3+4 PCa
All
12
5
100
12
5
100
24
5
84
29
6
100
<0.01
0.78
36
10
184
20
5
100
biopsy naïve + previously 
biopsied men
GS 3+3 PCa
GS ≥3+4 PCa
All
30
19
179
17
11
100
47
24
158
30
15
100
<0.01
0.21
77
43
337
23
13
100
ERSPC = European Randomized study of Screening for Prostate Cancer, TRUS-Bx = transrectal ultrasound-guid-
ed systematic biopsy, MRI-TBx = MRI-targeted biopsy, GS = Gleason score, PCa = prostate cancer
Table 1. Patient characteristics of all men who received a biopsy in the 5th screening round of the ERSPC 
Rotterdam
Patient characteristics of all biopsied men in the 5th screening round
Sextant TRUS-Bx
(Group 1)
12-core TRUS-Bx ± 
MRI-TBx
(Group 2)
All men
Median IQR Median IQR p-value Median IQR
Age (years) 73.2 72.2 – 74.1 73.1 72.4 – 73.8 0.82 73.1 72.3 – 74.0
PSA (ng/ml) 4.4 3.5 – 5.6 4.2 3.4 – 5.8 0.96 4.3 3.4 – 5.7
Prostate volume (ml) 48.3 35.3 – 68.4 52.9 36.8 – 70.9 0.53 50.2 35.9 – 70.1
Number of previous TRUS-Bx 1 0 – 2 1 0 – 2 0.48 1 0 – 2
Number % Number % p-value Number %
T-stage DRE T0 158 88 134 85 0.35 292 87
T2a 15 8 9 6 0.34 24 7
≥T2b 6 3 15 9 0.02 21 6
T-stage TRUS T0 151 84 135 85 0.78 286 85
T2a 25 14 20 13 0.73 45 13
≥T2b 3 2 3 2 0.88 6 2
Previous TRUS-Bx 0 79 44 74 47 0.62 153 45
1 48 27 35 22 0.32 83 25
2 29 16 34 22 0.21 63 19
3 15 8 12 8 0.79 27 8
4 8 4 3 2 0.19 11 3
Total 179 100 158 100 337 100
TRUS = transrectal ultrasound, TRUS-Bx = transrectal ultrasound-guided systematic biopsy, MRI-TBx = MRI-tar-
geted biopsy, IQR = Interquartile range, PSA = prostate-specific antigen, DRE = digital rectal examination
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higher in group 2 compared with group 1 (30% vs 17%, p <0.01). The low-grade PCa rate of 
12-core TRUS-Bx was significantly higher compared with sextant TRUS-Bx (28% vs 17%, p 
= 0.01), whereas the low-grade PCa rate of MRI ± TBx was significantly lower (7%, p <0.01). 
Table 3. Prostate cancer detection rates using different biopsy strategies without upfront risk-stratification
PCa detection rates using different biopsy strategies without upfront multivariable risk-stratification
Sextant TRUS-Bx
(Group 1; n=179)
12-core TRUS-Bx with 
MRI ± TBx (Group 2;  
n=158)
12-core TRUS-Bx
(Group 2a;  n=158)
MRI ± TBx
(Group 2b;  n=158)
number % number % number % number %
No biopsy - - - - - - 110 70
No PCa 130 73 87 55 94 59 20 13
GS 3+3 PCa 30 17 47 30 45 28 11 7
GS ≥ 3+4 PCa 19 11 24 15 19 12 17 11
Total 179 100 158 100 158 100 158 100
TRUS-Bx = transrectal ultrasound-guided systematic biopsy, MRI = Magnetic Resonance Imaging, TBx = targeted 
biopsy, PCa = prostate cancer, GS = Gleason score
TRUS-bx versus MRI ± Tbx outcomes in group 2
A total of 15% (24/158) men in group 2 were diagnosed with high-grade PCa. High-grade 
PCa was detected by TRUS-Bx only, MRI ± TBx only, or both in respectively 29% (7/24), 21% 
(5/24) and 50% (12/24) (supplementary table 1). An MRI ± TBx only and TRUS-Bx only strat-
egy would have missed high-grade PCa in respectively 4% (7/158) and 3% (5/158) men. A 
total of 30% (47/158) men in group 2 were diagnosed with low-grade PCa. Low-grade PCa 
was detected by TRUS-Bx only, MRI ± TBx only, or both in respectively 77% (36/47), 11% 
(5/47) and 13% (6/47).
Avoidance of MRI’s, biopsies and overdiagnosis by upfront risk-stratification 
(tertiary outcome)
Upfront RPCRC4-based stratification in group 1 would have avoided 67% (120/179) biop-
sies, while missing 33% (10/30) low-grade PCa and 26% (5/19) of high-grade PCa (table 4). 
RPCRC4-based stratification in group 2 would have avoided 65% (102/158) MRI’s and bi-
opsies, missing 68% (32/47) low-grade PCa and 17% (4/24) high-grade PCa. RPCRC4-based 
stratification in group 2a would have avoided an equal percentage of biopsies (65%) and 
low-grade PCa (66%), missing 29% (7/24) high-grade PCa. Although RPCRC4-based strati-
fication in group 2b would have missed 42% (10/24) high-grade PCa, almost all low-grade 
PCa diagnoses (94%; 44/47) would have been avoided. 
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biopsy complications
A total of 5.6% (19/337) men had post-biopsy fever, of whom 3.3% (11/337) were admit-
ted. The urosepsis admission rate was 3.4% (6/179) in group 1 and 3.2% (5/158) in group 2. 
One man was admitted for urinary retention (group 1) and another for a transient ischemic 
attack one day post-biopsy (group 2). No deaths occurred.
dISCUSSIOn
The benefit of a mortality reduction achieved by screening must be balanced against 
the harms of unnecessary biopsies and overdiagnosis, particularly in elderly men (7, 8). 
Although the American Urological Association recommends against routine screening in 
men aged ≥70 years (24), older men are frequently screened in daily practice (25, 26). The 
European Association of Urology recommends an individualized risk-adapted strategy for 
early detection in men with a good performance status and life expectancy ≥10 – 15 years 
(27). As the median life expectancy still increases and the incidence of poorly-differenti-
ated PCa increases with age, some men aged ≥70 years may still benefit from screening 
(9-11). Hence, patient-selection before biopsy is mandatory in this age group and could 
be achieved by the use of risk-stratification and MRI. In the present study we explored 
the potential such a strategy in repeatedly screened men aged 71 – 75 years in the ERSPC 
Rotterdam 5th screening round.
Table 4. Percentages of avoided MRI’s, biopsies and low-grade PCa by multivariable risk-stratification with 
the Rotterdam Prostate Cancer Risk Calculator 4.
Avoided MRI’s, biopsy procedures and overdiagnosis of low-grade PCa by multivariable risk-
stratification
RPCRC4 + 
Sextant TRUS-Bx
(Group 1; n=179)
RPCRC4 + 
12-core TRUS-Bx 
with MRI ± TBx 
(Group 2; n=158)
RPCRC4 + 
12-core TRUS-Bx 
(Group 2a; 
n=158)
RPCRC4 + 
MRI ± TBx 
(Group 2b;  
n=158)
number number number % number % number %
MRI avoided - - 102/158 65 - - 102/158 65
Biopsy procedure avoided 120/179 67 102/158 65 102/158 65 130/158 82
GS 3+3 PCa diagnosis avoided
Biopsy strategy = ref.
12-core TRUS-Bx ± TBx = ref.
10/30
-
33
-
32/47
32/47
68
68
29/45
31/47
64
66
8/11
44/47
73
94
GS ≥3+4 PCa diagnosis missed
Biopsy strategy = ref.
12-core TRUS-Bx ± TBx = ref.
5/19
-
26
-
4/24
4/24
17
17
2/19
7/24
11
29
3/17
10/24
18
42
RPCRC4 = Rotterdam Prostate Cancer Risk Calculator 4, TRUS-Bx = transrectal ultrasound-guided systematic 
biopsy, MRI = Magnetic Resonance Imaging, TBx = targeted biopsy, PCa = prostate cancer, GS = Gleason score, 
ref. = reference.
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The overall PPV in the 5th screening round was 36% (120/337) and thus considerably 
higher than the PPV in the first (25.5%) and consecutive (≈20%) screening rounds of the 
ERSPC Rotterdam (3). The high PPV at 5th screening could be explained by the fact that 
half of men received 12-core TRUS-Bx ± MRI-TBx (PPV = 45%; 71/158) instead of 6-core 
TRUS-Bx (PPV = 27%; 49/179). The 27% overall PPV of 6-core TRUS-Bx is still higher than 
expected based on previous screening rounds, probably due to the higher age at 5th 
screening (9-11). The overall PPV in biopsy naïve men was ≈50% and approximately half 
of PCa detected in these men were high-grade. In line with findings at previous screening 
rounds, it is evident that biopsy naïve men after attending 4 rounds of screening with a 
4-year interval (i.e. predominantly men with PSA <3.0 ng/ml for a long period) still can be 
diagnosed with high-grade disease (3). In addition, the PPV in previously biopsied men 
was still considerable (25%), most likely reflecting the known undersampling with 6-core 
TRUS-Bx (6). In line with previous screening rounds, 20% of PCa detected in previously 
biopsied men were high-grade (3). However, the fact that only 5% of previously biopsied 
men were actually diagnosed with high-grade PCa questions whether these men should 
be repeatedly screened using the PSA-based random TRUS-Bx algorithm. 
Half of men in the 5th screening round received sextant TRUS-Bx and half received 12-core 
TRUS-Bx and MRI ± TBx, allowing a comparison of different biopsy strategies. In a clinical 
setting, it was shown that 6-core TRUS-Bx undersamples (high-grade) PCa as compared 
with 12-core TRUS-Bx (6). Furthermore, MRI ± TBx detects significantly less low-grade PCa 
than TRUS-Bx (18, 19). The high-grade PCa detection of MRI ± TBx is at least equal com-
pared with TRUS-Bx in a clinical setting (18, 19). Recently, a small pilot study in the 10th 
screening round of the Göteborg trial investigated the value of MRI in a population-based 
screening setting (28). In men with PSA ≥3.0 ng/ml the low-grade PCa rates of 10-core 
TRUS-Bx and MRI ± TBx (cognitive) were respectively 13% (9/70) and 8% (5/65), while the 
high-grade PCa rates were respectively 13% (9/70) and 11% (7/65) (28). Accordingly, a 
similar high-grade PCa rate of sextant TRUS-Bx, 12-core TRUS-Bx and MRI ± TBx(fusion) 
was found in the present study (11%, 12% and 11%). Surprisingly, only the low-grade PCa 
rate of 12-core TRUS-Bx was higher compared with 6-core TRUS-Bx (28% vs 17%, p =0.01), 
suggesting that the use of an extended TRUS-Bx scheme would only increase the detection 
of low-grade disease in previously screened (and often biopsied) men. Less surprisingly, 
the low-grade PCa rate of MRI ± TBx was significantly lower (7%) as compared with 6-core 
TRUS-Bx (17%) and 12-core TRUS-Bx (28%), indicating that a screening strategy with only 
MRI ± TBx could significantly reduce overdiagnosis of low-grade disease. Furthermore, an 
MRI ± TBx strategy would cause a significant reduction of biopsies as more than two-thirds 
of population-based screened men with PSA ≥3.0 ng/ml  have a negative MRI (28).  
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Another strategy to reduce unnecessary biopsies and overdiagnosis is risk-stratification 
before biopsy.  Risk-stratification with the RPCRC is known to reduce the percentage of 
unnecessary TRUS-Bx by ≈33% (12-17). Furthermore, RPCRC4-based stratification could 
have the potential to reduce unnecessary MRI’s after a previous biopsy (22). In the present 
study, a screening strategy with RPCRC4-based stratification and the performance of only 
12-core TRUS-Bx would have avoided two-thirds of biopsies and low-grade PCa diagnoses, 
missing 29% (7/24) of high-grade PCa detected by the reference standard of MRI and 12-
core TRUS-Bx ± TBx performed in all men. A strategy with RPCRC4-based stratification and 
only MRI ± TBx reduces overdiagnosis to a minimum with a low-grade PCa rate of only 
2% (3/158), but misses 42% (10/24) of high-grade PCa. The optimal screening strategy 
seems to be the combination of RPCRC4-based stratification and the performance of 
both 12-core TRUS-Bx and MRI ± TBx as it avoids two-thirds of biopsies and low-grade PCa 
diagnoses, and misses only 17% (4/24) of high-grade PCa compared with 21% (5/24) of 
high-grade PCa missed by a TRUS-Bx all men approach. As the implementation of MRI in 
early PCa detection may be cost-effective (29, 30), this reduction in costs could certainly 
be achieved by the performance of additional MRI in only one-third of men (being at high-
risk according to risk-assessment) while omitting a biopsy in two-thirds of men. Thus, an 
approach with upfront risk-stratification and the combination of MRI and TRUS-Bx has the 
potential to substantially reduce the drawbacks of early PCa detection in elderly men. 
The MRI’s in the present study were reviewed by 3 expert radiologists with years of experi-
ence with additional consensus reading. Therefore, our results may not directly translate 
to a setting with a single radiologist with less experience. Furthermore, MRI-TBx was 
performed with the MRI-TRUS fusion technique and fusion equipment is not yet widely 
available. However, the (high-grade) PCa detection of cognitive MRI-TBx appears to be 
comparable with fusion MRI-TBx and in-bore MRI-TBx (18, 19). 
The present study is mainly limited by the relatively small sample size as well as the 
composition of our cohort. Men in the ERSPC Rotterdam 5th screening round were 
relatively old, were repeatedly screened and more than half of men were previously 
biopsied. Therefore, our results do not directly translate to a younger, screening naïve 
cohort. However, the nature of this cohort may help addressing how long to screen and 
find the so needed balance between harms and benefits in elderly men. Naturally, the 
presence of comorbidities (not taken into account in our study) plays a crucial role in the 
harm-to-benefit ratio of early detection in elderly men and thus the decision to screen the 
individual. However, personalized life expectancy estimation is proven to be very difficult. 
Currently, the median life expectancy of Dutch men aged 73 is 12.7 years according to the 
Dutch Central Bureau of Statistics. In our cohort, the median life expectancy might actually 
be higher due to selection of men with relatively few comorbidities for PSA screening and 
subsequent biopsy (31).
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Finally, a potential limitation of the present study is the method of allocation to group 1 
or 2. The decision of men on participation in the side study could potentially be influenced 
by others (i.e. research nurse) and introduce a selection bias. However, this decision was 
made before the outcome of the PSA measurement was known and patient characteristics 
in both groups were equal. The currently ongoing Göteborg-2 trial randomizes 40.000 
men between a PCa screening and control arm, implementing (consecutive) MRI at dif-
ferent PSA cut-off values (28). In time, this trial will further elucidate the role of MRI in 
population-based screening. 
COnCLUSIOnS
 A significant proportion of our cohort of repeatedly screened men aged ≥70 years, with 
often ≥1 previous biopsies, still harbored high-grade PCa. Our study results point towards 
a significant improvement of the harm-to-benefit ratio of early PCa detection in elderly 
men by multivariable risk-stratification and MRI. A screening strategy with upfront risk-
stratification and the combined performance of MRI and TRUS-Bx would have avoided 
two-thirds of biopsies and low-grade PCa diagnoses in our cohort, while maintaining the 
high-grade PCa detection of a TRUS-Bx all men approach. Further studies are needed to 
verify these result. 
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SUPPLEMEnTARY MATERIAL
Supplementary table 1. Crosstab of the MRI ± TBx vs. 12-core TRUS-Bx outcomes in men in the ERSPC Rot-
terdam 5th screening round (group 2) 
MRI ± Tbx vs. 12-core TRUS-bx outcomes in all men (group 2)
No MRI 
lesion
MRI-TBx
No PCa GS 3+3 PCa GS 3+4 PCa GS ≥4+3 
PCa
Total
TR
U
S-
Bx
No PCa 71 16 5 1 1 94
GS 3+3 PCa 34 2 6 2 1 45
GS 3+4 PCa 4 0 0 10 0 14
GS ≥4+3 PCa 1 2 0 0 2 5
Total 110 20 11 13 4 158
Supplementary table 2. Crosstab of the MRI ± TBx vs. 12-core TRUS-Bx outcomes in biopsy naïve men in 
group 2
MRI ± Tbx vs. 12-core TRUS-bx outcomes in biopsy naïve men (group 2)
No MRI 
lesion
MRI-TBx
No PCa GS 3+3 PCa GS 3+4 PCa GS ≥4+3 
PCa
Total
TR
U
S-
Bx
No PCa 25 7 1 1 0 34
GS 3+3 PCa 17 1 4 2 1 25
GS 3+4 PCa 4 0 0 8 0 12
GS ≥4+3 PCa 0 1 0 0 2 3
Total 46 9 5 11 3 74
Supplementary table 3. Crosstab of the MRI ± TBx vs. 12-core TRUS-Bx outcomes in previously biopsied 
men in group 2
MRI ± Tbx vs. 12-core TRUS-bx outcomes in previously biopsied men (group 2)
No MRI 
lesion
MRI-TBx
No PCa GS 3+3 PCa GS 3+4 PCa GS ≥4+3 
PCa
Total
TR
U
S-
Bx
No PCa 46 9 4 0 1 60
GS 3+3 PCa 17 1 2 0 0 20
GS 3+4 PCa 0 0 0 2 0 2
GS ≥4+3 PCa 1 1 0 0 0 2
Total 64 11 6 2 1 84
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Supplementary table 4. MRI-targeted biopsy outcomes in men in Group 2 with a suspicious lesion on MRI 
stratified for the whole prostate PI-RADS score
MRI-Tbx outcomes stratified for the PI-RAdS score
(Men in Group 2 with a positive MRI)
PI-RADS 3 PI-RADS 4 PI-RADS 5 Total
Number % Number % Number % Number %
No PCa 13 65 6 40 1 8 20 42
GS 3+3 PCa 5 25 4 27 2 15 11 23
GS 3+4 PCa 2 10 4 27 7 54 13 27
GS ≥4+3 PCa 0 0 1 7 3 23 4 8
Total 20 100 15 100 13 100 48 100
MRI-TBx = MRI-targeted biopsy, PI-RADS = prostate imaging reporting and data system, PCa = prostate cancer, 
GS = Gleason score
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AbSTRACT
Background: Multiparametric MRI (mpMRI) is increasingly used in men with suspicion of 
prostate cancer (PCa) after negative transrectal ultrasound (TRUS)-guided random biopsy. 
Risk-based patient selection for mpMRI could help to avoid unnecessary mpMRIs. 
Objective: To study the rate of potentially avoided mpMRIs after negative TRUS-guided 
random biopsy by risk-based patient selection using the Rotterdam Prostate Cancer Risk 
Calculator (RPCRC).
Design, Setting and Participants: 122 consecutive men received a mpMRI and subse-
quent MRI-TRUS fusion targeted biopsy in case of suspicious lesion(s) (Prostate Imaging 
Reporting and Data System ≥3) after negative TRUS-guided random biopsy. Men were 
retrospectively stratified according to the RPCRC biopsy advice to compare targeted bi-
opsy outcomes after risk-based patient selection with standard (Prostate-specific antigen 
and/or digital rectal examination-driven) patient selection.
Outcome measurements and Statistical Analysis: The rate of potentially avoided mpMRIs 
by RPCRC-based patient selection in relation to the rate of missed high-grade (Gleason 
≥3+4) PCa. Receiver operating characteristic curve analysis was performed to determine 
the area under the curve of the RPCRC for (high-grade) PCa. 
Results and limitations: Of the 60 men with a positive biopsy advice, 6 (10%) had low-
grade PCa and 28 (47%) had high-grade PCa in targeted biopsy. Of the 62 men with a 
negative advice, 2 (3%) had low-grade PCa and 3 (5%) had high-grade PCa. Upfront 
RPCRC-based patient selection would have avoided 62 (51%) of 122 mpMRIs and 2 (25%) 
of 8 low-grade PCa diagnoses, missing 3 (10%) of 31 high-grade PCa. The area under the 
curve of the RPCRC for PCa and high-grade PCa was respectively 0.76 (95% CI 0.67 - 0.85) 
and 0.84 (95% CI 0.76 - 0.93). 
Conclusions: Risk-based patient selection with the RPCRC can avoid half of mpMRIs after a 
negative prostate-specific antigen and/or digital rectal examination-driven TRUS-guided 
random biopsy. Further improvement in risk-based patient selection for mpMRI could be 
made by adjusting the RPCRC for MRI-targeted biopsy outcome prediction. 
Patient summary: The suspicion of prostate cancer remains in many men after a negative 
ultrasound-guided prostate biopsy. These men increasingly receive an often unnecessary 
MRI-scan. We found that patient selection for MRI based on the Rotterdam Prostate Cancer 
Risk Calculator biopsy advice could avoid half of the MRIs.  
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InTROdUCTIOn
To date, following an abnormal prostate specific antigen (PSA) level and/or digital rectal 
examination (DRE), the next step in assessing the presence of prostate cancer (PCa) is a 
transrectal ultrasound(TRUS)-guided random biopsy. This combination of tests is known 
to result in approximately 60 – 75% benign biopsy results, questioning (1) the actual need 
of the biopsy, and (2) the specificity of the biopsy (1, 2). Random TRUS-guided biopsy is 
especially poor at sampling the anterior, midline and apex region of the prostate, leading 
to an underdiagnosis of PCa (3, 4). Although relatively expensive, multiparametric MRI 
(mpMRI) is suggested and increasingly used instead of repeated TRUS-guided biopsy in 
men with a sustained suspicion of PCa after negative random biopsy (5). Currently available 
data show that targeted biopsies of suspicious mpMRI lesions improve the detection of 
significant PCa, especially after previous negative random biopsy (6-8). It has already been 
shown that applying an upfront multivariable risk-based approach can reduce the rate of 
unnecessary TRUS-guided random biopsies with approximately 30% (9-12). Therefore, we 
question whether upfront multivariable risk stratification could also be used before the 
decision to perform mpMRI in the many men confronted with a negative random biopsy 
while clinical suspicion of PCa remains. The objective of this study is to assess the rate of 
potentially avoidable mpMRIs by comparing risk-based patient selection using the Rot-
terdam Prostate Cancer Risk calculator (RPCRC), with PSA/DRE-driven patient selection.
MATERIAL And METHOdS
Study population  
From September 2013 until May 2015 a total of 122 men were referred from 12 different 
peripheral institutions to our tertiary referral center for a mpMRI after one or more previ-
ous negative random TRUS-guided biopsies. These men had a sustained suspicion of PCa 
according to the referring urologist, based on PSA (kinetics). The indication for the primary 
TRUS-guided biopsy in all referring centers was a PSA ≥3.0 ng/ml and/or an abnormal DRE, 
in accordance with the European Association of Urology guidelines (5). The biopsy scheme 
for the primary TRUS-guided biopsy consisted of sextant lateral biopsies with a minimum 
of 2 additional medial cores in all referring centers. The referring urologist ordered the 
performance of the mpMRI and targeted biopsy with or without additional random biopsy 
in our expert center. Treatment and follow-up after the mpMRI and targeted biopsy took 
place in the referring institutions. Data of the mpMRI and targeted biopsy were included in 
our prospective, institutional review board approved database. Men analyzed in this study 
have not been included in previous reports. 
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mpMRI protocol 
The mpMRI protocol consisted of T2-weighted imaging, diffusion-weighted imaging with 
apparent diffusion coefficient reconstructions, and dynamic contrast enhanced imaging 
according to the European Society of Urogenital Radiology guidelines (13). MRIs were per-
formed on a 3-T system (Discovery MR750, General Electric Healthcare) using a 32-channel 
pelvic phased-array coil. The images were analyzed by a single expert radiologist with 
more than 4 years of experience in prostate mpMRI at the start of this study. Individual 
lesions, as well as the whole prostate, were scored on the Prostate Imaging Reporting and 
Data System (PI-RADS) 5-point likelihood scale for significant PCa (13). Individual lesions 
with a PI-RADS score ≥3 were classified as suspicious. Suspicious lesions were delineated 
on the T2-weighted imaging, based on the areas with the lowest b-values on the apparent 
diffusion coefficient-maps. 
Targeted biopsy with the MRI-US fusion technique
MRI-targeted biopsy was performed using the MRI-US fusion technique. The MRI-US 
fusion was performed with the UroStation (Koelis). The UroStation implements elastic reg-
istration to fuse the MRI and three-dimensional TRUS images and allows guiding and the 
recording of biopsy core locations on the images (14). All suspicious MRI lesions (PI-RADS 
≥3) were targeted with 2 – 4 cores, depending on the lesion size. All biopsy procedures 
were performed by two experienced operators (urologists in training) who had managed 
appoximately 50 cases at the beginning of this study. In a subset of men additional random 
biopsies were taken on the order of the referring urologist. The random biopsy outcomes 
of these men are not analyzed within this study.
Pathological examination of the targeted biopsy cores
All targeted biopsy cores were examined by one expert uro-pathologist. Gleason score 
(GS) 3+3 PCa was defined as low-grade, while GS ≥3+4 PCa was classified as high-grade. 
The primary negative TRUS-guided biopsy specimens performed in the referring institu-
tions were not centrally reviewed. 
Retrospective assessment of the RPCRC biopsy advice
The RPCRC is a prediction model based on data of 3624 initially screened and 2896 
repeatedly screened men in the European Randomized study of Screening for Prostate 
Cancer (ERSPC) Rotterdam (9). In the screening arm of the ERSPC Rotterdam a sextant 
TRUS-guided biopsy was performed in men with a PSA ≥4.0 ng/ml and/or abnormal DRE, 
later on in men with a PSA ≥3.0 ng/ml (15). The RPCRC uses PSA, DRE, TRUS (hypoechoic le-
sions) and TRUS-measured prostate volume as prebiopsy variables and takes a previously 
performed negative biopsy into account. The RPCRC calculates the risk of finding PCa and 
the risk of finding high-grade (GS ≥3+4) and/or locally advanced (T-stage ≥T2C) PCa in 
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random biopsy. The RPCRC is available on internet (www.prostatecancer-riskcalculator.
com) and as an app for iOS/Android. The established PCa risk cut-off values to advise a 
TRUS-guided random biopsy are a risk of any PCa ≥20% and/or a risk of high-grade and/
or locally advanced PCa >3% (9). To assess whether these established PCa risk thresholds 
could also be used to select men for mpMRI, the RPCRC PCa risks and biopsy advice were 
retrospectively determined in all men using the preMRI clinical variables.
Statistical analysis
Statistically significant differences in patient characteristics after risk-stratification were 
assessed using the Mann-Whitney U test for continuous data and chi-square test for 
categorical data. The rate of (high-grade) PCa in targeted biopsy was compared between 
the RPCRC-positive and RPCRC-negative group. The diagnostic accuracy of the RPCRC for 
any-grade and high-grade PCa in targeted biopsy was quantified using receiver operating 
characteristic curve analysis. Calibration of the RPCRC for any-grade and high-grade PCa in 
targeted biopsy was explored graphically by the construction of validation plots. Statisti-
cal tests were 2-sided with the criterion of significance set at p <0.05. SPSS for Windows 
(Version 21.0. IBM Corp Armonk, NY, USA) was used for the statistical analysis. 
RESULTS
Patient characteristics
A total of 122 men with a median age of 63 years (IQR 59 – 66) received a primary negative 
TRUS-guided biopsy in one of the 12 referring institutions at a median PSA level of 8.0 ng/
ml (IQR 6.0 – 11.1). The median total number of negative TRUS-guided biopsies was 1 (IQR 
1 – 2) using a median number of 8 cores (IQR 8 – 10). After a median time since the last bi-
opsy of 1 year (IQR 0 – 2), the 122 men with a median age of 66 years (IQR 61 – 69) received 
mpMRI in our center. The sustained suspicion of PCa was mainly based on a high PSA-level: 
the median PSA was 13.0 ng/ml (IQR 8.8 – 18.1), as depicted in table 1. Only 27 (22%) men 
had a suspicious DRE and only 19 (16%) men had a suspicious TRUS. After stratification 
according to the RPCRC biopsy advice, men with a positive advice had significantly more 
often a suspicious DRE (37% vs 8%) and suspicious TRUS (32% vs 0%). Although the men 
with a positive advice had significantly higher median PSA-levels (14.7 vs 11.5 ng/ml), the 
most obvious difference was found in the TRUS-measured median prostate volume: men 
with a positive advice had significantly lower prostate volumes (39 vs 65 ml) resulting in a 
higher PSA-density (0.37 vs 0.19). 
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Table 1. Variables used for prostate cancer risk-stratification according to the Rotterdam Prostate 
Cancer Risk Calculator biopsy advice
Patient characteristics Characteristics
All men 
(median) IQR/%
negative 
RPCRC advice 
(median)
IQR/%
Positive 
RPCRC advice 
(median)
IQR/% p-value
PSA (ng/ml) 13.0 8.8 – 
18.1
11.5 8.3 – 
17.6
14.7 10.0 – 
20.4
0.047
TRUS volume (ml) 49 36 – 74 65 50 – 90 39 29 – 47 <0.001
Suspicious dRE 27 22% 5 8% 22 37% <0.001
Suspicious TRUS 19 16% 0 0% 19 32% <0.001
number of men 122 62 60
DRE = digital rectal examination; IQR = interquartile range; PSA = prostate specific antigen; RPCRC = Rotterdam 
Prostate Cancer Risk Calculator; TRUS = transrectal ultrasound.
mpMRI and targeted biopsy outcomes after RPCRC-based stratification 
Out of the 122 men, 54 (44%) had one or more suspicious lesions on mpMRI and 68 (56%) 
had a negative mpMRI. The 54 men with a suspicious mpMRI received targeted biopsy 
with a median number of 4 (IQR 3 – 5) cores. The targeted biopsy yielded no PCa in 15 
(28%) men and low-grade and high-grade PCa in respectively 8 (15%) and 31 (57%) men. 
Supplementary table 1 depicts the overall PI-RADS scores of the 54 suspicious mpMRIs 
with the corresponding targeted biopsy GS. The corresponding GS, location and diameter 
of the individual mpMRI lesions are depicted in Supplementary tables 3 – 5, respectively. 
After RPCRC-based stratification as depicted in Figure 1 and 2, only 3 (5%) out of 62 men 
with a negative advice were diagnosed with high-grade PCa (2 GS 3+4 and 1 GS 4+3) while 
2 (3%) had low-grade PCa.  Out of the 60 men with a positive advice, 28 (47%) men had 
high-grade PCa (15 GS 3+4 and 13 GS ≥4+3) and 6 (10%) had low-grade PCa in targeted 
biopsy. Upfront RPCRC-based patient selection for mpMRI would have avoided 62 (51%) 
out of 122 mpMRIs, 11 (73%) out of 15 false positive mpMRIs, and 2 (25%) out of 8 low-
grade PCa diagnoses, missing 3 (10%) out of 31 high-grade PCa. 
diagnostic accuracy of the RPCRC for high-grade PCa in targeted biopsy
With the established PCa risk cut-off values for a positive biopsy advice, the RPCRC had 
a sensitivity and specificity for high-grade PCa in targeted biopsy of 90% and 65%, re-
spectively. The area under the curve  of the continuous scores of the RPCRC for any-grade 
and high-grade PCa in targeted biopsy was 0.76 (95% CI 0.67 – 0.85) and 0.84 (95% CI 
0.76 – 0.93), respectively.
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Figure 1. Multiparametric Magnetic Resonance Imaging and targeted biopsy outcomes according 
to the Rotterdam Prostate Cancer Risk Calculator biopsy advice. mpMRI = multiparametric magnetic 
resonance imaging; PCa = prostate cancer, RPCRC = Rotterdam Prostate Cancer Risk Calculator, TBx = targeted 
biopsy.
Figure 2. Multiparametric magnetic resonance imaging and targeted biopsy outcomes according to 
the Rotterdam Prostate Cancer Risk Calculator biopsy advice. mpMRI = multiparametric magnetic reso-
nance imaging, PCa = prostate cancer, RPCRC = Rotterdam Prostate Cancer Risk Calculator.
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dISCUSSIOn
Current clinical practice mainly entails biopsy referrals based on elevated PSA-levels and/
or abnormal DRE. This approach results in many men who receive unnecessary random 
biopsies. Moreover, although the primary biopsy indication is often unfounded, the sus-
picion of PCa often remains after negative random biopsy. This results in the performance 
of many unnecessary expensive and burdening mpMRIs. Risk-based patient selection 
instead of PSA/DRE-driven selection for random biopsy reduces unnecessary biopsies 
and overdiagnosis (16, 17). Despite their added value, the use of prediction models before 
random biopsy is not well integrated in clinical practice. This could be due to lacking pre-
biopsy variables for risk-assessment at the time of the decision to biopsy. The decision to 
biopsy is often already made by the urologist based on PSA/DRE before a TRUS (including 
prostate volume measurement) is performed. Secondary risk-assessment before mpMRI 
could be more convenient than primary risk-assessment before TRUS-guided biopsy, since 
the prebiopsy variables are already known after the performance of the initial negative 
biopsy. 
The RPCRC has the highest diagnostic accuracy of all available prediction models for PCa 
in random biopsy, with an area under the curve of 0.79 (12). RPCRC-based patient selection 
reduces the number of unnecessary random biopsies with approximately 30% (9, 18-20). 
Although the RPCRC was designed on the basis of TRUS-guided sextant biopsy data in a 
screening cohort, it has been validated in numerous clinical cohorts of men receiving an 
extended random biopsy scheme (8 – 18 cores) (10, 19, 21, 22). As expected, assessment 
of the calibration showed a systematic underestimation of the (high-grade) PCa risk by 
the RPCRC. Most likely this is due to the higher detection rate of PCa by MRI-targeted 
biopsy compared with TRUS-guided random biopsy after previous negative biopsy (6-8). 
Despite this systematic underestimation the RPCRC biopsy advice performed well in our 
MRI-targeted biopsy cohort. Upfront patient selection according to the RPCRC would have 
avoided the performance of approximately 50% of mpMRIs in our cohort, while remaining 
a 90% sensitivity for high-grade PCa. The number of risk-stratified men with missed high-
grade PCa (3 (2%) out of 122) is acceptable. Naturally, these results should be confirmed 
with larger validation studies. In addition, the next logical step in order to improve the 
performance of the RPCRC in a targeted biopsy setting will be the addition of a calibration 
factor to the prediction model using mpMRI and targeted biopsy data. By enabling such 
an adjustment to the prediction model the number of risk-stratified men with missed 
high-grade PCa could possibly be reduced. 
Currently available data show the improved detection of significant PCa and decreased 
detection of insignificant PCa by MRI-targeted biopsy compared with TRUS-guided ran-
dom biopsy, especially after a previous negative biopsy (6-8). The mpMRI is increasingly 
used in case of (persistent) suspicion of PCa and it is imaginable that the MRI-targeted 
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biopsy will fully replace the TRUS-guided biopsy in the future. The increasing implementa-
tion of the mpMRI could be constrained in the future by a limited capacity, both logisti-
cally, financially, and in terms of shortage of expert radiologists. Hence risk-based patient 
selection for mpMRI is vital and the avoidance of approximately half of mpMRIs after previ-
ous negative biopsy could have a major clinical impact. In addition, the 73% reduction of 
false-positive mpMRIs and subsequent MRI-targeted biopsies by risk-stratification could 
have a considerable impact on patient well-being by the reduction of the (multiresistant) 
infection rate and patient distress.
The primary endpoint of this study was the rate of avoidable mpMRIs in relation to the 
rate of missed high-grade PCa by risk-stratification. To date, there is no consensus on the 
definition of “clinically significant” PCa in MRI-targeted biopsy (23). All GS 3+3 PCas in 
this study, regardless of the maximum cancer-core length, were considered “potentially 
indolent” since solitary GS 3+3 PCa on resection specimen is very unlikely to metastasize 
(24, 25) and tumor sampling by targeted biopsy is superior to random biopsy. Since up-
front RPCRC-based patient selection would have avoided the diagnosis of 2 (25%) out of 
8 potentially indolent tumors in our cohort, risk-based patient selection for mpMRI might 
have the potential to reduce overdiagnosis, besides avoiding unnecessary mpMRIs. All GS 
≥3+4 PCas were classified as high-grade, in accordance with the RPCRC definition, since 
the presence of biopsy Gleason pattern 4 or 5 is still the main determining factor for treat-
ment decisions. Although not all GS 3+4 PCas are aggressive and limited Gleason pattern 4 
in MRI-targeted biopsy might even be considered suitable for active surveillance by some, 
the oncological safety is not proven and this cannot be considered standard of care yet 
(26). 
The strength of this study lies in the fact that it represents a true clinical situation. 
Patients were referred from 12 different peripheral institutions to our expert center for 
mpMRI based on PSA and/or DRE. Since MRI-US fusion biopsy has a similar PCa detection 
rate as MRI-in-bore and cognitive targeted biopsy (6), our study results could be translated 
to all institutions with an expert radiologist performing any kind of targeted biopsies. Our 
study results are not limited by the learning curve phenomenon since the biopsy opera-
tors had managed a sufficient number of cases prior to the study. 
A limitation of this study is the fact that the analysis was restricted to targeted biopsy 
outcomes. The subgroup of men who received an additional random biopsy on request 
of the referring urologist was small (35 of 122) and the operator was not blinded for MRI-
lesions during the performance of the random biopsy. Random biopsy did not yield a 
single additional high-grade tumor on top of the targeted biopsy findings, underlining 
the limited additional value of blind sampling after previous negative biopsy (27).
Another limitation, as with the majority of studies on MRI-targeted biopsy, is the lack 
of a reference test. Random biopsy is not a sufficient reference test, especially after a pre-
vious negative biopsy. Transperineal template-guided biopsy as a gold standard would 
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have been a good reference test (28); however, this procedure would have been more 
appropriate in a study rather than a clinical setting. The fact that the mpMRI has a nega-
tive predictive value of 89 – 96% for high grade PCa in other expert centers reduces the 
importance of the lack of a reference test (28-31). 
COnCLUSIOnS
Multivariable risk-based patient selection with the RPCRC can avoid half of the mpMRI 
scans after a previous negative TRUS-guided random biopsy performed solely on the basis 
of an elevated PSA level and/or abnormal DRE. Further improvement in risk-based patient 
selection for mpMRIs could be made by enabling an adjustment to the prediction model 
when predicting MRI-targeted biopsy outcome. 
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SUPPLEMEnTARY MATERIAL
Supplementary table 1.  Targeted biopsy outcomes stratified according to the overall (whole pros-
tate) PI-RAdS score. 
Men with PI-RAdS 3 Men with PI-RAdS 4 Men with PI-RAdS 5 Total
number % number % number % number %
no PCa 5 50 9 47 1 4 15 28
GS 3+3 PCa 0 0 4 21 4 16 8 15
GS 3+4 PCa 2 20 2 11 13 52 17 31
GS 4+3 PCa 2 20 0 0 3 12 5 9
GS ≥4+4 
PCa
1 10 4 21 4 16 9 17
Total 10 100 19 100 25 100 54 100
PI-RADS = Prostate Imaging Reporting and Data System, PCa = prostate cancer, GS = Gleason Score.
Supplementary table 2.  Targeted biopsy outcomes stratified according to the PI-RAdS score of the 
individual mpMRI lesions
PI-RAdS 3 lesions PI-RAdS 4 lesions PI-RAdS 5 lesions Total
number % number % number % number %
no PCa 10 59 11 52 2 7 23 35
GS 3+3 PCa 1 6 4 19 4 14 9 14
GS 3+4 PCa 2 12 3 14 13 46 18 27
GS 4+3 PCa 2 12 0 0 3 11 5 8
GS ≥4+4 PCa 2 12 3 14 6 21 11 17
Total 17 100 21 100 28 100 66 100
PI-RADS = Prostate Imaging Reporting and Data System, PCa = prostate cancer, GS = Gleason Score
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Supplementary table 3. Targeted biopsy outcomes stratified according to the location of the indi-
vidual mpMRI lesions in the prostate
Targeted biopsy outcomes according to location of mpMRI lesions
number lesions GS 3+3 PCa GS ≥ 3+4 PCa
Right or Left
Right 30 5 (17%) 13 (43%)
left 26 4 (15%) 12 (46%)
both 10 0 (0%) 9 (90%)
Posterior or Anterior*
Posterior 33 2 (6%) 13 (39%)
Anterior 26 5 (19%) 18 (69%)
both 7 2 (29%) 3 (43%)
Peripheral or Transition zone
Peripheral zone 40 4 (10%) 16 (40%)
Transition zone 21 3 (14%) 15 (71%)
both 5 2 (40%) 3 (60%)
base, Mid or Apex
base 11 2 (18%) 4 (36%)
base & Mid 8 1 (13%) 6 (75%)
Mid 20 3 (15%) 5 (25%)
Mid & Apex 7 0 (0%) 6 (86%)
Apex 8 1 (13%) 4 (50%)
base & Mid & Apex 12 2 (17%) 9 (75%)
*Location posterior or anterior of the prostatic urethra according to the 27 regions of interest scheme as pub-
lished by Dickinson et al. Eur Urol. 2011;59:477-94.
Supplementary table 4. Size of the individual mpMRI lesions
Size of individual mpMRI lesions
Median IQR
Posterior* lesions (mm) 11 7 – 16.5
Anterior* lesions (mm) 22.5 14.5 – 31.5
All lesions (mm) 16 10 – 26
mm = millimeter, *Location posterior or anterior of the prostatic urethra according to the 27 regions of interest 
scheme as published by Dickinson et al. Eur Urol. 2011;59:477-94.
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AbSTRACT
Background: The European Randomized study of Screening for Prostate Cancer Risk 
Calculators (ERSPC-RCs) help to avoid approximately 33% of unnecessary transrectal 
ultrasound-guided systematic biopsies (TRUS-Bx). Multivariable risk-stratification could 
also avoid unnecessary biopsy procedures after the performance of MRI.
Objective: To adjust the ERSPC-RC3+DRE and ERSPC-RC4+DRE for the prediction of any 
grade and high-grade (Gleason score ≥3+4) prostate cancer (PCa) in 12-core TRUS-Bx ± 
MRI-targeted biopsy (MRI-TBx).
Design, setting and participants: A total of 961 consecutive men with a clinical suspicion 
of PCa received mpMRI and subsequent 12-core TRUS-Bx ± MRI-TBx (in case of PI-RADS 
≥3) in 5 different institutions between 2012 – 2016. Data of 504 biopsy naïve and 457 
previously biopsied men were used to adjust the ERSPC-RC3+DRE and ERSPC-RC4+DRE, 
respectively.   
Outcome measurements and statistical analysis: Logistic regression models were 
constructed including the linear predictor of the original ERSPC-RCs as a covariate after 
recalibration, as well as the overall PI-RADS score and age. The area under the curve (AUC) 
of the original ERSPC-RCs and the adjusted MRI-ERSPC-RCs for any and high-grade PCa 
was compared. Decision curve analysis was performed to assess the clinical utility of the 
MRI-ERSPC-RCs.
Results: The MRI-ERSPC-RC3 had a significantly higher AUC for high-grade PCa compared 
to the ERSPC-RC3+DRE: 0.84 (95%CI 0.81 – 0.88) vs 0.76 (95%CI 0.71 – 0.80), p <0.01. Simi-
larly, the MRI-ERSPC-RC4 had a higher AUC for high-grade PCa compared to the ERSPC-
RC4+DRE: 0.85 (95%CI 0.81 – 0.89) vs 0.74 (95%CI 0.69 – 0.79), p <0.01. Decision curve 
analysis showed net benefit for the MRI-ERSPC-RCs compared to the original ERSPC-RCs 
and a biopsy-all strategy at a high-grade PCa risk threshold of ≥5%. Using a ≥10% high-
grade PCa risk threshold to biopsy for both MRI-ERSPC-RCs in our total cohort of 961 men, 
25% (237/961) biopsies and 23% (34/146) low-grade PCa diagnoses are saved, missing 4% 
(14/345) high-grade PCa. 
Conclusions: In the present study the multiple externally validated ERSPC-RCs are adjusted 
for the prediction of any grade and high-grade PCa in 12-core TRUS-Bx ± MRI-TBx. The 
MRI-ERSPC-RC3 and MRI-ERSPC-RC4 have improved discriminative ability and application 
of these models in our cohort of men with a high clinical suspicion of PCa would have 
avoided 25% of biopsy procedures, missing 4% of high-grade PCa.
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Patient summary: The ERSPC risk calculators are known to help avoiding approximately 
one-third of unnecessary transrectal ultrasound-guided biopsies. In the present study, the 
original ERSPC risk calculators are updated, incorporating age and MRI data. Application of 
the updated MRI-ERSPC risk calculators could avoid unnecessary biopsy procedures after 
the performance of an MRI.  
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InTROdUCTIOn
In general, a transrectal ultrasound-guided systematic biopsy (TRUS-Bx) is performed as a 
first step in men with a suspicion of prostate cancer (PCa) based on an elevated prostate-
specific antigen (PSA) and/or an abnormal digital rectal examination (DRE). However, in 
60 – 75% of men the outcome of this TRUS-Bx is benign (1, 2). Moreover, up to 50% of 
those PCa detected by TRUS-Bx can be considered clinically insignificant (3). This indicates 
the need for a more specific, individually tailored selection for biopsy in order to reduce 
unnecessary biopsy procedures and the overdiagnosis of insignificant PCa. Several multi-
variable prediction models for PCa in TRUS-Bx are currently used in daily practice, with the 
European Randomized study of Screening for Prostate Cancer Risk Calculators (ERSPC-RCs) 
having high discriminative accuracy and being externally validated (4, 5). The ERSPC-RCs 
are based on data of men aged 55 – 74 years biopsied in the first screening round (n = 
3624) and second screening round (n = 2896) of the Rotterdam section of the ERSPC (6). It 
has been shown that using the ERSPC-RCs and applying cut-off values for the individually 
calculated probabilities of having biopsy detectable (high-risk) PCa reduces the percent-
age of unnecessary TRUS-Bx by 20 – 33% (6-12). Nowadays, multi-parametric magnetic 
resonance imaging (mpMRI) is increasingly used due to the high negative predictive value 
for clinically significant PCa of approximately 90% (13-15). The European Association of 
Urology (EAU) PCa guideline panel recommends the performance of a pre-biopsy mpMRI 
in men with a sustained suspicion of PCa after previous negative TRUS-Bx (15, 16). In ad-
dition, the panel recommends to risk-stratify as an initial step before the pre-biopsy MRI 
to confirm that the clinical suspicion of PCa is grounded (15, 16). Risk-stratification with 
the ERSPC-RC4 has been shown to avoid unnecessary MRI-scans in this setting (17, 18). 
After the performance of an MRI-scan, risk-based patient selection for (targeted) biopsy 
could help to avoid unnecessary biopsy procedures, especially in the absence of pre-MRI 
multivariable risk-stratification.   In the present study, we aim to augment the multiple 
externally validated ERSPC-RC3 and ERSPC-RC4 with the overall PI-RADS score and poten-
tially other relevant clinical information.
MATERIAL And METHOdS
Study population 
A total of 1353 consecutive men with a clinical suspicion of PCa (no prior PCa diagnosis) 
who received multi-parametric MRI and subsequent TRUS-Bx and/or targeted biopsy 
(TBx) between 2012 - 2016 were included in the prospective institutional review board 
approved databases of 5 individual institutions in Düsseldorf (n=723), Rotterdam (n=178), 
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The Hague (n=210), Amsterdam (n=160) and Den Bosch (n=82). Subgroups of the institu-
tional cohorts were reported previously (17, 19-21).  
Multi-parametric MRI
All MRI-scans were performed on a 3-Tesla MRI-scanner using a pelvic phased-array 
coil. The mpMRI protocol consisted of T2-weighted imaging (T2WI), diffusion-weighted 
imaging (DWI) with apparent diffusion coefficient (ADC) reconstructions, and dynamic 
contrast enhanced (DCE) imaging in four institutions (Düsseldorf, Rotterdam, The Hague 
and Amsterdam). In Den Bosch (n=82) a bi-parametric MRI protocol was used consisting 
of T2WI and DWI. The institutional radiologists who reviewed the MRI-scans all had years 
of experience in reading prostate MRI. All individual suspicious lesions were graded ac-
cording to the PI-RADS score (22, 23). Since the time period for (MRI-)data collection was 
predominantly before publication of PI-RADSv2 (23), the majority of MRI’s in the present 
study were graded according to PI-RADSv1 (22). 
Prostate biopsy
The prostate biopsy protocol varied among the individual institutions. In all institutions 
MRI-TBx was performed of each PI-RADS ≥3 lesion. The technique used for MRI-TBx varied 
amongst institutions (table 1): the MRI in-bore technique, as well as the MRI-TRUS fusion 
and cognitive fusion techniques were used. A total of 961 out of the 1353 consecutive 
men received a TRUS-Bx, with (in case of PI-RADS ≥3) or without (in case of PI-RADS 1 – 2) 
additional MRI-TBx. The biopsy procedures were all performed by experienced operators 
and all biopsy specimens were graded by dedicated uro-pathologists. All Gleason score 
(GS) 3+3 PCa were classified as low-grade PCa, regardless of the maximum cancer core 
length. GS ≥3+4 PCa was classified as high-grade disease. 
Adjustment of the ERSPC-RCs
The ERSPC-RC3 and ERSPC-RC4 are prediction models for PCa in sextant TRUS-Bx based 
on data of respectively 3624 men in the first screening round and 2896 men in the second 
screening round of the ERSPC Rotterdam (www.prostatecancer-riskcalculator.com) (6). 
Both the ERSPC-RC3 and ERSPC-RC4 use PSA, DRE (suspicious: no/yes), TRUS (suspicious: 
no/yes) and TRUS-measured prostate volume (continuous) as parameters. In addition, the 
ERSPC-RC4 takes the previous biopsy status (previous biopsy: no/yes) into account. The 
ERSPC-RC3+DRE and ERSPC-RC4+DRE are simplified models in which TRUS (suspicious: 
no/yes) is not included as a parameter and the prostate volume is used categorized (25ml, 
40ml or 60ml) as can be assessed by DRE. The ERSPC-RC3(+DRE) and ERSPC-RC4(+DRE) 
calculate the risk of any grade PCa and the risk of high-grade (GS ≥3+4) and/or locally ad-
vanced (T-stage ≥2C) PCa. In the present study, we aimed to augment the ERSPC-RC3+DRE 
and ERSPC-RC4+DRE by incorporating the overall PI-RADS score, for the prediction of any 
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grade and high-grade (GS ≥3+4) PCa in extended (12-core) TRUS-Bx ± MRI-TBx (in case 
of PI-RADS ≥3). In addition, as the ERSPC-RC3+DRE and ERSPC-RC4+DRE are developed 
based on data of men aged 55 – 74 years, age was included as a potential predictor in 
order to comply with the larger age range of men in daily clinical practice. . Data from the 
961 men from our cohort who received TRUS-Bx ± MRI-TBx (in case of PI-RADS ≥3) were 
used, of whom 504 biopsy naïve men were included in the adjusted MRI-ERSPC-RC3 and 
457 previously biopsied men were included in the MRI-ERSPC-RC4.
Statistical analysis
The multiple imputation by chained equations (MICE) algorithm was used to substitute 
missing DRE values. The MRI-measured prostate volume, calculated by the ellipsoid for-
mula (length x width x height x π/6), was categorized into the known volume classes of 
the ERSPC-RC3+DRE and ERSPC-RC4+DRE with cut-off values of <30 ml (25ml), 30 – 50 
ml (40ml) and >50 ml (60ml). The original ERSPC-RCs were recalibrated (re-estimation 
of the intercept and slope of the linear predictor) to  a clinical setting using data from 
the institutions in Rotterdam and Den Bosch (12, 17). Logistic regression analysis was 
performed to estimate the coefficients of the overall PI-RADS score and age in addition 
to the recalibrated ERSPC-RC3+DRE and ERSPC-RC4+DRE. The adjusted MRI-ERSPC-RC in-
cluded the linear predictor of the original ERSPC-RCs as a covariate. Bootstrap resampling 
was used for internal validation of the MRI-ERSPC-RCs and the calibration was explored 
graphically by the construction of calibration plots. The predictive accuracy of the original 
ERSPC-RCs and the MRI-ERSPC-RCs was assessed by the area under the receiver operating 
characteristic curve (AUC) and compared with the DeLong test. Decision curve analysis 
was performed to assess and compare the clinical utility of the original ERSPC-RCs and 
the MRI-ERSPC-RCs. The clinical utility of the models is expressed by the net benefit ratio, 
which weighs the benefits of (high-grade) PCa detected against the harms of unnecessary 
biopsies performed (24, 25). Tables were constructed displaying the number and percent-
age of biopsies saved vs (high-grade) PCa missed at different risk thresholds to biopsy 
of the MRI-ERSPC-RCs. Statistical tests were two sided with the criterion of significance 
set at p <0.05. Statistical analyses were performed with R version 3.3.1 (R Foundation for 
Statistical Computing, Vienna, Austria). 
RESULTS
Patient characteristics
Table 1 shows the patient characteristics of all 1353 men with a clinical suspicion of PCa 
who received mpMRI and subsequent biopsy between 2012 – 2016 in the 5 individual 
institutions. The median age, PSA and prostate volume were respectively 66 (IQR 60 – 71) 
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years, 8.7 (IQR 6.1 – 12.9) ng/ml and 49.7 (36.0 – 70.0) ml. DRE values were missing in 33% 
(441/1353) men. A total of 82% (1114/1353) men had an overall PI-RADS score ≥3. TRUS-Bx 
and MRI-TBx were performed with a median number of 12 cores (IQR 12 – 12) and 4 cores 
(IQR 3 – 6) per patient, respectively. MRI-TBx was performed using the in-bore technique 
in 32% (362/1126) men and using MRI-TRUS fusion and cognitive fusion in respectively 
64% (721/1126) and 4% (43/1126) men. A total of 16% (210/1353) men had low-grade 
PCa and 36% (483/1353) men had high-grade PCa. The patient characteristics of the 504 
biopsy naïve men who received TRUS-Bx ± MRI-TBx included in MRI-ERSPC-RC3 and the 
457 previously biopsied men included in MRI-ERSPC-RC4 are shown in table 2 and 3, 
respectively. In the 504 biopsy naïve men included in MRI-ERSPC-RC3 the low-grade and 
high-grade PCa detection rates were 16% (81/504) and 42% (213/504), respectively (table 
2). The low-grade and high-grade PCa detection rates in the 457 previously biopsied men 
included in MRI-ERSPC-RC4 were 14% (65/457) and 29% (132/457), respectively (table 3).
Tabel 2. Patient characteristics of men included in MRI-ERSPC-RC3: model for the prediction of any 
and high-grade PCa in TRUS-bx ± MRI-Tbx (in case of PI-RAdS ≥3) in biopsy naïve men. 
Patient characteristics of biopsy naïve men included in MRI-ERSPC-RC3 (n = 504)
no PCa (n=210; 
42%)
Any PCa (n=294; 
58%)
GS 3+3 PCa (n=81; 
16%)
GS ≥3+4 PCa (n=213; 
42%)
median IQR median IQR median IQR median IQR
Age (years) 62.0 56.0 – 
67.8
66.1 60.9 – 
72.2
65.0 58.3 – 70.0 67.0 61.9 – 73.0
PSA (ng/ml) 6.1 4.8 – 7.8 7.3 5.2 – 10.8 6.5 4.7 – 10.1 7.7 5.5 – 11.0
Prostate volume 
(ml)
56.5 39.8 – 
77.0
40.0 30.0 – 
52.0
42.0 29.5 – 58.0 40.0 30.0 – 51.0
number % number % number % number %
DRE 
Benign
Suspicious
Missing
116
23
71
55
11
34
116
102
76
39
35
26
44
18
19
54
22
23
72
84
57
34
39
27
PI-RADS
1 – 2
3
4
5
66
67
66
11
31
32
31
5
39
32
97
126
13
11
33
43
26
13
26
16
32
16
32
20
13
19
71
110
6
9
33
52
Total 210 100 294 100 81 100 213 100
IQR = interquartile range; PSA = prostate-specific antigen; DRE = digital rectal examination; PI-RADS = Prostate 
Imaging Reporting Reporting and Data System; ERSPC-RCs = European Randomized study of Screening for Pros-
tate Cancer Risk Calculators; GS = Gleason score; PCa = prostate cancer.
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Tabel 3. Patient characteristics of men included in MRI-ERSPC-RC4: model for the prediction of any 
and high-grade PCa in TRUS-bx ± MRI-Tbx (in case of PI-RAdS ≥3) in previously biopsied men.
Patient characteristics of previously biopsied men included in MRI-ERSPC-RC4 (n = 457)
no PCa (n=260; 
57%)
Any PCa (n=197; 
43%)
GS 3+3 PCa (n=65; 
14%)
GS ≥3+4 PCa (n=132; 
29%)
median IQR median IQR median IQR median IQR
Age (years) 65.4 61.1 – 
69.4
68.0 62.9 – 
72.0
65.9 58.2 – 69.9 68.0 65.0 – 72.8
PSA (ng/ml) 9.4 6.8 – 
13.6
11.0 7.4 – 16.0 9.0 6.5 – 14.8 11.7 7.7 – 17.5
Prostate volume 
(ml)
63.9 48.0 – 
88.8
42.0 30.0 – 
60.6
48.0 29.0 – 65.1 41.0 30.2 – 55.9
number % number % number % number %
DRE 
Benign
Suspicious
Missing
123
51
86
47
20
33
104
54
39
53
27
20
45
10
10
69
15
15
59
44
29
45
33
22
PI-RADS
1 – 2
3
4
5
106
56
78
20
41
22
30
8
24
16
98
59
12
8
50
30
20
9
26
10
31
14
40
15
4
7
72
49
3
5
55
37
Total 260 100 197 100 65 100 132 100
IQR = interquartile range; PSA = prostate-specific antigen; DRE = digital rectal examination; PI-RADS = Prostate 
Imaging Reporting Reporting and Data System; ERSPC-RCs = European Randomized study of Screening for Pros-
tate Cancer Risk Calculators; GS = Gleason score; PCa = prostate cancer.
Predictive accuracy of the original and adjusted ERSPC-RCs
Both the overall PI-RADS score and age added significantly to the original ERSPC-RC3+DRE 
and ERSPC-RC4+DRE. The discriminative ability of the MRI-ERSPC-RCs was significantly 
higher for both any grade and high-grade PCa compared with the original ERSPC-RCs 
(Table 4). The MRI-ERSPC-RC3 had a significantly higher AUC for high-grade PCa of 0.84 
(95%CI 0.81 – 0.88) compared to an AUC of 0.76 (95%CI 0.71 – 0.80, p <0.01) of the ERSPC-
RC3+DRE. Similarly, the AUC for high-grade PCa of the MRI-ERSPC-RC4 was significantly 
higher compared to the ERSPC-RC4+DRE: AUC of 0.85 (95%CI 0.81 – 0.89) vs AUC of 0.74 
(95%CI 0.69 – 0.79, p <0.01).
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Table 4. Comparison of the predictive accuracy of the original ERSPC-RCs and MRI-ERSPC-RCs.
Comparison of the predictive accuracy of the original and MRI-adjusted ERSPC-RCs
ERSPC-RC+dRE MRI-ERSPC-RC
(addition of PI-RAdS 
+ Age)
AUC 95% CI AUC 95% CI p-value
Any grade prostate cancer
Biopsy naïve:  ERSPC-RC3 (n = 504)
Previously biopsied:  ERSPC-RC4 (n = 457)
All men:  ERSPC-RC3/4 (n = 961)
0.779
0.708
0.756
0.738 – 0.819
0.659 – 0.757
0.725 – 0.786
0.839
0.791
0.823
0.805 – 0.872
0.748 – 0.834
0.797 – 0.849
0.02
<0.01
<0.01
High-grade (GS ≥3+4) PCa
Biopsy naïve:  ERSPC-RC3 (n = 504)
Previously biopsied:  ERSPC-RC4 (n = 457)
All men:  ERSPC-RC3/4 (n = 961)
0.757
0.742
0.758
0.714 – 0.799
0.693 – 0.791
0.726 – 0.789
0.843
0.850
0.852
0.808 – 0.878
0.813 – 0.887
0.827 – 0.876 
<0.01
<0.01
<0.01
AUC = area under the receiver operating characteristic (ROC) curve; CI = confidence interval.
decision curve analysis
Decision curve analysis showed improved performance of the MRI-ERSPC-RCs compared 
to the original ERSPC-RCs for both any grade and high-grade PCa (Figure 1a-b). For the 
MRI-ERSPC-RC3 net benefit (a potential net reduction in biopsies) compared to a biopsy-
all strategy and the ERSPC-RC3+DRE was observed at a risk threshold ≥10% for high-grade 
PCa (Figure 1a). For the MRI-ERSPC-RC4 net benefit was observed at a risk threshold ≥5% 
for high-grade PCa (Figure 1b).
biopsies saved vs (high-grade) PCa missed using the MRI-ERSPC-RCs
Table 5 depicts the number and percentage of biopsies saved and low- and high-grade 
PCa missed by applying different risk thresholds of the MRI-ERSPC-RC3 and MRI-ERSPC-
RC4 for high-grade PCa in all 961 men used to construct both models. At a risk threshold 
to biopsy of ≥10%, 25% (237/961) biopsies and 23% (34/146) low-grade PCa diagnoses are 
saved, missing 4% (14/345) high-grade PCa. 
96
Figure 1A-b. decision curves for any (Fig 1a) and high-grade (Fig 1b) PCa in TRUS-bx ± MRI-Tbx (in 
case of PI-RAdS ≥3) of the original and MRI-adjusted ERSPC-RCs in all (biopsy naïve and previously 
biopsied) men.
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dISCUSSIOn 
Risk-based patient selection for TRUS-Bx has been adopted in daily clinical practice, either 
by clinical judgement or by the use of risk calculators. Using an objective multivariable risk 
calculator like the original ERSPC-RCs has been shown to reduce the percentage of un-
necessary TRUS-Bx by 20 – 33% in several independent external validation studies (6-12). 
Nowadays, mpMRI is increasingly performed, especially in men with a sustained suspicion 
of PCa after previous negative TRUS-Bx (15, 16). The EAU PCa guideline panel recommends 
to risk-stratify before the performance of an MRI in previously biopsied men and it was 
previously shown that stratification based on the ERSPC-RC4 could avoid unnecessary 
MRI-scans in this setting (15-17). In the present study, we aimed to augment the original 
ERSPC-RCs by incorporating the overall PI-RADS score and age, showing that a multivari-
able risk-based approach could also be used to avoid unnecessary biopsy procedures after 
the performance of a pre-biopsy MRI. The original ERSPC-RC3+DRE and ERSPC-RC4+DRE 
already performed well in our cohort with an AUC for high-grade PCa of 0.76 (95%CI 
0.71 – 0.80) and 0.74 (95%CI 0.69 – 0.79), respectively. Nevertheless, the MRI-ERSPC-RCs 
had a significantly higher discriminative ability for high-grade PCa (AUC of 0.84 (95%CI 
0.81 – 0.88) and 0.85 (95%CI 0.81 – 0.89) for the MRI-ERSPC-RC3 and MRI-ERSPC-RC4, 
respectively) and decision curve analysis showed clear net benefit of the MRI-ERSPC-RCs, 
proving their ability to avoid unnecessary biopsy procedures even after risk-stratification 
pre-MRI with the original (recalibrated) ERSPC-RCs.
Obviously, the percentage of potentially avoidable biopsies after MRI is dependent on 
the composition of the cohort and thus on the degree of risk-stratification pre-MRI. Our 
cohort used to develop the MRI-ERSPC-RCs consisted of men with a high clinical suspicion 
of PCa, reflected by a high percentage of men with any grade PCa (51%; 491/961) and 
Table 5. biopsies saved vs prostate cancer detected/missed using different risk thresholds for high-
grade (GS ≥3+4) PCa of the MRI-ERSPC-RCs(3or4) in all men (n=961)
biopsies saved vs prostate cancer detected/missed using different MRI-ERSPC-RC(3or4) risk thresholds 
for high-grade (GS ≥3+4) PCa
Risk 
threshold 
(A) No. 
of men 
biopsied
(B) No. of 
biopsies 
saved (% of 
total A)
(C) No. of 
GS 3+3 PCa 
detected 
(% of A)
(D) No. of 
GS 3+3 PCa 
missed 
(% of total C)
(E) No. of GS 
≥3+4 PCa 
detected 
(% of A)
(F) No. of GS 
≥3+4 PCa 
missed 
(% of total E)
Total 961 - 146 (15.2%) - 345 (35.9%) -
3% 884 77 (8.0%) 135 (15.3%) 11 (7.5%) 344 (38.9%) 1 (0.3%)
5% 830 131 (13.6%) 128 (15.4%) 18 (12.3%) 341 (41.1%) 4 (1.2%)
10% 724 237 (24.7%) 112 (15.5%) 34 (23.3%) 331 (45.7%) 14 (4.1%)
15% 652 309 (32.2%) 107 (16.4%) 39 (26.7%) 325 (49.8%) 20 (5.8%)
20% 580 381 (39.6%) 90 (15.5%) 56 (38.4%) 313 (54.0%) 32 (9.3%)
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high-grade PCa (36%; 345/961). Nevertheless, the MRI-ERSPC-RCs still would have avoided 
25% of unnecessary biopsy procedures in our cohort using a ≥10% high-grade PCa risk 
threshold to biopsy, missing 4% of high-grade PCa. The good discriminative ability of 
the original ERSPC-RCs in our cohort (AUC for high-grade PCa of 0.76 (95%CI 0.71 – 0.80) 
and 0.74 (95%CI 0.69 – 0.79) for ERSPC-RC3+DRE and ERSPC-RC4+DRE, respectively) is 
consistent with the recently reported AUC’s for high-grade PCa of 0.81 and 0.76 for respec-
tively the ERSPC-RC3 and refitted ERSPC-RC4 in the large MRI study of Radtke et al. (26). 
Therefore, risk-based patient selection for mpMRI to avoid unnecessary MRI-scans using 
the original (recalibrated) ERSPC-RCs seems justified (17).
Next to the present study, two recent studies presented new PCa prediction models 
incorporating both clinical and MRI parameters (26, 27). Van Leeuwen et al. constructed a 
model based on data of 393 predominantly biopsy naïve (88%) men undergoing transperi-
neal template mapping biopsies (median 30 cores) incorporating the same parameters as 
used in the MRI-ERSPC-RCs: i.e. PSA, DRE, prostate volume, previous biopsy status, overall 
PI-RADSv1 score and age (27). The model had an AUC for significant PCa, defined as GS 
≥3+4 PCa with >5% grade 4 and/or ≥20% cores positive and/or ≥7 mm of PCa in any core, 
of no less than 0.88 (95%CI 0.85 – 0.92) in the construction cohort and 0.86 (95%CI 0.81 – 
0.92) in a validation cohort of 198 men (27). Similar to the present study, using a significant 
PCa risk threshold to biopsy of ≥10% would have avoided 28% of biopsy procedures in 
the cohort of van Leeuwen et al., missing 3% of insignificant PCa (27). Radtke et al. also 
used the previously mentioned parameters included in the MRI-ERSPC-RCs to fit new risk 
models for any grade and high-grade (GS ≥3+4) PCa based on data of 660 biopsy naïve 
and 355 previously biopsied men who received transperineal template mapping biopsies 
(median 24 cores) + fusion MRI-TBx of all PI-RADSv1 ≥2 lesions (26). In accordance with 
the present study, the risk models of Radtke et al. including PI-RADSv1 and age performed 
significantly better than the probabilities of the original ERSPC-RCs, calculated manually 
per single patient online (www.prostatecancer-riskcalculator.com) (26). However, with de-
cision curve analysis net benefit of these risk models was only observed beyond the ≥10% 
risk threshold for high-grade PCa (26). 
Unlike the newly fitted models presented in the previously mentioned studies (26, 
27), the MRI-ERSPC-RCs are constructed by augmenting the already multiple externally 
validated original ERSPC-RCs. After recalibration, the linear predictor of the original ERSPC-
RCs was included as a covariate together with the overall PI-RADS score and age. The MRI-
ERSPC-RCs do not predict (high-grade) PCa in transperineal template mapping biopsy, but 
rather the more commonly used extended (12-core) TRUS-Bx in combination with MRI-TBx 
in case of PI-RADS ≥3 lesions. Only the 961 who received a TRUS-Bx out of the total cohort 
1353 men were included in the MRI-ERSPC-RCs as the EAU PCa guideline recommends to 
perform both TRUS-Bx and MRI-TBx (in case of suspicious lesions) after the performance 
of a pre-biopsy MRI (15, 16). After external validation, the MRI-ERSPC-RCs will become 
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available for use in clinical practice on the ERSPC-RC website: www.prostatecancer-
riskcalculator.com. 
Strength of our study is the inclusion of data from 5 different institutions (2 countries) 
using different targeted biopsy approaches. This makes our study results more generaliz-
able, although it must be stated that no clear benefit of one targeted biopsy technique 
over another has been shown so far (28). To limit the number of parameters included in 
the MRI-ERSPC-RCs, thereby improving their clinical applicability, the ERSPC-RCs+DRE 
(models without TRUS outcome as a parameter) were augmented instead of the ERSPC-
RCs (models including TRUS outcome as a parameter). Our study has several limitations, 
one being the fact that one third of cases had missing DRE values. These missing DRE 
values were imputed using the (MICE) algorithm. Another limitation is the fact that the 
majority of MRI-scans in our study were graded according to PI-RADSv1 (22), as the time 
period for (MRI-)data collection was predominantly before introduction of the PI-RADSv2 
grading system (23), which might perform slightly better (29). A final limitation is the fact 
that bi-parametric instead of multi-parametric MRI was performed in 1 out of 5 institutions 
with the smallest subcohort (n = 82).
COnCLUSIOn
Multivariable risk-based patient selection for biopsy after mpMRI can avoid unnecessary 
systematic and/or targeted biopsies, even after risk-stratification pre-MRI. In the present 
study we augment the multiple externally validated ERSPC-RC-3 and ERSPC-RC-4 by incor-
porating the overall PI-RADS score and age. The MRI-ERSPC-RC3 and MRI-ERSPC-RC4 have 
improved discriminative ability and application of these models in our cohort of men with 
a high clinical suspicion of PCa would have avoided 25% of biopsy procedures, missing 4% 
of high-grade PCa.
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AbSTRACT 
Objectives: A total of 15 men who died of prostate cancer had cT1/2 biopsy Gleason Score 
≤6 prostate cancer at prevalence screening in the European Randomized study of Screen-
ing for Prostate Cancer Rotterdam. Our objective was to explain (part of ) these prostate 
cancer deaths by undergrading with the classical Gleason score.
Methods: Biopsy specimens of 98 men with classical Gleason score ≤6 or 3+4=7 at preva-
lence screening in the European Randomized study of Screening for Prostate Cancer Rot-
terdam were retrospectively reviewed by two pathologists using the International Society 
of Urological Pathology 2014 modified Gleason score. These 98 men included 15 men 
with cT1/2 classical Gleason score ≤6 who died of prostate cancer (cases) and 83 randomly 
selected men with classical Gleason score ≤6 or 3+4=7 (controls). The primary outcome 
was the reclassification rate from classical Gleason score ≤6 to modified Gleason score 
3+4=7 (grade group 2) stratified for prostate cancer death. The secondary outcome was 
the rate of cribriform/intraductal carcinoma in Gleason score-reclassified men stratified for 
prostate cancer death. 
Results: A total of 79 out of 98 men had classical Gleason score ≤6 prostate cancer. A 
total of 8 out of 15 (53%) prostate cancer deaths with classical Gleason score ≤6 were 
reclassified to modified Gleason score 3+4=7, compared with 16 out of 64 (25%) men with 
non-fatal prostate cancer (p = 0.017). A total of 5 out of 8 (63%) Gleason score-reclassified 
men with fatal prostate cancer had cribriform/intraductal carcinoma, compared with 2 out 
of 16 (13%) Gleason score-reclassified men with non-fatal prostate cancer (p = 0.011).
Conclusions: Part of the prostate cancer deaths with Gleason score ≤6 at prevalence 
screening in the European Randomized study of Screening for Prostate Cancer Rotterdam 
could be explained by biopsy undergrading. This study confirms that the International So-
ciety of Urological Pathology 2014 modified Gleason score is more accurate for prognostic 
assessment based on prostate biopsy than the classical Gleason score.
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InTROdUCTIOn
PSA-based prostate cancer (PCa) screening in the European Randomized study of Screen-
ing for Prostate Cancer (ERSPC) Rotterdam resulted in a 32% PCa-specific mortality reduc-
tion in the core age group of 55 – 69 years (1). During a median follow-up of 12.8 years, 
a total of 151 PCa deaths occurred in the screening arm (1). Remarkably, 22 (14.6%) of 
these 151 PCa deaths were diagnosed with Gleason score (GS) ≤6 PCa on sextant prostate 
biopsy in the prevalence (first) screening round. A total of 15 (68%) out of these 22 fatal 
PCa with GS ≤6 at prevalence screening had cT1/2-stage disease, and thus were classified 
as low-risk. As GS ≤6 PCa on radical prostatectomy (RP) is very unlikely to metastasize (2-4), 
a high-grade tumor component not detected by biopsy is most likely responsible for PCa 
death in these men. The high-grade tumor component could either have been missed 
due to insufficient tumor sampling by random sextant biopsy or due to undergrading of 
the biopsy specimens. Apart from human reading error, undergrading could have been 
caused by insufficiencies in the classical GS (cGS), used to grade the biopsy specimens 
in the prevalence screening round of the ERSPC Rotterdam (1993–1999). In 2005, the 
International Society of Urological Pathology (ISUP) modified GS (mGS) was adopted (5). 
Biopsy grading according to the ISUP 2005 mGS tends to decrease the number of G S≤6 
PCa and increase the number of GS 3+4=7 PCa (6-9). Although challenged by some, it 
has been shown that prognostic prediction based on prostate biopsy is more accurate 
with the ISUP 2005 mGS as compared with the cGS (9-13). Recently, an updated GS was 
proposed based on the ISUP consensus conference in November 2014 (14, 15). The ISUP 
2014 mGS significantly outperforms the ISUP 2005 mGS in terms of prognostic prediction 
(16). Hypothetically, part of the PCa deaths with biopsy GS≤6 at prevalence screening in 
the ERSPC Rotterdam could be explained by undergrading with the cGS. In the present 
study, we compared the reclassification rate from biopsy cGS ≤6 to ISUP 2014 mGS 3+4=7 
(grade group 2) at prevalence screening in men who did or did not die of PCa to assess the 
rate of PCa deaths with GS ≤6 that could be explained by biopsy undergrading.
METHOdS
ERSPC Rotterdam
The study population and protocol of the ERSPC Rotterdam have previously been described 
in detail (17). Starting in 1993, a total of 42.376 men aged 54 – 74 years were randomized 
to a screening or control arm in a 1:1 ratio. In the screening arm, men were offered PSA 
testing with a 4-year interval until the age of 75 years. Random sextant biopsy was initially 
offered to men with a PSA ≥4.0 ng/ml and/or abnormal digital rectal examination (DRE), 
later on it was offered to men with a PSA ≥3.0 ng/ml. The PCa-specific mortality was the 
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primary end-point of the ERSPC. The cause of death was assessed for all men with a PCa 
diagnosis (both in and outside the screening protocol) through linkage with the national 
cancer registry and subsequent patient chart review by an independent monitoring com-
mittee. Death as a result of a PCa intervention-related complication was classified as PCa 
death according to the Causes of Death Committee protocol. The study was approved by 
the institutional ethical review board (MEC 1994-152), and written informed consent with 
guarantee of confidentiality was obtained from the participants. For the current analysis, 
a follow-up until the end of 2012 was used, as follow-up and cause-of-death assessment 
was complete up to and including 2012.
Retrospective consensus review with the ISUP 2014 mGS
Until the end of 2012, a total of 15 men diagnosed with cT1/2 cGS ≤6 PCa in the prevalence 
screening round of the ERSPC Rotterdam (1993 – 1999) died of PCa (1). These men were 
selected as cases for the current case-control study. Subsequently, a computer-assisted 
random selection was performed of 85 controls out of all other men diagnosed at preva-
lence screening with cGS ≤6 or 3+4=7 PCa (n = 963). The randomly selected control group 
consisted of both men with cGS ≤6 and men with cGS 3+4=7, so that the uropathologists 
knew they would not solely review biopsy specimens originally graded as cGS ≤6. In 98 
out of the 100 selected men the biopsy specimens were available for pathological review. 
In the 2 remaining men the biopsy specimens were no longer present in our biorepository. 
The 98 biopsy specimens, originally scored using the cGS, were reviewed independently 
by 2 expert uropathologists (THK, GJL) for grading with the ISUP 2014 mGS. One of the 
uropathologists (THK) originally graded all biopsy specimens during the prevalence 
screening round with the cGS. Both pathologists were blinded for the original cGS (6 or 
3+4=7) and patient outcome during follow-up after the PCa diagnosis. After the patholo-
gists independently graded all biopsy specimens, consensus on the mGS was reached in 
all cases after common re-evaluation and open discussion.  
Statistical analysis
Clinical patient characteristics were compared between men who did or did not die of 
PCa. The interobserver agreement between the pathologists for the mGS (i.e. 6 or ≥3+4=7) 
was assessed both proportionally and with the Cohen’s К statistic. The rates of reclassi-
fication from cGS ≤6 to mGS 3+4=7 (grade group 2) were compared in all 98 men after 
stratification for PCa death, biochemical recurrence (BCR) after initial treatment by RP 
or radiotherapy (RT) and the development of PCa metastasis during follow-up until the 
end of 2012. BCR was defined as 2 consecutive PSA measurements ≥0.2 ng/ml with an 
interval of 2 – 3 months after RP or a PSA ≥2.0 ng/ml above the PSA-nadir after RT. The 
distribution of the grade 4 growth patterns were compared between the GS upgraded 
men who died or did not die of PCa to determine a potentially higher rate of cribriform 
111
6
and/or intraductal carcinoma (IDC) growth in men with fatal disease. Cribriform growth 
and IDC were combined for analysis as both entities are equally associated with poor 
clinical outcome, they often coexist and their morphological distinction is often difficult 
(18). Inter-group comparison of continuous and categorical data was carried out using 
the Mann-Whitney U test and χ2 test, respectively. Statistical tests were 2-sided with the 
criterion of significance set at p <0.05. SPSS for Windows (Version 21.0; IBM, Armonk, NY, 
USA) was used for the statistical analysis.
RESULTS
Patient characteristics at PCa diagnosis
The patient characteristics at diagnosis of the 98 selected men stratified for PCa death are 
shown in table 1. After stratification for PCa death there were no statistically significant 
differences in median age (67.7 vs 68.8 yrs), the proportion of men with a suspicious DRE 
(52% vs 53%) and the proportion of men who received active treatment with curative 
intent (91% vs 94%). The median serum PSA at diagnosis was significantly higher in men 
with fatal PCa (7.6 vs 5.0 ng/ml, p = 0.007). Furthermore, men with fatal PCa had a higher 
number of positive cores at sextant biopsy and higher maximum percentage of cancer 
core involvement. Although not statistically significant, the proportion of men receiving 
immediate RT was higher in the fatal PCa group (65% vs 42%), possibly reflecting higher-
risk disease. In the non-fatal PCa group, 5 men received delayed active treatment after a 
median period of 3.5 yrs (IQR 1.3 – 4.2) of Watchful Waiting (WW): 4 men received RT while 
1 man was treated by RP. Only 1 out of the 15 men with cT1/2 cGS ≤6 and PCa death during 
a median follow-up of 13.7 years (IQR 10.1 – 15.3) did not receive active treatment. Sup-
porting Table 1 depicts the (not-revised) prostatectomy cGS of all 40 men who received 
RP at diagnosis.
Consensus review with the ISUP 2014 mGS
The expert pathologists individually agreed on the ISUP 2014 mGS (i.e. 6 or ≥3+4=7) in 
84 out of 98 (86%) men. There was substantial interobserver agreement with a Cohen’s 
κ of 0.70. After consensus was reached on the mGS in the discordant cases, a total of 24 
out of 79 (30%) men were upgraded from biopsy cGS ≤6 to mGS 3+4=7 PCa (grade group 
2). Biopsy revision of the 19 men with cGS 3+4=7 yielded downgrading to mGS 6 (grade 
group 1) in 2 out of 19 (10.5%) men and upgrading to mGS 4+3=7 (grade group 3) in 2 out 
of 19 (10.5%) men. 
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GS reclassification rates stratified for bCR, metastases and PCa death
After stratification for PCa death, as shown in table 2, the GS reclassification rate from 
cGS ≤6 to mGS 3+4=7 was significantly higher in men with fatal PCa (53%) in comparison 
with men who did not die of PCa (25%, p = 0.017). Table 3 shows that 26 out of 85 (31%) 
men who were treated at diagnosis developed BCR during a median PSA follow-up of 
8.9 yrs (IQR 5.6 – 12.9). Although statistically insignificant, the GS reclassification rate was 
higher in men who developed BCR (40%) as compared with men who did not (26%). The 
GS reclassification rate was also higher in men who developed PCa metastasis (46%) as 
compared with men who did not (27%, p = 0.129). As 2 men died of a PCa intervention-
related complication before clinical metastases occurred, the number of PCa deaths (17) 
was higher than the number of men who developed PCa metastases (15). One man died 
of a cardiovascular complication that was initiated by RP. The other man had castration-
Table 1. Clinical patient characteristics. 
no Prostate cancer death
(81 controls)
Prostate cancer death
(15 cases + 2 controls)
Median IQR Median IQR p-value
Age at diagnosis (years) 67.7 62.0 – 70.8 68.8 63.1 – 71.6 0.306
PSA  at diagnosis (ng/ml) 5.0 3.6 – 7.6 7.6 4.9 – 21.5 0.007
Maximum Cancer Core 
Involvement (%)
20 10 – 60 50 20 – 80 0.092
n % n % p-value
Suspicious dRE 42 52 9 53 0.935
T-stage T1C 39 48 8 47 0.666
T2A 23 28 6 35
T2B 6 7 2 12
T2C 13 16 1 6
number positive cores 1 25 31 3 18 0.036
2 29 36 5 29
3 14 17 1 6
≥4 13 16 8 47
Classical Gleason Score ≤6 64 79 15 88 0.382
3+4=7 17 21 2 12
Active treatment 74 91 16 94 0.706
RP 35 43 5 29
RT 34 42 11 65
Delayed RP/RT after WW 5 62 0 0
Watchful Waiting 7 9 1 6 0.706
Total no. of men 81 100 17 100
PSA = prostate-specific antigen, DRE = digital rectal examination, RP = radical prostatectomy, RT = radiotherapy, 
WW = Watchful Waiting, IQR = Interquartile range
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resistant PCa without clinical metastases, but died after an endoscopic intervention for 
refractory hematuria caused by radiation cystitis. 
Table 2. Classical vs. Modified Gleason score after stratification for prostate cancer death. 
ISUP 2014 Modified Gleason score % reclassification of 
classical GS*
6 (G1) 3+4=7 (G2) 4+3=7 (G3) Total
Cl
as
si
ca
l G
le
as
on
 s
co
re
no Prostate cancer death (n=81)
≤ 6 48 16 0 64 25%
3+4=7 2 14 1 17 18%
Total 50 30 1 81 24%
Prostate cancer death (n=17)
≤ 6 7 8 0 15 53%
3+4=7 0 1 1 2 50%
Total 7 9 1 17 53%
*Reclassification can be both up- or downgrading
ISUP = International Society of Urological Pathology, GS = Gleason Score, G = Grade group
Table 3. Classical vs. Modified Gleason score after stratification for biochemical recurrence and prostate 
cancer metastasis.
ISUP 2014 Modified Gleason score % reclassification of 
classical GS*
6 (G1) 3+4=7 (G2) 4+3=7 (G3) Total
Cl
as
si
ca
l G
le
as
on
 s
co
re
no biochemical recurrence after initial curative therapy (n=59)
≤ 6 34 12 0 46 26%
3+4=7 2 11 0 13 15%
Total 36 23 0 59 24%
biochemical recurrence after initial curative therapy (n=26)
≤ 6 12 8 0 20 40%
3+4=7 0 4 2 6 33%
Total 12 12 2 26 38%
no Prostate cancer metastasis (n=83)
≤ 6 48 18 0 66 27%
3+4=7 2 14 1 17 18%
Total 50 32 1 83 25%
Prostate cancer metastasis (n=15)
≤ 6 7 6 0 13 46%
3+4=7 0 1 1 2 50%
Total 7 7 1 15 47%
*Reclassification can be both up- or downgrading
ISUP = International Society of Urological Pathology, GS = Gleason Score, G = Grade group
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distribution of grade 4 growth patterns in GS reclassified men
Table 4 shows the distribution of the grade 4 growth patterns in all men with mGS ≥ 3+4=7 
(grade group 2). The most common growth patterns in GS reclassified men were fused 
glands (17/24 men) and ill-formed glands (15/24 men). All men with IDC also had cribri-
form growth in their biopsy specimen. GS reclassified men with fatal PCa had significantly 
more cribriform/IDC growth as compared with men who did not die of PCa (63% vs 13%, 
p = 0.011). 
Table 4. Distribution of grade 4 growth patterns in men reclassified to modified Gleason score 3+4=7.
Reclassified from cGS ≤ 6 to ISUP 2014 mGS 3+4=7
no Prostate cancer death Prostate cancer death
n % n % p-value
Ill-formed 10 63 5 63 1.000
Fused 10 63 7 88 0.204
Glomeruloid 1 6 1 13 0.602
Cribriform 2 13 5 63 0.011
IDC 2 13 4 50 0.046
Cribriform / IDC 2 13 5 63 0.011
No. of men 16 100 8 100
median IQR median IQR p-value
% grade 4 7.5 5.0 – 27.5 15.5 8.0 – 20.0 0.256
cGS = classical Gleason score, ISUP = International Society of Urological Pathology, mGS = modified Gleason 
score, IDC = intraductal carcinoma, IQR = interquartile range 
dISCUSSIOn
Although GS ≤6 PCa on RP is very unlikely to metastasize (2-4) a substantial number of 15 
PCa deaths in the ERSPC Rotterdam were men diagnosed at prevalence screening with 
cT1/2 biopsy cGS ≤6 PCa (1). A high-grade tumor component not detected by (initial) 
pathological review of the biopsy specimens is most likely to be responsible for the PCa 
death in these men. As all but one of these men received active treatment, the main expla-
nations for the “missed” high-grade tumor component could either be insufficient tumor 
sampling by sextant biopsy or undergrading of the biopsy specimens. In the present 
study, we showed that the reclassification rate from cGS ≤6 to mGS 3+4=7 (grade group 2) 
was significantly higher in men with fatal PCa (53%) compared with men who did not die 
of PCa (25%). This shows that a substantial part of the PCa deaths with GS ≤6 at prevalence 
screening in the ERSPC Rotterdam could be explained by biopsy undergrading. 
In the ISUP 2005 mGS and subsequently the ISUP 2014 mGS the definition of Gleason 
pattern 3 was further specified, moving some architectural patterns from Gleason pattern 
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3 to the pattern 4 category, and as a consequence the definition of pattern 4 is expanded, 
causing a shift of PCa graded as biopsy GS ≤6 towards GS 3+4=7 (14, 19). After revision of 
biopsy specimens, upgrading to ISUP 2005 mGS 3+4=7 occurs in 19–45% of men originally 
diagnosed with cGS ≤6 (6-9). The upgrading rate of 30% in our study is in line with these 
previous findings. To our knowledge, we are the first to report on a higher GS upgrad-
ing rate in men who died of PCa. Although statistically not significant, the GS upgrading 
rate also tended to be higher in the present study in men who developed BCR and PCa 
metastasis. Previous studies reported on the superior prognostic prediction of the biopsy 
ISUP 2005 mGS as compared with the cGS, both for BCR after RP (9-11) and for PCa-specific 
survival in men on WW (12). Recent evidence suggests further improvement of prognostic 
prediction with the biopsy ISUP 2014 mGS (16). The findings of our study support that 
the ISUP 2014 mGS is a more accurate tool for prognostic assessment based on prostate 
biopsy than the cGS. As the main goal of the present study was to explain (part of ) the 
PCa deaths in the ERSPC Rotterdam with GS ≤6 at prevalence screening by undergrading 
with the cGS, our study was not designed for a comparison between grading with the ISUP 
2005 mGS and the ISUP 2014 mGS.
Although enabling a more accurate prognostic prediction, upfront grading with the 
ISUP 2014 mGS probably would not have affected the PCa death rate in our cohort from 
the pre-active surveillance era as 90 out of 98 (92%) men received active treatment with 
curative intent. Nowadays, active surveillance is increasingly implemented in biopsy GS ≤6 
PCa. As the oncological safety of Active Surveillance in men with (limited) Gleason pattern 
4 is not yet proven it is essential to select only those men with low-grade disease (20). 
The mGS, that was implemented ever since the rise of active surveillance as a treatment 
modality, probably allows a superior patient selection for active surveillance as compared 
with the cGS. In the near future, patients with (limited) Gleason pattern 4 could be selected 
for active surveillance based on the grade 4 growth pattern. Cribriform growth and IDC 
in prostate biopsy have been shown to be equally associated with a poor cancer-specific 
survival as compared with men without cribriform/IDC growth (18). The present study 
confirmed cribriform/IDC growth as a risk factor for PCa death, with a higher rate of 
cribriform/IDC growth in GS reclassified men with fatal PCa. Cribriform growth and IDC 
were combined for analysis as both entities often coexist and can be hard to distinguish. 
Combining cribriform growth and IDC does not alter the prognostic value and morpho-
logical distinction between the separate entities by additional immunohistochemistry is 
no longer needed. 
Besides biopsy undergrading, undersampling by sextant biopsy is probably the most 
important cause of “missed” high-grade tumor components in the fatal PCa with GS ≤6 at 
prevalence screening. Extended systematic biopsy core schemes increase the PCa detec-
tion rate by a factor of 1.3 (21). Systematic biopsy insufficiently samples anterior tumors 
(22, 23), not only leading to underdetection but also undergrading of tumors. Upgrading 
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of biopsy GS ≤6 on RP occurs in approximately 40% of cases (24, 25). In our cohort a total of 
7 men with cT1/2 cGS ≤ 6 and PCa death were not reclassified with the mGS. Three of these 
men were treated by RP. As shown in supplementary table 1, all 3 had a high-grade tumor 
component in the RP specimen (cGS 5+4, 3+5 and 4+3), indicating insufficient tumor 
sampling by random sextant biopsy. The development of a high-grade tumor component 
after the initial diagnosis during WW could not be responsible for the PCa death in the 15 
men with cT1/2 cGS ≤6, since all but one of these men received active treatment (5 RP and 
9 RT).
Besides grading with the ISUP 2014 mGS, GS upgrading could be caused by a general 
shift upwards of the perception of patterns (Gleason inflation) after the introduction of 
the mGS. Furthermore, pathological (double reading) revision of the biopsy specimens 
with correction of initial diagnostic errors could also yield GS upgrading. Highly variable 
levels of intraobserver (43 – 78%) and interobserver (36 – 81%) agreement of the GS have 
been reported (26-28). The 86% interobserver agreement in our study is in line with the 
approximately 80% interobserver agreement found in most studies using the mGS [10]. 
In the present study, consensus review was only carried out for the mGS. However, we 
would not expect a variation of interobserver cGS variability between subgroups after 
stratification for PCa death, nor would we expect a variation in Gleason inflation. Thus, the 
difference in the rate of upgrading to mGS 3+4=7 between men who did and did not die 
of PCa in our cohort is most likely primarily based on undergrading with the cGS.
The strength of this study lies in the double reading of the biopsy specimens and the ac-
curate long-term follow-up. However, as we only had follow-up until the end of 2012, more 
PCa deaths might have occurred in our cohort afterwards. The present study is also limited 
by the fact that our small cohort included only a fraction of all cGS 3+3 and 3+4 PCa in the 
prevalence screening round of the ERSPC Rotterdam. Finally, the sextant prostate biopsy 
performed in our cohort detects less (significant) PCa as compared with extended biopsy 
core schemes used in current clinical practice. 
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SUPPLEMEnTARY MATERIAL
Supporting table 1. (Not-revised) Classical Gleason score of the Radical Prostatectomy specimens at initial 
diagnosis stratified for Prostate Cancer Death.
Radical Prostatectomy Classical Gleason score
≤ 6 ≥ 3+4=7 Total
bi
op
sy
 M
od
ifi
ed
 G
le
as
on
 
sc
or
e
no Prostate cancer death (n=35)
6 22 0 22
≥ 3+4=7 7 6 13
Total 29 6 35
Prostate cancer death (n=5)
6 0 3 3
≥ 3+4=7 2 0 2
Total 2 3 5

 Chapter 7
Compliance rates with the Prostate 
Cancer Research International: 
Active Surveillance (PRIAS) protocol 
and disease reclassifi cation in 
noncompliers. 
Leonard P. Bokhorst, Arnout R. Alberts, Antti Rannikko, 
Riccardo Valdagni, Tom Pickles, Yoshiyuki Kakehi, 
Chris H. Bangma, Monique J. Roobol, for the 
PRIAS study group.
EUROPEAN UROLOGY (2015) 6 8, 8 1 4 – 8 2 1
122
AbSTRACT
Background: Men with prostate cancer on active surveillance are advised to follow strict 
follow-up schedules and switch to definitive treatment if risk reclassification occurs. How-
ever, some men might not adhere to these strict protocols. 
Objective: To determine the number of non-compliers and disease reclassification rates in 
men not complying with the follow-up protocol of the Prostate cancer Research Interna-
tional: Active Surveillance (PRIAS) study.  
Design, setting, and participants: 4547 men with low-risk prostate cancer were included 
and prospectively followed on active surveillance. Men were regularly examined using 
PSA, DRE, and repeat biopsies and advised to switch to definitive treatment if disease 
reclassification occurred (>cT2c, Gleason score >3+3, >2 cores positive, or PSA-doubling 
time (PSA-DT) 0-3 year). 
Outcome measurements and statistical analysis: Rates of men not complying with the 
follow-up visits or recommendation to discontinue active surveillance were reported. 
Biopsy outcome (Gleason score >=7 or > 2 cores positive) between compliers and non-
compliers was compared using cox proportional hazard analysis.  
Results and limitations: The compliance rate with PSA visits was 91%. In contrast compli-
ance rates with standard repeat biopsies decreased over time (81%, 60%, 53%, and 33% 
for 1, 4, 7, and 10 years after diagnosis respectively). Yearly repeat biopsies in men with 
faster rising PSA (PSA-DT 3-10 year) was low at less than 30%, although these men had 
higher upgrading rates at repeat biopsy (25-30% versus 16%). A PSA-DT of 0-3 year was 
the most common recommendation to discontinue, nevertheless 71% continued active 
surveillance. Men with PSADT 0-3 year were at higher risk of upgrading on repeat biopsy 
(HR 2.02; 95% CI 1.36-3.00) as compared to men without fast rising PSA.
Conclusion: Some men and their physician do not comply with an active surveillance 
follow-up protocol. Especially yearly repeat biopsies in men with fast rising PSA, are often 
ignored, as is the recommendation to discontinue active surveillance due to a very fast 
rising PSA. Although these men are at increased risk of having higher Gleason scores on 
repeat biopsy, the majority still presents favorable tumor characteristics. A fast rising PSA 
should therefore not be a recommendation to advice active treatment, but should rather 
serve as a criterion for stricter follow-up. In addition, we should aim to find ways of safely 
reducing the amount of biopsies to increase adherence to active surveillance protocols.   
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Patient summary: In this report we looked at the compliance with a large active surveil-
lance protocol for low risk prostate cancer. We observed reluctance with yearly biopsies 
due to a fast rising PSA, despite a higher risk of disease progression. Further research 
should aim to safely reduce the amount of repeat biopsies in men on active surveillance, 
to increase protocol adherence.  
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InTROdUCTIOn
Active surveillance for prostate cancer is a treatment option aimed at reducing the nega-
tive side effects of radical treatment, while at the same time preserving the option for cura-
tive treatment. It does so by strictly following men and only offering curative treatment to 
those that show signs of disease progression / reclassification. However, optimal criteria 
for follow-up, inclusion and exclusion are currently still being investigated. Most common 
protocols include criteria based on a combination of PSA tests, digital rectal examinations 
(DRE), and repeated prostate biopsies to both include patients and define disease reclas-
sification (1-6). Some men and their physicians might however choose to deviate from 
these strict protocols, ignoring either the follow-up schedule or the advice to switch to 
curative treatment.  
The aim of the current analysis is to determine the number of men who do not comply 
with the protocol of the Prostate cancer Research International: Active Surveillance (PRIAS) 
study. The PRIAS study is currently the largest prospective study on active surveillance, 
including over 100 centers in 17 countries aimed to represent a real world situation (1). 
Furthermore, follow-up of men not complying with the approved protocol allows us to 
evaluate the protocol by investigating their intermediate term outcomes (i.e. Gleason 
score upgrading at repeat biopsy). 
PATIEnTS And METHOdS
In the PRIAS study men with low risk prostate cancer are prospectively followed on active 
surveillance (7). All centers enter data on inclusion and follow-up trough an online tool 
(www.prias-project.org), which automatically provides all recommendations for follow-up 
based on the protocol (7). Criteria for inclusion are: Gleason score <=3+3, <=cT2c, PSA 
<=10ng/ml, <= two cores positive for prostate cancer, PSA density <=0.2ng/ml/ml, and 
fitness for curative treatment. A minimum number of biopsy cores taken is advised based 
on prostate volume (prostate volume <40cm3: 8 cores, 40-60cm3: 10 cores, >60cm3: 12 
cores), but is not a strict inclusion criterion. As of 2012 men with minimal Gleason score 
3+4 disease (<=10% core involvement) can be included if aged >=70 year (n=24)(for 
follow-up all regular criteria apply except for Gleason score, which can be 3+4 on repeat 
biopsy). 
Men are followed using PSA testing every 3 months the first 2 years and every 6 months 
thereafter. Digital rectal examination is advised every 6 months the first 2 years and every 
year thereafter. Repeat biopsies are done 1,4,7,10, and subsequent every 5 years after di-
agnosis. Yearly repeat biopsies are only advised if PSA doubling time (PSA-DT) is between 
3 and 10 years. PSA-DT is calculated using all available PSA values since diagnosis by plot-
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ting the base 2 logarithm of the PSA values against the time since diagnosis. The PSA-DT 
is then calculated as the reciprocal value of the slope of the regression line through these 
points. PSA-DT is only used if at least 4 PSA values are available. A bone scan is recom-
mended if PSA >=20ng/ml. Criteria used to recommend a switch to definitive treatment 
are: Gleason score >3+3, >2 biopsy cores positive for prostate cancer, >cT2c, and a PSA-DT 
of 0-3 year (if at least 4 PSA values are available) on any of the follow-up visits (figure 1). 
Follow-up for the current analysis ended 31 December 2014.  
Figure 1A. Follow-up schedule of the PRIAS study
Figure 1b. Active surveillance: criteria for follow-up (old protocol until 2015)
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Compliance with the follow-up schedule was studied per year of being on active surveil-
lance. Men were defined as being compliant with the PSA visits if in the first 2 years at least 
3 PSA tests were done per year and at least 1 PSA test in the years thereafter. A biopsy 6 
months before or after the designated time for the biopsy was classified as being compli-
ant with that biopsy. Standard biopsies should have been done in year 1, 4, 7, and 10 in 
men with >1.5, >4.5, >7.5, and >10.5 years of follow-up respectively to classify as being 
compliant. Men with a PSA-DT of 3-10 years within the years with no scheduled standard 
repeat biopsy (years 2, 3, 5, 6, 8, 9 after inclusion, see figure 1) should have had a biopsy in 
that year. Two definitions were used for non-compliance with a protocol based reason to 
Figure 1C. Active surveillance: criteria for follow-up (new protocol)
Figure 1 – (A) Follow-up schedule for the PRIAS study. Month 0 represents the time of diagnosis. Rbx 
is standard after 1, 4, 7, and 10 yr, and every 5 yr thereafter. If PSA-dT is 0–10 yr, Rbx every year is ad-
vised. no more than one biopsy per year should be performed. (b,C) Follow-up criteria for the PRIAS 
study (b) up to 2015 and (C) after 2015. PRIAS = Prostate Cancer Research International Active Surveillance; 
PSA = prostate-specific antigen; DRE = digital rectal examination; RBx = repeat biopsy; PSA-DT = PSA doubling 
time; PCa = prostate cancer. 
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discontinue active surveillance: at least 1 PSA visit or at least 1 biopsy after the protocol 
recommendation to discontinue.  
Statistical analysis
Upgrading in men not complying with a recommendation to biopsy
The number of men with upgrading (Gleason score >6 or >2 cores positive) on the second 
standard repeat biopsy (year 4) was compared for men without a PSA-DT between 3 and 
10 in the second and third year and men with a PSA-DT between 3 and 10 during that 
period, but who did not receive an early repeat biopsy, using the Chi-square test. In addi-
tion, a comparison was made with the number of men with upgrading on repeat biopsy in 
year 2 or 3 triggered by a PSA-DT between 3 and 10. For equal comparison all men had the 
first scheduled repeat biopsy in year 1. 
Upgrading in men not complying with a recommendation to discontinue
As the number of previous biopsies during follow-up could influence upgrading rates we 
only reported upgrading rates on the second repeat biopsy during follow-up for men who 
ignored a recommendation to discontinue active surveillance on the first repeat biopsy 
during follow-up (either Gleason score >6 or > 2 cores positive) or ignored a recommenda-
tion to discontinue in-between the first and second repeat biopsy (due to a PSA-DT of 0-3 
year). As comparison, upgrading rates on the second repeat biopsy during follow-up for 
men without a previous recommendation to discontinue were reported. As time between 
the first two biopsies could differ between these groups we conducted a cox proportional 
hazard analysis with correction for age, PSA and number of positive cores at the first repeat 
biopsy and PSA density at diagnosis to predict upgrading on the second repeat biopsy. For 
this analysis PSA-DT 0-3 was assumed to be at the time of the first repeat biopsy, as most 
PSA-DT 0-3 occurred within 1 year of the first repeat biopsy (8). For all analysis SPSS for 
windows (Version 21.0. Armonk, NY: IBM Corp.) was used. 
RESULTS
Until the end of follow-up 4547 men were included and followed on active surveillance 
in the PRIAS study. As inclusion and follow-up is still ongoing, the median time on active 
surveillance for all men was only 1.5 years, but 750 men were followed for more than 4 
years and 94 men for more than 7 years. 
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Compliance with PSA and biopsy visits
During follow-up 91% of patients complied with all PSA visits. After year 7 a slight decrease 
in compliance with the scheduled PSA visits was seen (figure 2). The rate of compliance 
with all advised biopsy visits was lower at 70%. Compliance rates with the standard biop-
sies (year 1, 4, 7, and 10) decreased over the years with 1867/2306 men (81%) complying 
with the 1 year repeat biopsy, 333/559 (60%) with the 4 year repeat biopsy, 27/51 (53%) 
with the 7 year repeat biopsy, and 1/3 men (33%) with the 10 year repeat biopsy. Overall 
compliance rates with the yearly repeat biopsies due to a PSA-DT of 3-10 years was low 
ranging from 226/702 men (24%) in year 2 to 1/11 men (9%) in year 8 (figure 2). Of 750 
men with more than 4 years of follow-up, 222 (30%) complied with all advised biopsies. 
Men with a biopsy advise in year 2 or 3 (due to a PSA-DT of 3-10 years) who did not 
comply, more often had upgrading (Gleason >6 and/or >2 cores positive) on repeat biopsy 
at year 4, as compared to men without a PSA-DT of 3-10 years in year 2 or 3 (25% versus 
16% respectively, p=0.028). Men with a PSA-DT of 3-10 in year 2 and 3 who did have a 
biopsy in year 2 or 3, were upgraded in 27% and 30% of cases respectively (table 1). In year 
7 50 men had a repeat biopsy. Of the 22 men that fully complied with the biopsy protocol 
1 (5%) had a Gleason score >=7. Of the 28 that did not fully comply, 5 (18%) had a Gleason 
score >=7 (p=0.15). 
Figure 2. Percentage of men complying with prostate-specific antigen (PSA) testing and prostate 
biopsies among men on active surveillance per year (standard repeat biopsies are highlighted).
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Compliance with recommendation to discontinue active surveillance
During follow-up 10 men had clinical stage >=T3 of which 2 continued AS (20%), 535 men 
had a Gleason score  >6 at any repeat biopsy of which 96 continued AS (18%), 734 men 
had >2 cores positive for prostate cancer at any repeat biopsy of which 175 continued 
AS (24%), and 915 men had a PSA-DT of 0-3 year of which 651 continued AS (71%). The 
percentage of men continuing active surveillance were lower if a stricter definition was 
used (figure 3). Of all men who continued active surveillance despite a recommendation 
to discontinue 329 out of 839  (varying from 245/651 for PSA-DT of 0-3 year to 1/2 for 
clinical stage >=T3) eventually switched of active surveillance after a median follow-up of 
1.0 year after their recommendation to discontinue, and 510 out of 839 are still on active 
surveillance for a median of 1.7 year. 
Table 1. Outcome in men complying and not complying with advice to undergo prostate biopsies.
Group 1* Group 2* Group 3* Group 4*
biopsies during follow-
up
PSA-dT 
3-10
bx PSA-dT 
3-10
bx PSA-dT 
3-10
bx PSA-dT 
3-10
bx
   Year 1 Yes Yes Yes Yes
   Year 2 Yes No No - Yes Yes No -
   Year 3 Yes No No - Yes Yes
   Year 4 Yes Yes
Age at diagnosis, 
median (IQR)
64.9 (61.3-69.9) 65.9 (60.2-70.7) 64.4 (60.3-69) 64.5 (59.4-70.3)
PSA at diagnosis, 
median (IQR)
5.1 (3.6-6.4) 5.7 (4.4-7.5) 5.4 (4.4-6.6) 5.5 (4.4-6.9)
Outcome prostate 
biopsy in:
Year 4 Year 4 Year 2 Year 3
   no prostate cancer 58 (43%) 101 (47%) 61 (33%) 44 (37%)
   Gleason ≤6 56 (42%) 97 (45%) 100 (54%) 57 (48%)
   Gleason 3+4 15 (11%) 10 (5%) 18 (10%) 12 (10%)
   Gleason 4+3 3 (2%) 5 (2%) 3 (2%) 2 (2%)
   Gleason ≥8 2 (1%) 2 (1%) 4 (2%) 5 (4%)
   >2 cores positive 23 (17%) 25 (12%) 42 (23%) 28 (23%)
   Gleason >6 or >2 cores 
positive
34 (25%)a 34 (16%) 51 (27%) 36 (30%)
Total 134 (100%) 215 (100%) 186 (100%) 120 (100%)
*For comparison all men had a biopsy in year 1 and:
Group 1: Non-compliers: no biopsy in year 2 or 3 despite PSA-DT of 3-10 year in year 2 or 3
Group 2: Compliers: no recommendation for biopsy in year 2 or 3
Group 3: Compliers: PSA-DT of 3-10 year in year 2 and a biopsy in year 2
Group 4: Compliers: PSA-DT of 3-10 year in year 3 and a biopsy in year 3
a: p = 0.028 versus group 2. 
PSA-DT = prostate-specific antigen doubling time; Bx = biopsy; IQR: interquartile range.
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Men who continued active surveillance, and subsequently had a second repeat biopsy, 
despite >2 cores positive for prostate cancer or a PSA-DT of 0-3 year more often had a 
Gleason score >6 (15% and 16% respectively), as compared to men without a recommen-
dation to discontinue (11%, table 2). After correction for other variables and time between 
biopsies, both a PSA-DT between 0-3 and >2 cores positive on first repeat biopsy were 
significant predictors of upgrading on the second repeat biopsy (table 3). 
Table 2. Outcome of second repeat biopsy in men continuing active surveillance despite protocol 
advice to switch to active treatment either at the first repeat biopsy (Gleason >6, >2 cores positive) 
or between first and second repeat biopsy (PSA-dT ≤3 year), compared with men adhering to the 
protocol (no protocol based reason to discontinue).
no protocol advice 
to discontinue
Continuation despite protocol advice
biopsies during follow-
up
PSA-dT 0-3 year a >2 cores 
positive with 
PCa b
Gleason score 
>6 b
   Year 1 1st Bx 1st Bx 1st Bx 1st Bx
   Year 2, 3, or 4 2nd Bx 2nd Bx 2nd Bx 2nd Bx
Age at diagnosis, 
median (IQR)
64.7 (59.8-69.5) 64.5 (60.6-69.9) 65.9 (59.9-70.3) 68.4 (62.1-71.5)
PSA at diagnosis, 
median (IQR)
5.6 (4.3-7) 5.1 (3.6-6.4) 4.9 (3.5-6.6) 5.6 (5-7.3)
Time from first to 
second repeat biopsy, 
median (IQR)
2.2 (1.1-3.0) 1.5 (1.0-2.9) 1.3 (1.0-2.9) 0.5 (0.5-1.9)
Time between PSA-dT 
0-3 and second repeat 
biopsy, median (IQR)
- 1.4 (1.0-2.6) - -
Outcome second repeat 
biopsy
   no PCa 267 (43%) 81 (37%) 4 (12%) 1 (8%)
   Gleason ≤6 283 (46%) 103 (47%) 24 (73%) 4 (33%)
   Gleason 3+4 45 (7%) 21 (10%) 2 (6%) 6 (50%)
   Gleason 4+3 10 (2%) 6 (3%) 1 (3%) 0 (0%)
   Gleason ≥8 11 (2%) 8 (4%) 2 (6%) 1 (8%)
   >2 cores positive 83 (13%) 12 (5%) 15 (45%) 5 (42%)
   Gleason >6 or >2 cores 
positive
120 (19%) 64 (29%) 18 (55%) 7 (58%)
Total 616 (100%) 219 (100%) 33 (100%) 12 (100%)
a In year 1, 2, 3 or 4.
b In year 1.
Bx = biopsy; PSA = prostate-specific antigen; PSA-DT = PSA doubling time; IQR = interquartile range; PCa: pros-
tate cancer
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Figure 3. Percentage of men not complying with protocol reasons for discontinuation of active sur-
veillance. 
Table 3. Multivariable cox proportional hazards model predicting upgrading (Gleason >6 and/or >2 
cores positive) at the second repeat biopsy during follow-up.
HR (95% CI) p-value
Age first repeat biopsy 1.00 (0.98 – 1.02) 0.9
PSA first repeat biopsy 1.00 (0.93 – 1.07) >0.9
PSA second repeat biopsy 1.05 (0.99 – 1.11) 0.078
PSA density at diagnosis (0.1 increase) 1.26 (0.88 – 1.82) 0.2
Gleason >6 first repeat biopsy (but continued active surveillance) 3.59 (1.62 – 7.98) 0.002
number of positive cores first repeat biopsy <0.001
   0 Reference
   1 2.12 (1.48 – 3.03) <0.001
   2 3.19 (2.22 – 4.59) <0.001
   ≥3 (but continued active surveillance) 4.32 (2.43 – 7.66) <0.001
PSA-dT between first and second repeat biopsy 0.002
   Always >10 years or negative Reference
   At least once from 10-3 years 1.45 (1.02 – 2.08) 0.039
   At least once from 3-0 years (but continued active surveillance) 2.02 (1.36 – 3.00) <0.001
HR = hazard ratio; CI = confidence interval; PSA = prostate-specific antigen; PSA-DT: PSA doubling time
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dISCUSSIOn
The PRIAS study is currently the largest active surveillance study worldwide. It was aimed 
to provide a real world representation of active surveillance outside the more strictly con-
trolled academic centers, by including both academic, non-academic and private practices 
across 17 countries and 4 continents. We observed a substantial proportion of men who 
did not comply with the repeat biopsies schedule. Especially the yearly biopsies due to 
a faster rising PSA were often ignored. PSA kinetics were in addition regularly put aside 
as recommendation to discontinue active surveillance. Both men ignoring the follow-up 
schedule and criteria for discontinuation of active surveillance were at increased risk of 
disease upgrading. Although a substantial number still presented with favorable disease 
characteristics on repeat biopsy.   
We observed a clear decrease over time in the percentage of men receiving the stan-
dard repeat biopsies, from 81% in the first year, 60% and 53% in the fourth and seventh 
year, to 33% in the tenth year of follow-up. Although not recorded as standard, several 
common reasons for not complying with these standard repeat biopsies were recorded. 
Some examples included “patient does not want biopsy”, “PSA stable”, “no signs of disease 
progression on previous biopsy” or “complications on last biopsy”. This seems to indicate 
that the repeat biopsies might put a substantial strain on men. As compared to PSA test-
ing, which was most often strictly complied with, biopsies are considered uncomfortable. 
In addition, several complications are recorded such as pain, hematuria, or even sepsis (9). 
These complications will result in some men declining repeat biopsies (10). Furthermore, 
increasing age (median age at diagnosis, 4, 7, and 10 year was 65.8, 69.5, 72.2, and 76.0 
respectively) or previous negative biopsies combined with unchanging PSA values, might 
reassure both physicians and patients of stable disease which might not become clinically 
significant. This assumptions seems to be confirmed by biopsy results in men with a nega-
tive PSA-DT or a PSA-DT >10 years. In these men a biopsy 4 years after diagnosis showed 
Gleason score >6 in only 8% (group 2, table 1). This questions whether yearly biopsies for 
everyone, as used in some active surveillance studies (2, 11, 12), are justified. As active 
surveillance is primarily aimed at reducing the side effects of aggressive treatment to 
improve quality of life, one might argue that the small portion of men that might benefit 
from yearly biopsies does not outweigh the additional burden and its possible reduction 
of quality of life. Especially in men with a slow rising PSA (PSA-DT negative of >10 years) 
the risk of upgrading was low, which could trigger some patients and their physicians to 
switch to a watchful waiting strategy, avoiding further biopsies.   
Men with a PSA-DT of 3-10 year do seem to have a higher risk of having higher grade 
and extent of disease. In year 2 and 3 approximately 30% of men with a biopsy due to a 
PSA-DT of 3-10 year were upgraded (Gleason >6 or >2 cores positive). Men who ignored 
the biopsy advise in year 2 or 3 seemed to have a similar rate of upgrading if biopsied 
133
7
in year 4. This indicates that for 10-15% of men ignoring the recommendation to have 
a repeat biopsy based on PSA kinetics, upgrading is delayed by 1-2 year. Despite the 
increased risk, which was published before (1, 13), many men do not have yearly biopsies. 
It seems important that during theoretical design of active surveillance follow-up sched-
ules, practical adoption and compliance should not be disregarded. Instead we need to 
develop follow-up schedules that are acceptable to those who follow it. Less harmful ways 
of monitoring tumor progression, such as MRI (14), might be incorporated in the protocol 
design to improve compliance. In the PRIAS study we initiated a side study to investigate if 
replacing yearly biopsies in men with fast rising PSA by MRI with targeted biopsies in case 
of visible tumor progression could substantially reduce the amount of biopsies (protocol 
available on www.prias-project.org). Even if such an approach will delay active treatment 
for some, the reduced strains of follow-up might outweigh the harms.
  Of the 4 protocol based recommendations to discontinue active surveillance, a PSA-DT 
for 0-3 year occurred most frequently. At the same time this was the recommendation 
most often ignored. More than 70% of men (or perhaps more likely their physicians) 
did not comply with the recommendation to discontinue active surveillance. More men 
presented with a Gleason score >6 in this group as compare to men not having a PSA-DT 
of 0-3 years. The higher risk of upgrading remained after correction for other variables. 
This correlation between PSA-DT and biopsy outcome was reported before in the PRIAS 
study (1, 13), but not in another study (15). Differences could be due to variances in study 
population or to the relatively small numbers in the later study (15). If looked at the out-
come on radical prostatectomy of men who did discontinue active surveillance, 29% of 
men who discontinued due to a low PSA-DT only had unfavorable outcomes (defined as 
Gleason >=4+3 or cT3-4 disease)(16). Low PSA-DT was also found to be a strong predic-
tor of biochemical recurrence after radical treatment (6). However, despite these higher 
risks, a substantial part of men still had favorable disease characteristics. As many men 
might thus be excluded from active surveillance without having true unfavorable disease, 
and many men and their physicians did not follow the advice to discontinue, the recom-
mendation to discontinue active surveillance if PSA-DT is 0-3 years was removed from the 
PRIAS protocol as of 2015 (see figure 1 for new follow-up schedule). Instead more frequent 
(yearly) repeated biopsies, preferably sampling the anterior transition zone, are advised as 
with a PSA-DT of 3-10 years. If available and MRI with targeted biopsies could be done to 
rule out large anterior tumors in men with fast rising PSA.  
Another recommendation to discontinue active surveillance that occurred frequently 
and was sometimes ignored was >2 cores positive for prostate cancer. These men had 
higher rates of Gleason score >6 at repeat biopsy than men with only 1 or 2 cores positive. 
However, a previous analysis indicated that a substantial part of men had Gleason 6 pros-
tate cancer if subsequently treated with radical prostatectomy (16). As metastasis in men 
with true Gleason 6 disease, irrespective of tumor volume, seems very rare (17, 18), the 
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number of cores positive for prostate cancer might currently only function as a surrogate 
for higher grade disease. If targeted biopsies could (partially) eliminate this undergrading 
problem, determining the extent of the tumor might become obsolete in the future. In the 
PRIAS MRI side study the number of cores is therefore omitted as a criterion to recommend 
active treatment (protocol available on www.prias-project.org).  
Outcome in the current analysis was defined as the outcome on repeat biopsy. Although 
this allows for a comparison of compliers and non-compliers the effect on more definitive 
outcomes (e.g. prostate specific death) could currently not be assessed, as no such events 
were reported yet. Longer follow-up is warranted to assess the effect of non-compliance 
on definitive outcomes. 
COnCLUSIOn
Some men with low risk prostate cancer on active surveillance do not comply with the 
schedule for follow-up and recommendations to switch to active treatment. Repeat bi-
opsies,  especially yearly biopsies in men with fast rising PSA, are often ignored, as is the 
recommendation to discontinue active surveillance due to a very fast rising PSA. Although 
these men are at increased risk of having higher Gleason scores on repeat biopsy, the 
majority still presents favorable tumor characteristics. A fast rising PSA should therefore 
not be a recommendation to advice active treatment, but should rather serve as a criterion 
for stricter follow-up. In addition, reducing the amount of yearly biopsies might increase 
the amount of men complying with the active surveillance protocol. 
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AbSTRACT
Objectives: To assess the value of risk-stratification based on magnetic resonance imag-
ing (MRI) and prostate-specific antigen density (PSA-D) in reducing unnecessary biopsies 
without missing Gleason pattern 4 prostate cancer in men on active surveillance. 
Patients and methods: In all, 210 men on active surveillance with Gleason score 3+3 
prostate cancer received a first MRI and if indicated (Prostate Imaging Reporting and Data 
System (PI-RADS) score ≥3) targeted biopsy (TBx) using MRI-transrectal ultrasonography 
(TRUS) fusion. The MRI was performed 3 months after diagnosis (group A: n = 97), at 
confirmatory biopsy (group B: n = 39) or at surveillance biopsy after one or more repeat 
TRUS-guided systematic biopsies (TRUS-Bx) (group C: n = 74). The primary outcome was 
upgrading to Gleason score ≥3+4 prostate cancer based on MRI ± TBx in groups A, B and 
C. Biopsy outcomes were stratified for the overall PI-RADS score and PSA-D to identify a 
subgroup of men in whom a biopsy could have been avoided as no Gleason score upgrad-
ing was detected. 
Results: In all, 134/210 (64%) men had a positive MRI and 51/210 (24%) men Gleason 
score upgrading based on MRI-TBx. The percentage of Gleason score upgrading based on 
MRI-TBx was 23% (22/97), 23% (9/39) and 27% (20/74) in respectively groups A, B and C. 
Additional Gleason score upgrading detected by TRUS-Bx occurred in 8% (3/39) of men 
in group B and 6% (1/17) of men who received TRUS-Bx in group C. No Gleason score 
upgrading was detected by MRI-TBx in men with a PI-RADS score of 3 and a PSA-D <0.15 
ng/ml2 (n = 15), nor by TRUS-Bx in men with a PI-RADS score of 1 – 3  and  PSA-D <0.15 ng/
ml2 (n = 15).  
Conclusion: At least one out of five men on active surveillance with Gleason score 3+3 
prostate cancer at diagnostic TRUS-Bx show Gleason score upgrading based on first MRI 
± TBx at baseline, confirmatory or surveillance biopsy. Men with a PI-RADS score of 1 - 3 
and PSA-D <0.15 ng/ml2 did not show Gleason score upgrading at MRI ± TBx or TRUS-Bx at 
each time point of surveillance. Thus risk-stratification based on PI-RADS and PSA-D may 
reduce unnecessary follow-up biopsy procedures in men on active surveillance. 
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InTROdUCTIOn
Active surveillance is a widely used strategy for low-risk prostate cancer (PCa) with proven 
oncological safety at long-term follow-up (1, 2). However, the repeatedly performed 
transrectal ultrasound-guided systematic biopsies (TRUS-Bx) during follow-up are bur-
dening, causing low compliance and in addition can cause infectious complications (3-5). 
Follow-up compliance is essential for the oncological safety of active surveillance, thus 
strategies are needed to reduce unnecessary biopsies. Magnetic resonance imaging (MRI) 
is increasingly used in men on active surveillance and could help to select those men who 
need a repeat biopsy. An MRI ± targeted biopsy (TBx) strategy could reduce the number 
of follow-up biopsies by omitting TRUS-Bx in the absence of suspicious lesions (one third 
of men on active surveillance) and potentially even MRI-TBx in the absence of radiological 
progression of a known lesion (6-8). However, little is known of the performance of MRI ± 
TBx during follow-up after the confirmatory biopsy. It can be hypothesized that the high-
grade (Gleason score (GS) ≥3+4) PCa detection rate of MRI ± TBx is low at surveillance 
biopsy as a significant proportion of men have already been reclassified based on the 
confirmatory biopsy (2). In addition, MRI ± TBx is known to miss high-grade PCa detected 
by TRUS-Bx in 4 – 14% of men at confirmatory biopsy (6, 9-16). In the present study we aim 
to assess the percentage of men with GS upgrading (GS ≥3+4) based on the outcome of 
MRI ± TBx in our prospective cohort of men on active surveillance who received their first 
MRI at baseline 3 months after diagnosis, at time of the confirmatory (first repeat) biopsy 
or at surveillance biopsy after one or more prior repeat biopsies. Furthermore, we stratified 
biopsy outcomes for the overall Prostate Imaging Reporting and Data System (PI-RADS) 
score and PSA density, known predictors of GS upgrading, with the aim to selectively 
identify those men that may not benefit from MRI-TBx and/or additional TRUS-Bx. 
PATIEnTS And METHOdS
Study population  
From November 2013 until November 2016 a total of 216 consecutive men on active 
surveillance for low-grade (GS 3+3) PCa received a first multi-parametric MRI ± TBx at 
our tertiary referral center. On request of the referring urologist the MRI ± TBx could be 
combined with an additional TRUS-Bx. A total of 6 of the 216 men were excluded in the 
current study, as they had a positive MRI but did not receive MRI-TBx. The remaining 210 
men were included in the current study, as the only exclusion criterion was the presence of 
high-grade (GS ≥3+4) PCa. A total of 111/210 (53%) men were participants of the Prostate 
cancer Research: International Active Surveillance (PRIAS) study (www.prias-project.org), 
an international web-based active surveillance study with strict criteria for inclusion at 
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diagnosis (GS 3+3, T-stage ≤cT2C, PSA ≤10 ng/ml, ≤2 positive cores, PSA density <0.2 ng/
ml2) and follow-up (17). Within the MRI-PRIAS side study an MRI ± TBx is performed at 
baseline 3 months after diagnosis and during every repeat TRUS-Bx scheduled at 1, 4, 7 
and 10 years after diagnosis (Figure 1). Inclusion in the MRI-PRIAS side study is however 
also possible after one or more repeat TRUS-Bx. The only reclassification criterion in the 
MRI-PRIAS side study is the presence of high-grade PCa at repeat (targeted) biopsy. The re-
maining 99/210 (47%) men in the present study had low-grade PCa but were followed-up 
outside of the PRIAS protocol, as they did not meet the strict PRIAS inclusion criteria (PSA 
>10 ng/ml and/or >2 positive TRUS-Bx cores) or were referred from a center not participat-
ing in PRIAS. All relevant data were included in our prospective, institutional review board 
approved database. 
Multi-parametric MRI
The institutional mpMRI protocol included T2-weighted imaging (T2WI), dynamic 
contrast-enhanced (DCE) imaging and diffusion-weighted imaging (DWI) with apparent 
diffusion coefficient (ADC) reconstructions, as previously described (18), according to the 
PI-RADS version 2 guidelines (19). MRI was performed on a 3-T system (Discovery MR750, 
General Electric Healthcare, Chicago, USA) using a 32-channel pelvic phased-array coil. 
All MRIs were reviewed by one urogenital radiologist (IS) with over 4 years of prostate 
MRI experience at the start of this study. Individual lesions were scored according to the 
PI-RADSv2  5-point likelihood scale for significant PCa (19). MRIs were classified as positive 
in cases of one or more PI-RADS ≥3 lesions.
MRI-targeted biopsy 
All men with a positive MRI received MRI-TBx. The MRI-TRUS fusion technique was used 
(UroStation™, Koelis, Meylan, France) to perform MRI-TBx of all suspicious lesions. MRI le-
sions were targeted with 2 – 4 cores. An additional TRUS-Bx (8 – 12 cores) was performed 
in all men at confirmatory biopsy and in a subset of men at surveillance biopsy on request 
of the referring urologist. The biopsy procedures were performed by three operators (AA, 
F-JD, LB) who had managed approximately 50 cases at the beginning of this study. 
Pathological review of biopsy specimens
One expert uro-pathologist (GL) reviewed all biopsy specimens according to the Interna-
tional Society of Urological Pathology (ISUP) 2014 modified GS (20). GS upgrading was 
defined as any GS ≥3+4 PCa found by MRI ± TBx and/or TRUS-Bx. 
Study design
Men were stratified into 3 groups according to timing of the MRI using the MRI-PRIAS 
follow-up scheme (figure 1); i.e. MRI at baseline 3 months after diagnosis (group A), at 
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confirmatory TRUS-Bx 1 year after diagnosis (group B) or at surveillance biopsy after one or 
more prior repeat TRUS-Bx (group C). The primary objective of our study was to compare 
the percentage of men with GS upgrading based on MRI-TBx in groups A, B and C. The 
secondary objective was the identification of a subgroup of men, after stratification by PI-
RADS score and PSA density, in whom the percentage of GS upgrading based on MRI-TBx 
is very low or absent. The tertiary objective was the identification of a subgroup of men in 
whom the percentage of GS upgrading based on TRUS-Bx is very low or absent. 
Statistical analysis
Statistically significant differences in continuous patient characteristics at time of diag-
nosis and at time of MRI were assessed with the Kruskal-Wallis test, while the χ2 test for 
trend was used to test for differences in categorical patient characteristics and the GS 
upgrading rates between groups (A, B and C). In accordance with the Standards of Report-
ing for MRI-Targeted biopsy studies (START) recommendations cross tabulation of biopsy 
outcomes was performed in the subgroup of men in groups B + C who received additional 
TRUS-Bx to compare the percentage of GS upgrading detected by MRI ± TBx vs TRUS-Bx 
(21). MRI-TBx and TRUS-Bx outcomes were stratified for the overall PI-RADS score and PSA 
density as these parameters are known to be strong predictors of GS upgrading (22-24). 
The previously described PSA density threshold of 0.15 ng/ml2 was used for stratification 
(24-27). Histograms of the stratified biopsy outcomes were constructed to visualize in 
which subgroup of men GS upgrading did not occur. The PSA density was calculated us-
ing the MRI-measured prostate volume. The MRI-measured volume was calculated by the 
prolate ellipsoid formula (length x width x height x π/6). Statistical tests were two-sided 
with the criterion of significance set at p <0.05. Statistical analyses were performed with 
SPSS for Windows (Version 21.0. IBM Corp., Armonk, NY, USA).
RESULTS
Patient characteristics at prostate cancer diagnosis and at time of MRI
In all, 210 men on active surveillance for GS 3+3 PCa received a first MRI in our institution. 
The median age and median PSA level at diagnosis of GS 3+3 PCa were respectively 65 
years (IQR 60 – 70) and 7.0 ng/ml (IQR 5.2 – 9.6) (table 1). A total of 37/210 (18%) men had 
more than 2 positive TRUS-Bx cores at diagnosis. A total of 97/210 (46%) men received 
MRI at baseline (Group A), while 39/210 (19%) men received their first MRI at confirmatory 
biopsy (Group B) and 74/210 (35%) men at surveillance biopsy (Group C). The percentage 
of men with only one positive TRUS-Bx core at diagnosis was significantly higher in Group 
C (65%) as compared to Group A (45%) and Group B (46%). Other patient characteristics at 
diagnosis did not significantly differ between the groups. At the time of the first MRI, men 
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in Group C had a significantly higher median PSA level (9.5 ng/ml) as compared to men 
in Group A (7.7 ng/ml) and Group B (7.1 ng/ml). Men in Group B tended to have a lower 
median PSA density (0.13 ng/ml2) as compared to men in Group A (0.18 ng/ml2) and group 
C (0.17 ng/ml2) (table 2). 
Percentage of Gleason score upgrading according to the timing of the  MRI
A total of 134/210 (64%) men had a positive MRI and a total of 51/210 (24%) men were 
upgraded to GS ≥3+4 PCa based on MRI-TBx (table 3). The percentage of GS upgrading 
based on MRI-TBx was similar in Group A (23%, 22/97), Group B (23%, 9/39) and Group C 
(27%, 20/74). The percentage of GS ≥4+3 PCa found by MRI-TBx was significantly higher in 
Group C (15%, 11/74) as compared to in Group A (3%, 3/97) and Group B (3%, 1/39). The 
high-grade tumor was located in the peripheral zone in 39/51 (76%) GS upgraded men 
and in the transitional zone in 11/51 (22%) upgraded men, while one man had high-grade 
PCa in both posterior and anterior MRI-TBx. 
Identification of a subgroup of men who may not benefit from MRI-targeted  
biopsy 
Figure 2 shows a histogram of GS upgrading based on MRI-TBx stratified for PI-RADS and 
PSA density. In the group of men with a PSA density <0.15 ng/ml2 no GS upgrading oc-
curred based on MRI-TBx in case of PI-RADS 3 (n = 15). In case of PI-RADS 4 and a PSA 
density <0.15 ng/ml2 3 out of 26 (12%) men showed GS upgrading based on MRI-TBx. 
In men with PI-RADS 5, the percentage of GS upgrading was high both in case of a PSA 
density <0.15 ng/ml2 (83%, 5/6) and a PSA density ≥0.15 ng/ml2 (74%, 17/23). 
Identification of a subgroup of men who may not benefit from TRUS-guided 
systematic biopsy
Additional GS upgrading (not detected by MRI-TBx) occurred in 3 out of 39 (8%) men who 
received TRUS-Bx at confirmatory biopsy and 1 out of 17 (6%) who received TRUS-Bx at 
surveillance biopsy. The cross tabulation of MRI ± TBx outcomes vs TRUS-Bx outcomes in 
men in Group B + C is shown in table 4. The percentage of GS ≥3+4 PCa detected by MRI ± 
TBx (79%, 15/19) and TRUS-Bx (74%, 14/19) was comparable. In all 10 men who upgraded 
based on both MRI-TBx and TRUS-Bx positive cores for high-grade PCa of both biopsy 
approaches were located in the same quadrant of the peripheral zone. Figure 3 shows a 
histogram of GS upgrading based on TRUS-Bx stratified for PI-RADS score and PSA density 
<0.15 ng/ml2. No GS upgrading occurred based on TRUS-Bx in men with PI-RADS 1 – 3 and 
PSA density <0.15 ng/ml2 (n = 15). 
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Table 3. biopsy outcomes stratified for timing of the first MRI
biopsy outcomes at first MRI 
Group A
MRI at Baseline
Group b
MRI at 
confirmatory 
biopsy
Group C
MRI at 
surveillance 
biopsy
Total Cohort
number % number % number % p-value number %
Men receiving MRI ± Tbx 97 100 39 100 74 100 / 210 100
Negative MRI (no TBx) 37 38 12 31 27 36 0.719 76 36
No GS upgrading in TBx 38 39 18 46 27 36 0.604 83 40
GS upgrading in TBx 22 23 9 23 20 27 0.791 51 24
GS 3+4 PCa 19 20 8 21 9 12 0.366 36 17
GS ≥4+3 PCa 3 3 1 3 11 15 0.006 15 7
Men receiving additional 
TRUS-bx
/ / 39 100 17 100 / 56 100
No additional GS 
upgrading in TRUS-Bx
/ / 36 92 16 94 0.809 52 93
Additional GS upgrading 
in TRUS-Bx
/ / 3 8 1 6 0.809 4 7
GS 3+4 PCa / / 2 5 0 0 0.342 2 4
GS ≥4+3 PCa / / 1 3 1 6 0.538 2 4
MRI = magnetic resonance imaging, TBx = targeted biopsy, TRUS-Bx = transrectal ultrasound-guided systematic 
biopsy, IQR = interquartile range, PI-RADS = prostate imaging reporting and data system, GS = Gleason score, 
PCa = prostate cancer
Figure 2. MRI-targeted biopsy outcomes stratified for the overall PI-RAdS score and PSA density  MRI 
= magnetic resonance imaging, TBx = targeted biopsy, PI-RADS = prostate imaging reporting and data system, 
PSA-D = PSA density, GS = Gleason score, PCa = prostate cancer
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Figure 3. TRUS-guided systematic biopsy outcomes stratified for the overall PI-RAdS score and PSA 
density  TRUS-Bx = Transrectal Ultrasound-guided systematic biopsy, PI-RADS = prostate imaging reporting 
and data system, PSA-D = PSA density, GS = Gleason score, PCa = prostate cancer
dISCUSSIOn
Repeated TRUS-Bx in men on active surveillance are often considered burdening, causing 
a drastic decline in biopsy compliance with longer follow-up (3, 4). However, compliance 
with follow-up testing is needed for the detection of initially missed high-grade PCa that 
has the potential to metastasize. Therefore, strategies are needed to reduce unnecessary 
biopsies and select only those men who need a repeat biopsy. MRI is increasingly imple-
mented in men on active surveillance and an MRI ± TBx strategy omitting repeat TRUS-Bx 
could reduce both the number of follow-up biopsies, as well as the number of cores per 
biopsy procedure. However, MRI ± TBx is known to miss high-grade PCa detected by TRUS-
Bx at confirmatory biopsy (6, 9-16). Moreover, a recent study showed a significantly lower 
percentage of GS upgrading based on MRI ± TBx as compared to TRUS-Bx in a cohort of 
103 men at surveillance biopsy (28). In contrast, we surprisingly showed a similar percent-
age of GS upgrading based on MRI ± TBx after one or more repeat biopsies (27%; group C) 
as compared to at baseline (23%; group A) and confirmatory biopsy (23%; group B). MRI ± 
TBx missed  high-grade PCa detected by TRUS-Bx in 3 out of 39 (8%) men at confirmatory 
and 1 out of 17 (6%) men at surveillance biopsy. 
The stable percentage of GS upgrading at different time points in our study is consistent 
with the stable percentage of reclassification (≠GS upgrading) of approximately 25% 
found at each repeat TRUS-Bx in the PRIAS study (2). The slightly higher percentage of GS 
≥3+4 PCa (27%) and significantly higher percentage of GS ≥4+3 PCa (15%) in MRI-TBx in 
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group C as compared to in group A and B could be due to (selection for MRI of men with) a 
higher risk of upgrading, translated by a higher median PSA density. In line with our study, 
several studies reported MRI ± TBx missing high-grade PCa in 4 - 9% of men on active 
surveillance (6, 11-16). Two recent studies using an extended 14-core TRUS-Bx scheme 
even reported a percentage of 12 - 14% of men in whom MRI ± TBx missed high-grade 
PCa (9, 10). A follow-up strategy with only MRI ± TBx thus inevitably misses high-grade PCa 
detected by TRUS-Bx. The question is whether the benefit of a reduction of one third of 
follow-up biopsy procedures and a significant reduction of cores per procedure outweighs 
the harm of missing a high-grade PCa in 4 - 14% of men at a specific time point during 
follow-up on active surveillance.  Answering this question one has to keep in mind that 
these missed high-grade PCa might be detected later on during follow-up without miss-
ing the window of curability (29). Furthermore, one has to keep in mind that the previously 
Table 4. MRI ± Tbx vs. TRUS-bx outcomes in the subgroup of men receiving TRUS-bx  
MRI ± Tbx vs. TRUS-bx outcomes at confirmatory biopsy (group b)
Negative 
MRI
MRI-TBx
No PCa GS 3+3 PCa GS 3+4 PCa GS ≥4+3 PCa Total
TR
U
S-
bx
No PCa 4 5 1 0 0 10
GS 3+3 PCa 7 2 8 3 0 20
GS 3+4 PCa 0 1 1 5 0 7
GS ≥4+3 PCa 1 0 0 0 1 2
Total 12 8 10 8 1 39
MRI ± Tbx vs. TRUS-bx outcomes at surveillance biopsy (subgroup of group C)
Negative 
MRI
MRI-TBx
No PCa GS 3+3 PCa GS 3+4 PCa GS ≥4+3 PCa Total
TR
U
S-
bx
No PCa 2 0 0 0 0 2
GS 3+3 PCa 3 1 4 0 2 10
GS 3+4 PCa 0 0 0 3 0 3
GS ≥4+3 PCa 0 0 1 0 1 2
Total 5 1 5 3 3 17
MRI ± Tbx vs. TRUS-bx outcomes in all men (group b + subgroup of group C)
Negative 
MRI
MRI-TBx
No PCa GS 3+3 PCa GS 3+4 PCa GS ≥4+3 PCa Total
TR
U
S-
bx
No PCa 6 5 1 0 0 12
GS 3+3 PCa 10 3 12 3 2 30
GS 3+4 PCa 0 1 1 8 0 10
GS ≥4+3 PCa 1 0 1 0 2 4
Total 17 9 15 11 4 56
MRI = magnetic resonance imaging, MRI-TBx = MRI-targeted biopsy, TRUS-Bx = transrectal ultrasound-guided 
systematic biopsy, PCa = prostate cancer, GS = Gleason score
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reported excellent long-term disease-specific survival of men on active surveillance is 
based on follow-up with TRUS-Bx only (1). This long-term disease-specific survival is not 
expected to be worse with an MRI ± TBx strategy as the previously reported sensitivity of 
MRI ± TBx for high-grade PCa (71 - 89%) is at least equal as compared to the sensitivity of 
TRUS-Bx (63 - 76%) (6, 9, 14-16). 
Although MRI seems to be helpful in patient selection for repeat biopsy, solely imple-
menting an MRI ± TBx follow-up strategy does not seem to be sufficient as high-grade 
PCa would be missed and two thirds of men would still need to be biopsied. Recently, 
two robust models for the prediction of GS upgrading at repeat TRUS-Bx were presented 
based on large datasets of men on active surveillance who did not receive MRI (30, 31). A 
multivariable risk-based approach in the presence of MRI seems the way forward to reduce 
unnecessary biopsies (18). Walton Diaz et al. presented an acceptably discriminating pre-
diction model (AUC 0.71) incorporating MRI parameters for the prediction of high-grade 
PCa at confirmatory MRI-TBx + TRUS-Bx (32). In a validation cohort of 85 men this model 
would have saved 27 – 68% of biopsies, with a corresponding NPV of 91 – 81% for high-
grade PCa (15). Satasivam et al. presented a prediction model incorporating MRI and clini-
cal variables with good discriminative ability (AUC 0.85) for GS upgrading at confirmatory 
TRUS-Bx (11). Validation of this model is needed to prove its ability to reduce unnecessary 
biopsies. Interestingly, the strongest predictor for GS upgrading in this model is the PSA 
density. PSA density was already known to be predictive for GS upgrading at repeat TRUS-
Bx in the absence of MRI (33, 34). More recently, it was shown that PSA density remains 
a strong predictor for GS upgrading when combined with the PI-RADS score in men on 
active surveillance who received MRI (22-24). After stratification for the overall PI-RADS 
score and PSA density using the previously described cut-off of 0.15 ng/ml2 (24-27) no GS 
upgrading was found based on MRI-TBx in men with a PI-RADS score 3 and PSA density 
<0.15 ng/ml2, nor at additional TRUS-Bx in men with PI-RADS 1 – 3 and PSA density <0.15 
ng/ml2. In line with our findings Washino et al. showed no GS upgrading based on MRI-TBx 
+ TRUS-Bx in biopsy naïve men with PIRADS 1 – 3 and PSA-density <0.15 ng/ml2 (27). This 
suggests that men on active surveillance with PI-RADS 1 – 3 and PSA-density <0.15 ng/
ml2 may not benefit from a follow-up biopsy. Obviously, the percentage of avoided biopsy 
procedures by omitting repeat biopsy in these men depends on the characteristics of the 
active surveillance cohort. In our cohort 49% (37/76) of men with PI-RADS 1 – 2 and 44% 
(15/34) of men with PI-RADS 3 had a PSA density <0.15 ng/ml2. Hopefully, a robust predic-
tion model incorporating PI-RADS and PSA density will be available in the near future to 
enable risk-based patient selection for repeat biopsy rather than simply stratifying patients 
based on these clinical parameters. Such a prediction model could be built from the large 
dataset of the Movember GAP3 project (35). 
While the risk of developing metastasis and PCa death is significantly higher in men on 
active surveillance with GS 3+4 as compared to GS 3+3 PCa, men with GS 4+3 PCa have 
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the highest risk of clinical progression with longer follow-up (36). Therefore, active surveil-
lance in men with GS ≥3+4 PCa cannot be considered standard of care yet (37). As in most 
other institutions, patients in our institution with GS ≥3+4 PCa are generally not enrolled 
in an active surveillance program and the finding of upgrading to any GS ≥3+4 PCa during 
follow-up usually means switch to active treatment with curative intent. Nevertheless, the 
high GS upgrading and/or reclassification rates of men on active surveillance trigger the 
need to extend the active surveillance inclusion and follow-up criteria and (limited) GS 3+4 
disease is nowadays considered suitable for active surveillance by some. In the near future, 
selection of men with GS 3+4 PCa for active surveillance could be based on the prognostic 
predictors of clinical disease progression cribriform and/or intraductal carcinoma growth 
and the percentage of grade 4 disease (20, 38, 39). 
A major strength of the present study is that is represents the true clinical setting. Men 
in our prospective cohort were referred from 8 different peripheral institutions and did not 
all fulfill the strict inclusion criteria of the PRIAS study (www.prias-project.org). Our study is 
mainly limited by the fact that only a subgroup of men at surveillance biopsy received an 
additional TRUS-Bx next to the MRI ± TBx (17/74, 23%), making it hard to draw conclusions 
from the comparison between both biopsy strategies. However, our findings from this 
comparison were in line with several previous studies. Furthermore, all men who received 
a first MRI were included in our study, regardless of time since diagnosis of low-grade PCa. 
The percentages of GS upgrading based on MRI ± TBx could be different in men who have 
received a previous MRI ± TBx (22, 23). Finally, multi-parametric MRI used in the present 
study, consisting of T2WI, DWI and DCE imaging is not yet widely available. Bi-parametric 
MRI (T2WI + DWI) is more feasible and less expensive and could therefore help to widely 
implement MRI in men on active surveillance. Within PI-RADS version 2 the DCE images 
are used to differentiate between PI-RADS 3 or 4 lesions in the peripheral zone (19). Only 
4 out of 71 (6%) men in the present study with an overall PI-RADS score 4 would have 
been classified as having a suspicion score of 3 based on bi-parametric MRI, 3 of whom 
had high-grade PCa in MRI-TBx. However, as all 4 men had a PSA density ≥0.15 ng/ml2 the 
conclusion of the present study (i.e. MRI-TBx may be avoided in men with PI-RADS 3 and 
PSA density <0.15 ng/ml2) remains unchanged with the use of bi-parametric MRI.
In conclusion, at least one out of five men with GS 3+3 PCa at diagnostic TRUS-Bx in 
our present cohort had GS upgrading based on first MRI ± TBx at baseline, confirmatory 
or surveillance biopsy. Men with PI-RADS 1 - 3 and a PSA density <0.15 ng/ml2 did not 
show GS upgrading at MRI ± TBx or TRUS-Bx at each time point of surveillance. Therefore, 
risk-stratification based on PI-RADS and PSA density may reduce unnecessary follow-up 
biopsy procedures in men on active surveillance. 
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As stated in the introduction section (Chapter 1) there are two main objectives of this 
thesis. The first objective is to study how a reduction of the harms of PSA-based prostate 
cancer screening can be established without affecting the benefit (Part 1). The second 
objective is to study how current protocols on active surveillance can be improved (Part 
2). Several research questions regarding these objectives will be answered in this general 
discussion. In addition, future perspectives will be discussed. 
PART 1: CAn WE REdUCE THE HARMS OF PROSTATE CAnCER SCREEnInG 
WITHOUT AFFECTInG THE bEnEFIT OF A REdUCTIOn OF METASTATIC dISEASE 
And PROSTATE CAnCER MORTALITY?
Can we select those men who may benefit from screening and refrain from 
screening in those who may not benefit? 
Since the introduction of opportunistic PSA-based prostate cancer screening in the early 
1990’s the incidence of metastatic disease has decreased by half in the United States (1). 
PSA-based screening reduces the chance of dying from prostate cancer by 50% when com-
paring men screened multiple times between the age of 55 – 74 years to those men not 
screened at all (2). The men that truly benefit from screening are those in whom a prostate 
cancer is detected (and subsequently treated) that otherwise would have certainly caused 
metastatic disease or death. Looking at the data from the large randomized trials (RCT) it 
is safe to conclude that most men within the age range 50 – 74 years do not benefit from 
screening. No less than a 1000 men need to be screened to prevent 1 – 2 prostate cancer 
deaths and 3 cases of metastatic disease at 13 years of follow-up (3, 4). Lifetime estimates 
on the basis of the RCT data show that 100 men need to be screened and 5 men need to be 
diagnosed with prostate cancer to prevent 1 prostate cancer death (5). Ideally, we should 
only screen those men who will actually benefit and refrain from screening in those who 
will not, thereby preventing the screening-related harms of unnecessary testing and over-
diagnosis. Unfortunately, upfront selection of those men who will benefit from screening 
is impossible. Besides the fact that we are not able to predict whether someone harbors 
a prostate cancer with the potential to metastasize before screening that individual, it is 
impossible to predict whether the events of prostate cancer metastases and death will oc-
cur before the competing risk of death from another cause. To date, we are able to identify 
certain groups of men with an elevated risk of prostate cancer (death) in which PSA-based 
screening is most likely more beneficial. Examples are men with a positive family history 
and men from African descent (6-8). Furthermore, we are able to identify men with screen-
detected prostate cancer who may (in potential) benefit from the early detection based 
on the histological characteristics of the tumor and the estimated life expectancy. Due 
to their potential to cause metastatic disease, Gleason ≥3+4 prostate cancers are often 
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considered clinically significant. The detection of such clinically significant tumors in men 
with a life expectancy long enough to develop metastases could be considered a surro-
gate of benefit of PSA-based screening. Similarly, the detection of a clinically insignificant 
tumor (often defined as Gleason 3+3 prostate cancer) could be considered a surrogate 
of overdiagnosis, although a higher-grade tumor component is easily undersampled and 
grade progression of non-aggressive cancers does occur (9-12). Naturally, the harm of an 
unnecessary biopsy is evident in case of a benign outcome of that biopsy. The net-benefit 
effect of PSA-based screening within a specific population can be expressed as the ratio of 
these surrogates of benefit and harm of screening. Obviously, prostate cancer screening 
should only be considered in those populations in whom a positive benefit-to-harm ratio 
could be achieved. This benefit-to-harm ratio is dependent on the weight (or importance) 
that is adjudged to the benefit and harms of screening. For example, for the individual 
of 60 years who regards his chance of dying from prostate cancer being reduced by only 
20% (i.e. from 3% to 2.4%) as far more important than a 60% chance of being confronted 
with a prostate cancer diagnosis that in potential would not have hurt him if not detected 
(with subsequent potential consequences for the quality of life) his benefit-to-harm ratio 
of PSA-based screening will be positive. Therefore, virtually all international guidelines 
recommend to engage in the process of shared-decision making when dealing with the 
individual (Chapter 2). 
Improvement of the benefit-to-harm ratio of PSA-based screening on a population 
level can either be achieved by an increase in benefit or a decrease of the harms. Ideally, 
prostate cancer screening would reduce the disease-specific mortality to 0% instead of 
50%. Although a 0% prostate cancer mortality caused by screening is wishful thinking, 
the relative mortality reduction achieved in the European Randomized study of Screening 
for Prostate Cancer may very well be increased by several adjustments to the screening 
protocol used (in most centers) within this study. Examples of these adjustments will be 
discussed in detail in the next sections of the general discussion and an optimal screening 
strategy will be proposed. An increase in the relative reduction of metastatic disease and 
prostate cancer mortality could be achieved by screening within a wider age range com-
pared to the core age of 55 – 69 years in the ERSPC study (13). Furthermore, an increase 
in benefit of screening could be established by narrowing the 4 year screening interval as 
used in most centers in the ERSPC (14). Finally, the benefit of screening could most likely 
be increased by adjusting the PSA and sextant TRUS-guided systematic biopsy screen-
ing algorithm, thereby detecting clinically significant prostate cancer at an earlier stage 
and hence increase the chance of cure. Additional kallikrein biomarkers next to PSA have 
the potential to increase the specificity for clinically significant prostate cancer. Also, the 
sextant TRUS-guided systematic biopsy could be replaced by an extended 12-core TRUS-
biopsy scheme and even include MRI-targeted biopsy cores (Chapter 3). 
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Within which age range should we screen?
The ERSPC provided level 1 evidence for a relative mortality reduction caused by PSA-
based screening in the core age group of 55 – 69 years (3). Besides a further improvement 
in the screening algorithm within this age range it could very well be that outside this 
age range men can benefit from prostate cancer screening. A recent analysis from the 
Göteborg trial showed a similar prostate cancer-specific mortality reduction at 17-years of 
follow-up in men aged 50 - 54 years compared to the ERSPC core age group of 55 - 69 years 
(13). The age cut-off of 50 years for men at normal risk of prostate cancer (no family history 
and not from African descent) is already implemented in the prostate cancer screening 
guidelines of several associations, such as the European Association of Urology and the 
American Urological Association (Chapter 2). In men aged under 50 years (symptomatic) 
prostate cancer is rare and there is no direct evidence for a screening-induced mortality 
reduction within this age category. Nevertheless, as a baseline PSA value in men aged 45 
– 49 years has been shown to be predictive of prostate cancer metastases several decades 
later (15), some guidelines include the measurement of baseline PSA in men at normal risk 
aged under 50 years (Chapter 2). 
Next to the age to start prostate cancer screening, the age to stop is also subject of debate. 
There is currently still no level 1 evidence for a screening-induced mortality reduction 
in men aged ≥70 years. As men become older their life expectancy decreases and the 
benefit that can be achieved by early detection of prostate cancer therefore becomes less. 
Microsimulation screening analysis (MISCAN) has shown that  any benefit of PSA-based 
screening in men aged ≥70 years is offset by a reduction in their quality of life (5, 16). 
Nevertheless, men aged ≥70 years, often with multiple comorbidities, are frequently 
screened in daily practice in the United States (17, 18). In Europe, a similar trend can be 
observed. A Swedish study in showed a high prevalence (up to 46%)  of PSA testing in 
men aged 70 – 79 years in Stockholm County (19). In the United Kingdom, Italy and the 
Netherlands PSA testing by general practitioners has been shown to be skewed towards 
men above 70 years (20-22). As the median life expectancy of Western men still increases 
and the incidence of aggressive prostate cancer increases with age, some men ≥70 years 
may benefit from early detection (23-25). As stated previously, this is only the case in men 
with a life expectancy long enough for a clinically significant prostate cancer to become 
symptomatic if left untreated. Both the European Association of Urology and the Ameri-
can Urological Association guidelines now state that men with a life expectancy ≥10 – 15 
years should be considered for PSA-based screening rather than applying an absolute age 
criterion (26, 27) (Chapter 2). 
The median life expectancy of Dutch men aged 70 years and 75 years is 14.6 years and 
11.2 years, respectively (28). The median life expectancy of Dutch men requesting to be 
screened within this age category may actually be higher than the average median life 
162
expectancy (healthy screenee effect) (29, 30). Therefore, it is safe to state that a large 
proportion of men aged 70 – 75 in the Netherlands meet the criteria of the European 
Association of Urology and the American Urological Association guidelines and are eli-
gible for PSA-based screening. In Chapter 3 it was shown that Dutch men within this age 
category (71 – 75 years) often harbor clinically significant prostate cancer, even after being 
repeatedly screened. As the median life expectancy of Dutch men aged 80 years is still 
8.1 years (28), a highly selected subgroup of Dutch men aged 75 – 80 years might even 
benefit from screening. Naturally, life expectancy is not just dependent on age but also 
on comorbidities (31). Unfortunately, the confidence interval of a life expectancy estima-
tion becomes wider as the life expectancy itself increases. The 10 year life expectancy as 
estimated by clinicians has been shown to be pessimistic and not very accurate (29). The 
10 year life expectancy as predicted by available models and calculators unfortunately 
provides only modest improvement in accuracy and it is unclear whether these models 
provide any advantages over the available government life tables (29). Moreover, not only 
the estimated life expectancy but also the quality of life should be taken into account. 
Finally, the availability of a biomarker with increased specificity compared to PSA, which 
could help to selectively identify elderly men with aggressive prostate cancer, could sig-
nificantly increase the net-benefit ratio of screening in men aged ≥75 years. 
With which interval should we screen?
In Rotterdam as well as in most other centers within the ERSPC study men were screened 
with PSA with intervals of 4 years (32). However, in the Swedish section of the ERSPC study 
men were screened with intervals of only 2 years (33). Screening with 2 year instead of 4 
year intervals resulted in a 40% relative reduction of prostate cancers detected in an ad-
vanced stage and, on the other hand, an increased detection of low-risk prostate cancers 
(14). Unfortunately, this cannot be translated directly into an increase in cancer-specific 
mortality reduction. A rough estimation based on the difference in prostate cancer mor-
tality between the Rotterdam and Göteborg sections of the ERSPC indicates that using 
a 2 year instead of 4 year screening interval could result in a 10% higher relative cancer-
specific mortality reduction (32, 33). Consequently, the EAU guideline recommends a 2 
year screening interval in men initially at risk based on the baseline PSA value (26). As 
clinically significant interval cancers even occur with a 2 year screening interval, one could 
argue that a 1 year screening interval could provide additional benefit, especially in men 
with a high baseline PSA. As a treatment delay for up to 1 year in general has a relatively 
limited effect on the oncological outcome (34), a screening interval shorter than 1 year 
does not seem to be beneficial. Based on data suggesting it could be safe to prolong the 
screening interval to up to 8 years in case of a very low baseline PSA (15), the European 
Association of Urology guidelines panel suggests a risk-based approach to determine the 
screening interval in men with a low baseline PSA (26). In the optimal screening strategy 
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within this general discussion, a screening interval of 2 years is proposed. A one year 
screening interval can be used on indication in case of a high prostate cancer risk but 
benign outcome on biopsy. 
PSA threshold to biopsy
An increase in the detection of clinically significant prostate cancer could be established 
by lowering the PSA threshold to biopsy (35). In most men in the ERSPC study a PSA cut-
off value to biopsy of 3.0 ng/ml was used. However, it was previously shown that a total 
of 14% and 2% of men with a PSA below 3.0 ng/ml harbor any grade and high-grade 
(Gleason ≥3+4) prostate cancer, respectively (36). Within a small pilot study in the 10th 
screening round of the Göteborg trial a total of 11% and 5% of men with a PSA of 1.8 – 3.0 
ng/ml had any grade and high-grade prostate cancer, respectively (35). Lowering the PSA 
threshold to biopsy increases the sensitivity, but also decreases the specificity, meaning 
that it increases the percentage of unnecessary prostate biopsies (36, 37). Moreover, the 
ratio between clinically significant and insignificant prostate cancers is more unfavor-
able as the PSA threshold to biopsy is lower (36). In addition, a large proportion of those 
clinically significant prostate cancers missed in men with a PSA below 3.0 ng/ml could 
probably be detected at subsequent screening without losing the window of curability, 
under the condition that the screening interval is not too wide. 
Extended TRUS-biopsy and multiparametric MRI
In the ERSPC study the classical sextant TRUS-guided systematic biopsy was used for the 
detection of prostate cancer. It is known that clinically significant prostate cancer can be 
missed due to undersampling by TRUS-guided systematic biopsy. The TRUS-biopsy is 
especially poor at sampling the anterior, midline and apex region of the prostate (38, 39). 
Recently, the PROstate MR Imaging Study (PROMIS) showed that the sensitivity of a 10 – 12 
core TRUS-biopsy for high-grade (Gleason ≥3+4) PCa in biopsy naïve men was as low as 
48% with transperineal template mapping biopsy as the reference standard (40). Add-
ing additional cores to the (sextant) TRUS-biopsy scheme increases the prostate cancer 
detection but does not necessarily improve the ratio between clinically significant and 
insignificant prostate cancers detected (41, 42). In Chapter 3 we showed that performing 
a 12-core TRUS-biopsy instead of a sextant TRUS-biopsy in repeatedly screened men aged 
71 – 75 years only increased the low-grade prostate cancer detection, not the high-grade 
prostate cancer detection. Nowadays, multiparametric MRI is increasingly used due to its 
high negative predictive value for clinically significant prostate cancer of approximately 
90% (40, 43, 44). The previously mentioned PROMIS study showed a significantly higher 
sensitivity for high-grade (Gleason ≥3+4) prostate cancer of multiparametric MRI in biopsy 
naïve of 88% compared to a 48% sensitivity of TRUS-biopsy (40). A targeted biopsy can 
be performed of suspicious lesions on MRI. In a clinical setting, an MRI with targeted 
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biopsy strategy instead of TRUS-biopsy strategy detects less clinically insignificant pros-
tate cancer, while the detection of clinically significant prostate cancer by an MRI with 
targeted biopsy strategy is at least equal with fewer biopsy cores needed (45, 46). This 
was confirmed in a population-based screening setting in Chapter 3: while TRUS-biopsy 
and MRI with targeted biopsy had a similar sensitivity for high-grade prostate cancer of 
79% and 71% respectively, the sensitivity of TRUS-biopsy for low-grade prostate cancer 
was considerably higher (89%) compared to MRI with targeted biopsy (23%). MRI-targeted 
biopsy seems to particularly detect more clinically significant prostate cancer in previously 
biopsied men (45-47). The performance of the MRI-targeted versus TRUS-biopsy strategy 
in biopsy naïve men is currently investigated in a randomized fashion in the ongoing 
multicenter PRECISION trial (48). Although MRI and targeted biopsy seems to outperform 
TRUS-biopsy in a clinical setting (40, 45, 46), most experts agree that MRI-targeted biopsy 
currently does not replace TRUS-biopsy as it still misses 10 – 20% of clinically significant 
prostate cancers (40, 45, 46). Therefore, a combined approach of both TRUS-biopsy and 
MRI-targeted biopsy (in case of a positive MRI) is recommended by the European Asso-
ciation of Urology guidelines panel after the performance of a pre-biopsy MRI (26, 44). 
However, as shown in Chapter 3 the combined approach of TRUS-biopsy and MRI-targeted 
biopsy does not only detect 10 – 20% more clinically significant prostate cancer but also 
drastically increases the detection of clinically insignificant prostate cancer. Nevertheless, 
the biopsy procedure in the optimal screening strategy of this general discussion consists 
of a 10 – 12 core TRUS-biopsy combined with an MRI-targeted biopsy in case of suspicious 
lesions.
Should we continue screening in previously biopsied men?
Naturally, the chance of harboring (clinically significant) prostate cancer decreases after 
the performance of a biopsy with benign outcome. Whereas 25% of men who received a 
sextant TRUS-biopsy in the first screening round of the ERSPC Rotterdam were diagnosed 
with prostate cancer, only 12% of previously biopsied men in round 2 and 15% of previ-
ously biopsied men in round 3 harbored prostate cancer (49). Moreover, the ratio between 
significant and insignificant disease detected is less favorable after a previous negative 
biopsy. Although 44% of men diagnosed with prostate cancer in the first screening round 
of the ERSPC Rotterdam had clinically significant disease, the percentage of clinically 
significant disease in previously biopsied men in  screening round 2 and 3 was only 21% 
and 16%, respectively (49). Similarly, in Chapter 3 we showed that 25% of the previously bi-
opsied men in the fifth screening round of the ERSPC Rotterdam harbored prostate cancer 
and that only 20% of those prostate cancers were high-grade. Thus, after a previous biopsy 
the chance of having prostate cancer at repeat biopsy is decreased by approximately 50%, 
as well as the chance of a detected prostate cancer being clinically significant. This indi-
cates that men should be carefully selected for repeat biopsy. Nevertheless, as some previ-
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ously biopsied men still harbor clinically significant prostate cancer, even after 4 previous 
screens (Chapter 3), repeat screening could be beneficial at least for some of these men. A 
study from the Rotterdam section of the ERSPC showed a 0.03% prostate cancer mortality 
at 11 years of follow-up in men biopsied at initial screening, compared to a 0.35% prostate 
cancer mortality in whole screening arm (50). This suggests that the chance of dying from 
prostate cancer at 11 years of follow-up is reduced by more than 90% after being biopsied 
(50). Therefore, the absolute mortality reduction that can be achieved by screening after 
a previous negative biopsy is limited. This emphasizes the need for a risk-based approach 
to select those men for repeat screening after a previous biopsy who may still benefit and 
refrain from screening in those who may not. A recent study using data from the Danish 
Prostate Cancer Registry showed that the 20 year cumulative prostate cancer mortality in 
men with a negative initial biopsy and PSA ≤10 ng/ml was only 0.7%, compared to 3.6% 
and 17.6% in men with a negative initial biopsy and PSA 10 – 20 ng/ml and PSA >20 ng/
ml, respectively (51). 
Although our understanding of whom may benefit from PSA-based prostate cancer 
screening has improved over the years, it seems that we have not succeeded up to day 
to increase the screening-induced benefit without also increasing the harms. All of the 
previously discussed measures that would increase the detection of clinically significant 
prostate cancer would also increase unnecessary testing and the detection of clinically 
insignificant disease. A better approach to improve the benefit-to-harm ratio of PSA-based 
prostate cancer screening would be to drastically reduce the harms, preferably while 
maintaining the currently established benefit. This could be achieved by the implementa-
tion of multivariable risk-stratification and magnetic resonance imaging.  
Can we select those men who need a biopsy using currently available 
prediction models, thereby avoiding unnecessary biopsies and overdiagnosis? 
Multivariable risk-based patient selection for TRUS-biopsy
A screening algorithm with a PSA threshold of 3.0 ng/ml to perform a TRUS-biopsy results 
in a benign outcome in 60 – 75% of biopsied men (41, 49) and up to half of the detected 
prostate cancers being clinically insignificant (52). Patient selection for TRUS-biopsy 
based on their actual risk of (high-grade) prostate cancer, can reduce the percentage 
of unnecessary biopsies and cause a more favorable significant-to-insignificant ratio of 
prostate cancers detected. Several prostate cancer prediction models are available (53, 
54), the web-based risk calculators from the Prostate Cancer Prevention Trial (PCPT-RC) 
and the Rotterdam section of the ERPSC (ERSPC-RCs) being well externally validated and 
most frequently used in daily practice. In addition to PSA, the PCPT-RC includes the digital 
rectal examination (DRE), age, ethnicity, family history and number of previous negative 
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biopsies (55). The parameters in the ERSPC-RCs are PSA, DRE, prostate volume (assessed 
by DRE or TRUS), TRUS and previous biopsy status (56). The ERSPC-RCs have been shown 
to outperform the PCPT-RC in several external validation studies (57-60), most likely due 
to the inclusion of prostate volume in the models (61, 62). A meta-analysis showed a 
significantly higher predictive accuracy of the ERSPC-RC3 as compared to the PCPT-RC 
with an AUC for TRUS-biopsy detected prostate cancer of 0.79 (95%CI 0.77 – 0.81) and 0.66 
(95%CI 0.63 – 0.68), respectively (54). Application of the ERSPC-RC3 doubles the sensitiv-
ity of PSA testing (44% instead of 21%) without losing specificity (54). Patient selection 
for TRUS-biopsy based on a specific risk cut-off for (high-grade) prostate cancer of the 
ERSPC-RCs has been shown to reduce the percentage of unnecessary biopsy procedures 
by 20 – 33% in multiple external validation studies (56, 59, 61-67). A screening algorithm 
with a PSA threshold to biopsy of 4.0  instead of 3.0 ng/ml results in a similar reduction 
of biopsy procedures but misses considerably more clinically significant prostate cancer 
as compared to an ERSPC-RC based screening algorithm. Therefore, the Dutch General 
Practitioners guideline was adapted in 2014, lowering the PSA cut-off for referral to the 
urologist from 4.0 to 3.0 ng/ml, with the remark that the urologist should risk-stratify 
before TRUS-biopsy using the ERSPC-RC (68, 69). 
Both the PCPT-RC and the ERSPC-RC3 have been updated. The PCPT-RC 2.0 was ad-
justed for the prediction of low-grade and high-grade prostate cancer (instead of any 
grade prostate cancer), incorporating the percentage free PSA as a parameter (70). More 
recently, the ERSPC-RC3 was adjusted for the prediction of low-risk (defined as Gleason 
≤3+4 without cribriform and/or intraductal carcinoma) and high-risk (Gleason 3+4 with 
cribriform and/or intraductal carcinoma or Gleason ≥4+3) prostate cancer, incorporating 
age in the model (71). In addition, improvements have been made in the biomarker field. 
Two novel kallikrein assays, the Prostate Health Index (([–2]proPSA / freePSA) × √PSA) and 
the 4Kscore (panel of total PSA, free PSA, intact PSA and hK2), have been introduced with 
the intend to avoid unnecessary biopsies in men with a PSA of 2 – 10 ng/ml (72, 73). The 
PHI and 4Kscore have a similar discriminative ability, although there is a lack of compara-
tive studies up to day (74). Very recently, a novel marker called the IsoPSA was added to the 
line of kallikrein assays. This structure-based assay detects both known and unknown PSA 
isoforms and showed promising results in a multicenter cohort of 261 men (75). Although 
the novel kallikrein markers outperform PSA and have a similar discriminative ability as 
compared to multivariable risk calculators (75-78), their added value to the prediction of 
those risk calculators is relatively limited, questioning whether these kallikrein markers 
are worthy of their additional costs. The inclusion of new genetic markers in prediction 
models, although potentially even more expensive, may further improve the results of 
multivariable risk-stratification (79, 80).
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Multivariable risk-based patient selection for MRI
Besides avoiding unnecessary TRUS-biopsies, multivariable risk-stratification could also 
avoid the performance of unnecessary pre-biopsy MRIs. The European Association of Urol-
ogy guidelines panel recommends to risk-stratify as an initial step before the performance 
of a pre-biopsy MRI in order to confirm that the clinical suspicion of prostate cancer is 
grounded (26, 44). In Chapter 3, men in the fifth screening round of the ERSPC Rotterdam 
were retrospectively stratified based on the ERSPC-RC4. In this repeatedly screened cohort 
of men aged 71 – 75 years, it was shown that upfront stratification using the ERSPC-RC4 
would have avoided no less than 67% of sextant TRUS-biopsies and 65% of pre-biopsy 
MRIs with 12-core TRUS-biopsies (± targeted biopsies). Although a screening algorithm 
with upfront risk-stratification and the performance of 12-core TRUS-biopsy would have 
avoided two-thirds of biopsy procedures and low-grade prostate cancer diagnoses, it also 
would have missed 29% of high-grade prostate cancers as detected by the performance 
of MRI and 12-core TRUS-biopsy (± targeted biopsy) in all men. A screening strategy with 
upfront risk-stratification and the combined performance of MRI and 12-core TRUS-biopsy 
(± targeted biopsy) is considered the optimal strategy, as it would have avoided two-thirds 
of biopsy procedures and low-grade PCa diagnoses, missing only 17% of high-grade pros-
tate cancers. The high-grade prostate cancer detection rate with this optimal screening 
algorithm was higher as compared to a 12-core TRUS-biopsy in all men approach (13% 
vs 12%). In Chapter 4, the ERSPC-RC4 was applied retrospectively to a clinical cohort of 
122 previously biopsied men with a sustained suspicion of prostate cancer who received 
MRI and targeted biopsy in the presence of PI-RADS ≥3 lesions. It was shown that upfront 
stratification based on the ERSPC-RC4 would have avoided the performance of 51% of 
pre-biopsy MRIs and 25% of low-grade prostate cancers as detected by targeted biopsy, 
missing only 10% of high-grade prostate cancer. Due to the higher prostate cancer de-
tection of MRI-targeted biopsy compared to (sextant) TRUS-biopsy, particularly in men 
with a previous negative biopsy, calibration showed a systematic underestimation of 
the ERSPC-RC4 of the (high-grade) prostate cancer risk. Therefore, it was concluded that 
recalibration to a clinical setting with extended TRUS-biopsy and MRI-targeted biopsy 
could further improve the performance of the model. In chapter 5, the ERSPC-RC3(+DRE) 
and ERSPC-RC4(+DRE) were recalibrated to the clinical setting based on data from men 
from Rotterdam and Den Bosch. The recalibrated ERSPC-RC3 and ERSPC-RC4 performed 
well in a multicenter cohort of 961 men who received MRI and 12-core TRUS-biopsy (± 
targeted biopsy) with an AUC for high-grade prostate cancer of 0.76 (95%CI 0.71 – 0.80) 
and 0.74 (95%CI 0.69 – 0.79), respectively. This is in line with a German study showing an 
AUC for high-grade prostate of 0.81 and 0.76 of the ERSPC-RC3 and refitted ERSPC-RC4 
in a cohort of 1015 men who received transperineal template mapping biopsy and MRI-
targeted biopsy (81). Therefore, it can be concluded that multivariable risk-stratification 
with the (recalibrated) ERSPC-RCs could help to avoid unnecessary, costly MRIs. To validate 
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this finding, the prospective multicenter MR PROPER (MRI of the Prostate with Prior Risk-
assessment) study will be conducted in the Netherlands comparing the (high-grade) 
prostate cancer detection after ERSPC-RC based stratification of TRUS-biopsy with MRI-
targeted biopsy, as well as the cost-effectiveness and the quality of life. 
Based on the current evidence it can be concluded that multivariable risk-stratification, 
preferably with the ERSPC-RC, should be performed before selecting men for biopsy in 
order to reduce overdiagnosis, unnecessary biopsy procedures and even MRI’s. Therefore, 
multivariable risk-stratification is an essential part of the optimal screening strategy as 
proposed in this general discussion.
Can magnetic resonance imaging help to improve currently available 
prediction models? 
Apart from upfront risk-stratification pre-MRI to avoid unnecessary MRI-scans, multivari-
able risk-stratification could also be used to avoid unnecessary (targeted) biopsy proce-
dures after the performance of an MRI. Obviously, the added benefit of risk-stratification 
after the performance of an MRI depends on the degree of risk-stratification (none, based 
on clinical judgement or multivariable risk-stratification) pre-MRI. Recently, two new 
prostate cancer prediction models were developed, incorporating the clinical parameters 
as included in the ERSPC-RCs (PSA, DRE, prostate volume and previous biopsy status) as 
well as age and the PI-RADS score (81, 82). Van Leeuwen et al. constructed a model based 
on data of 393 predominantly biopsy naïve men who received transperineal template 
mapping biopsy (82). The model had an AUC for clinically significant prostate cancer, 
defined as Gleason ≥3+4 PCa with >5% grade 4 and/or ≥20% cores positive and/or ≥7 
mm of prostate cancer in any core, of no less than 0.88 (95%CI 0.85 – 0.92) in the construc-
tion cohort and 0.86 (95%CI 0.81 – 0.92) in a validation cohort of 198 men (82). Using a 
significant prostate cancer risk threshold to biopsy of ≥10% would have avoided 28% of 
biopsy procedures in their cohort, missing 3% of clinically insignificant prostate cancer 
(82). Radtke et al. also used the previously mentioned parameters to construct new risk 
models for any grade and high-grade (Gleason ≥3+4) prostate cancer based on data of 
660 biopsy naïve and 355 previously biopsied men who received transperineal template 
mapping biopsy + MRI-targeted biopsy (81). The risk models of Radtke et al., including 
PI-RADS and age, performed significantly better than the original ERSPC-RC3 and ERSPC-
RC4 (81). However, with decision curve analysis net benefit of these risk models was only 
observed beyond the ≥10% risk threshold for high-grade prostate cancer (81). In Chapter 
5, we constructed MRI-ERSPC-RCs based on data of 504 biopsy naïve and 457 previously 
biopsied men from 5 institutions in Germany and the Netherlands who received MRI and 
12-core TRUS-biopsy (± targeted biopsy). Unlike the newly developed models in the previ-
ously mentioned studies (81, 82), the MRI-ERSPC-RCs were constructed by augmenting 
the already multiple validated original ERSPC-RCs. After recalibration, the linear predictor 
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of the original ERSPC-RCs was included as a covariate together with the PI-RADS score 
and age. In accordance with the risk models of Radtke et al. (81), the MRI-ERSPC-RCs 
performed significantly better than the original ERSPC-RCs: the AUC for high-grade PCa 
was 0.84 (95%CI 0.81 – 0.88) and 0.85 (95%CI 0.81 – 0.89) for the MRI-ERSPC-RC3 and MRI-
ERSPC-RC4 respectively, compared to an AUC of 0.76 (95%CI 0.71 – 0.80) and 0.74 (95%CI 
0.69 – 0.79) for the original ERSPC-RC3+DRE and ERSPC-RC4+DRE, respectively. Moreover, 
decision curve analysis showed clear net benefit of the MRI-ERSPC-RCs, proving their abil-
ity to avoid unnecessary biopsy procedures even after risk-stratification pre-MRI with the 
original (recalibrated) ERSPC-RCs. Using a ≥10% high-grade prostate cancer risk threshold 
of the MRI-ERSPC-RCs to biopsy would have avoided 25% of biopsy procedures in our 
multi-institutional cohort of 961 men, missing 4% of high-grade prostate cancers. External 
validation of the MRI-ERSPC-RCs is needed before application in daily clinical practice. 
Conclusion
In PSA-based prostate cancer screening a positive benefit-to-harm ratio is mandatory. Im-
provement in this benefit-to-harm ratio can be achieved either by increasing the benefit 
or reducing the harms. Increasing the benefit (i.e. reducing the incidence of metastatic dis-
ease and cancer-specific mortality) could be achieved by a wider age range to screen (i.e. 
50 – 75 years instead of 55 – 69 years for men at normal risk), screening more intensely (i.e. 
narrowing the screening interval), use of a lower PSA threshold to biopsy or new kallikrein 
markers (i.e. PHI, 4K-score or IsoPSA), or increasing the clinically significant prostate cancer 
detection of the biopsy (i.e. increasing the number of biopsy cores or targeting the cores). 
Unfortunately, measures to improve the benefit of prostate cancer screening usually also 
increase the harms (i.e. unnecessary testing  and overdiagnosis of clinically insignificant 
disease). On the other hand, certain measures to reduce the harms of screening, such as 
stopping screening in men with a life expectancy less than 10 years and stricter selection 
of previously biopsied men for repeat screening and biopsy, do not necessarily reduce the 
benefit of screening. The optimal screening strategy as proposed in this general discussion 
(figure 1) includes upfront multivariable risk-stratification followed by multiparametric 
MRI and the combined performance of TRUS-biopsy and MRI-targeted biopsy (in the pres-
ence of PI-RADS ≥3 lesions), as it significantly reduces the harms of screening without 
affecting the benefit. Multivariable risk-stratification after MRI may in potential add to this 
screening algorithm.
170
Fi
gu
re
 1
. S
cr
ee
ni
ng
 s
tr
at
eg
y 
w
it
h 
m
ea
su
re
s 
to
 re
du
ce
 th
e 
ha
rm
s 
w
it
ho
ut
 a
ff
ec
ti
ng
 th
e 
be
ne
fit
 P
Ca
 =
 p
ro
st
at
e 
ca
nc
er
; T
RU
S-
Bx
 =
 tr
an
sr
ec
ta
l u
ltr
as
ou
nd
-g
ui
de
d 
sy
s-
te
m
at
ic
 b
io
ps
y;
 T
Bx
 =
 ta
rg
et
ed
 b
io
ps
y;
 P
I-R
AD
S 
= 
Pr
os
ta
te
 Im
ag
in
g 
Re
po
rt
in
g 
an
d 
D
at
a 
Sy
st
em
; *
in
 h
ig
hl
y 
se
le
ct
ed
 m
en
 a
ge
d 
<5
0 
ye
ar
s (
fa
m
ili
al
 p
re
di
sp
os
iti
on
, A
fri
ca
n 
de
sc
en
t) 
or
 a
ge
d 
>7
5 
ye
ar
s (
w
ith
 li
fe
 e
xp
ec
ta
nc
y 
≥1
0 
ye
ar
s)
 sc
re
en
in
g 
ca
n 
be
 b
en
efi
ci
al
; *
*l
ife
 e
xp
ec
ta
nc
y 
es
tim
at
io
n 
is
 b
as
ed
 o
n 
ei
th
er
 a
 ca
lc
ul
at
or
 o
r g
ov
er
nm
en
t l
ife
 ta
bl
e 
**
*m
ea
su
re
s 
to
 re
du
ce
 th
e 
ha
rm
s o
f s
cr
ee
ni
ng
, w
ith
ou
t a
ffe
ct
in
g 
th
e 
be
ne
fit
, a
re
 sh
ow
n 
in
 a
 te
xt
 b
ox
 w
ith
 re
d 
ou
tli
ne
.
171
9
Future perspectives
The European Association of Urology guidelines still only recommend a pre-biopsy MRI in 
men with a sustained suspicion of prostate cancer after a previous negative biopsy (26, 44). 
Nevertheless, some expert group are already in favor of performing a pre-biopsy MRI in 
biopsy naïve men (40, 48). Drawbacks of performing a pre-biopsy MRI in biopsy naïve men 
are the additional costs, as well as a current lack of logistical capacity and radiologists and 
urologists with expertise in prostate MRI and targeted biopsy. One modelling study from 
Nijmegen suggested that a diagnostic pathway with pre-biopsy MRI and in-bore targeted 
biopsy instead of a TRUS-biopsy driven diagnostic pathway could be cost-effective in the 
Netherlands (83). A more recent modelling study from the same group suggested that 
an MRI-TRUS fusion biopsy diagnostic pathway, compared to a TRUS-biopsy and in-bore 
targeted biopsy pathway, is the most cost-effective (84). Although adding MRI and fusion 
targeted cores to the TRUS-biopsy increases the costs of the diagnostic procedure, the 
improved accuracy of the diagnosis would result in cost-effectiveness of the diagnostic 
pathway (84). It must be stated that the outcomes of these modelling studies are very 
dependent on the input of the models (i.e. assumptions), such the costs for a multipa-
rametric MRI. In the Netherlands, the costs for a multiparametric MRI of the prostate are 
currently only €317,- (as per January 2017) (84), whereas the costs of a multiparametric 
MRI in the United States are considerably higher. The costs of prostate MRI can be reduced 
by performing bi-parametric (T2-weighted imaging and Diffusion Weighted Imaging) 
instead of multiparametric MRI, as the dynamic contrast-enhanced images add little to the 
diagnostic accuracy of the multiparametric MRI (85). Naturally, the costs of an MRI-TRUS 
fusion biopsy diagnostic pathway (as well the TRUS-biopsy pathway) can be substantially 
reduced by upfront multivariable risk-stratification. The reduction of unnecessary MRIs 
and biopsies achieved by multivariable risk-stratification is probably approximately 33% 
in a clinical setting with biopsy naïve men, up to 50% in a clinical setting with previously 
biopsied men (Chapter 4) and even 66% in a population-based setting with repeatedly 
screened men (Chapter 3). The lack of logistical capacity and expert radiologists and urolo-
gists are perhaps even larger drawbacks than the costs associated with the performance 
of a pre-biopsy MRI in all biopsy naïve men. The equipment for an MRI-driven diagnostic 
pathway (i.e. MRI-scanners and fusion biopsy devices) is not yet widely accessible globally 
and should be expanded in those centers that already implement these techniques. The 
radiologists and urologists with expertise in multiparametric MRI and targeted prostate 
biopsy are still relatively scarce and for a drastic increase in the demand of expertise large 
scale training programs will have to be conducted. The European Association of Urology 
is currently initiating such a training program for urologists in collaboration with experts 
from University College London Hospital. Thus, although there are reasonable drawbacks 
of an MRI-driven diagnostic pathway, these drawbacks can be overcome at least partially. 
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The pre-biopsy MRI is here to stay and will be increasingly implemented in the near future, 
not only in previously biopsied men but also in biopsy naïve men. 
Another subject of debate is whether PSA-based prostate cancer screening will continue 
to be conducted in the opportunistic setting or whether organized PSA-based screening 
should be implemented in the (near) future. It has become clear that opportunistic PSA-
based screening as conducted in current clinical practice is relatively ineffective, despite 
the fact that the drawbacks of screening are well known (16, 86). An analysis from the 
Göteborg trial showed an increasing incidence of prostate cancer caused by both op-
portunistic and organized screening, but an opportunistic screening-induced relative 
disease-specific mortality reduction of only 12% compared to 42% for organized screen-
ing (87). Opportunistic PSA-based screening results in significantly more overdiagnosed 
prostate cancers, with almost twice the number of men needed to be diagnosed (23 vs 
13) to avoid one prostate cancer death (87). The ineffectiveness of opportunistic screening 
is caused by the fact that it is often not according to best protocol as provided by the 
evidence. A systematic review showed a large variation in the degree of follow-up (i.e. 
repeat PSA testing) by general practitioners after a normal PSA test internationally (88). In 
the Netherlands, follow-up PSA testing by general practitioners after an initial normal PSA 
(<4.0 ng/ml) has been shown to be as low as 19% (22). Similarly, only 52% of Dutch men 
with an elevated initial PSA (4 – 10 ng/ml) at the general practitioner receive a follow-up 
test (22). Perhaps most importantly, men with an elevated PSA are often not referred by 
the general practitioner to the urologist (for prostate biopsy), both in the Netherlands and 
internationally (22, 88). Finally, wide scale opportunistic screening takes place interna-
tionally of men with little or no chance of benefit based on their age and comorbidities 
(17-21). In the Netherlands, half of men who receive an initial PSA test is aged ≥70years, 
of whom half are aged ≥80 years (22). The screening of older men with comorbidities is 
one of the important reasons for loss in quality-adjusted life years (QALYs) and thus low 
net benefit op PSA-based opportunistic screening in Microsimulation screening analysis 
(MISCAN) (16). The only way to improve the poor benefit-to-harm ratio of current wide-
spread opportunistic screening is to make sure that screening will be performed in an 
organized fashion according to a protocol based on the best available evidence. Although 
offering PSA-based prostate cancer screening in an organized setting is controversy, the 
fact that the US Preventive Services Task Force (USPSTF) recently changed their level-D 
recommendation (89) (i.e. recommendation against screening) on prostate cancer screen-
ing to a level-C recommendation (90) (i.e. individualized decision making on screening) 
may indicate a changing landscape. Practically, organized PSA-based screening would 
mean removal of screening from the office of the general practitioner (and urologist) and 
transferring it to specialized facilities (despite the logistical and financial drawbacks as-
sociated). Whether such organized screening should then be available only for those who 
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choose to be screened (after the process of shared decision making) or be actively offered 
in a population-based program is another subject of debate. At 13 years of follow-up, 
the number needed to screen and number needed to diagnose to prevent one prostate 
cancer death in the ERSPC study is 781 and 27 respectively (3), which is below the number 
needed to screen in breast cancer trials (91). On a life time basis, an estimated total of 100 
men need to be screened and 5 men need to be diagnosed to prevent one prostate cancer 
death (5). Microsimulation SCreening Analysis (MISCAN) based on the ERSPC data showed 
that a population-based screening program could be cost-effective when limited to two 
or three PSA screens (with subsequent sextant TRUS-biopsy if elevated) between the ages 
of 55 – 59 years (92). However, the estimated relative cancer-specific mortality reduction 
on a lifetime basis with this screening strategy was only 13% (92). New modelling stud-
ies, estimating the benefit-to-harm ratio and cost-effectiveness of PSA-based screening 
when taking into account multivariable risk-stratification and multiparametric MRI, can 
help determine whether a Dutch population-based prostate cancer screening program 
is indicated in the (near) future. A setting in which regional care paths are transparent, 
shared by all levels of health care including general practitioners, and followed within a 
quality control program, might be the optimal feasible setting for exploring the level of 
implementation and the outcome of prostate cancer screening (93, 94). There is opportu-
nity to follow this idea in the years to come.
PART 2: CAn WE IMPROVE CURREnT PROTOCOLS On ACTIVE SURVEILLAnCE 
FOR CLInICALLY InSIGnIFICAnT PROSTATE CAnCER? 
Can we selectively identify those men who are suitable for surveillance based 
on magnetic resonance imaging and the prostate cancer growth pattern?  
Active surveillance is a strategy to reduce overtreatment of tumors with a low potential  of 
causing morbidity and/or mortality if left untreated, thereby improving the quality of life 
of men diagnosed with low-risk prostate cancer (95, 96). Nowadays, over 40% of men with 
low-risk prostate cancer in the US are enrolled in an active surveillance program (97). In 
Sweden, the use of active surveillance in men with very low-risk prostate cancer increased 
from 57% in 2009 to 91% in 2014 (98, 99). Similarly, the use of active surveillance in  Swed-
ish men with low-risk prostate cancer increased from 40% in 2009 to 74% in 2014 (98, 
99). Active surveillance has been shown to be a safe strategy for carefully selected men. 
The disease-specific survival of large cohorts with long-term follow-up from Toronto and 
Johns Hopkins (US) was 98 – 100% and 94 – 99% at 10 years and 15 years of follow-up, 
respectively (100, 101). The global Prostate cancer Research International: Active Surveil-
lance (PRIAS) study, coordinated from the Erasmus University Medical Center, is the largest 
observational active surveillance cohort worldwide. To date, PRIAS has included over 
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6.500 patients in over 20 countries. Also in PRIAS, an excellent 10 year disease-specific 
mortality (<1%) is observed (102). Apparently, within the available follow-up data men 
who harbor disease with metastatic potential are adequately filtered out after diagnosis 
(patient inclusion) or during follow-up using eligibility criteria for surveillance. According 
to most guidelines and protocols men with a T-stage ≤2, a Gleason score 3+3 with ≤2 
positive biopsy cores and a PSA <10 ng/ml are suitable for active surveillance (103). Unfor-
tunately, many newly diagnosed prostate cancer patients do not meet these strict eligibil-
ity criteria, although only a subgroup would develop metastatic disease if left untreated. 
Furthermore, although initially considered suitable for surveillance, many men experience 
disease reclassification during follow-up and have to switch to active therapy after all.
In the Toronto and Johns Hopkins cohort the disease reclassification rates were 24 – 35% 
and 36 – 49 % at 5 and 10 years of follow-up, respectively (100, 101). In PRIAS, no less 
than 60% of men initially considered suitable for surveillance has received some form of 
active treatment after 10 years of follow-up (102). A substantial proportion of 10 – 20% 
of men in these large active surveillance cohorts reclassify at confirmatory biopsy only 
one year after diagnosis (100-102). Although disease reclassification on follow-up biopsy is 
the most common trigger for active treatment, other triggers are PSA-kinetics and patient 
choice, often driven by anxiety (104).
The fact that a high percentage of men is not considered suitable for active surveillance 
at diagnosis or reclassifies early during follow-up indicates the need of more flexible 
eligibility criteria. In general, the eligibility criteria could be broadened by the inclusion 
of higher volume Gleason 3+3 disease and/or higher-grade (i.e. Gleason ≥3+4) disease. 
Retrospective studies have shown that “true Gleason 3+3 disease”, i.e. Gleason 3+3 pros-
tate cancer according to the ISUP 2014 modified Gleason score on radical prostatectomy 
specimen, virtually does not metastasize and therefore does not cause disease-specific 
mortality (105-107). Therefore, active treatment of “true Gleason 3+3 disease” with curative 
intent, regardless of the tumor volume, could be regarded as overtreatment per definition. 
Unfortunately, the diagnosis of “true Gleason 3+3 disease” can only be ascertained with 
certainty after a radical prostatectomy has been performed. Up to now, treatment selec-
tion (i.e. active surveillance or active treatment with curative intent) is often only based 
on the histological outcome of the TRUS-guided systematic biopsy, although upgrading 
of the TRUS-biopsy Gleason score on radical prostatectomy specimen occurs in 25 – 40% 
of cases (108-110). The multi-parametric MRI can help to improve the correlation between 
the biopsy Gleason score and the “true Gleason score” by guiding the biopsy operator to 
the location of the tumor. This can result in a more accurate characterization of the tumor 
at diagnosis, and thus a better selection of men who are suitable for active surveillance. In 
Chapter 8, a total of 23% of men who were originally considered suitable for active surveil-
lance based on the diagnostic TRUS-biopsy Gleason score 3+3 was reclassified (Gleason 
score ≥3+4) based on a baseline MRI ± targeted biopsy. The improved patient selection 
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for surveillance by the performance of a baseline MRI ± targeted biopsy and inherent 
reclassification of a subgroup of men results in a higher percentage of men who remain 
on surveillance during follow-up. The high NPV (approximately 90%) of multi-parametric 
MRI for high-grade disease tackles the sampling error of the diagnostic TRUS-biopsy 
(109). Proportionally, reclassification during follow-up will more often be caused by the 
relatively rare phenomenon of true grade progression (1 – 3% per person per year) (10, 
11). The partial elimination of the TRUS-biopsy sampling error by the performance of MRI 
± targeted biopsy allows to no longer use tumor volume (i.e. number of positive biopsy 
cores; percentage of biopsy core involvement) of Gleason 3+3 disease as a surrogate for 
higher grade disease. Thus, a baseline MRI ± targeted biopsy can early identify men with 
higher-grade disease who are not suitable for surveillance, but on the other hand can con-
firm suitability of men with high-volume Gleason 3+3 disease. A baseline MRI ± targeted 
biopsy is already recommended by the UK NICE guideline and should be performed, if 
accessible, in all men with Gleason 3+3 disease on diagnostic TRUS-biopsy who are con-
sidered for active surveillance.
As indicated earlier, more men could be considered for active surveillance if Gleason score 
3+4 disease would not be a strict exclusion criterion. In the ProtecT trial men were ran-
domized between active monitoring, surgery and radiotherapy, regardless of their biopsy 
Gleason score, with an allocation of approximately 550 men in each treatment arm (111). A 
total of 23% of men in the ProtecT study had biopsy Gleason ≥3+4 disease (111). Data from 
this RCT show that twice as many men in the active monitoring arm developed metastatic 
disease at a median follow-up of 10 years as compared to the surgery and radiotherapy 
arm (111), indicating that active surveillance is usually not the preferred treatment strat-
egy in men with Gleason ≥3+4 prostate cancer. This is confirmed by long-term follow-up 
data from the Toronto active surveillance cohort which includes a total of 128 men (out 
of 945) with Gleason 3+4/4+3 disease due to less stringent inclusion criteria at the be-
ginning of their study (112). The cumulative incidence of metastatic disease at 15 years 
of follow-up in men with Gleason 3+4 and 4+3 disease was no less than 16% and 37%, 
respectively (112). Based on these data active surveillance in all men with TRUS-biopsy 
Gleason 3+4 prostate cancer is not to be recommended, let alone in men with Gleason 
4+3 disease. Nevertheless, some men with (limited) Gleason 3+4 prostate cancer might be 
good candidates for surveillance. Gleason grade 4 disease is heterogeneous, consisting of 
various histological growth patterns (ill-formed, fused, cribriform and glomeruloid) (113). 
Apart from the percentage of grade 4 disease, both the cribriform growth pattern (114-
118) as well as intraductal carcinoma (IDC) (118-123) have been shown to be associated 
with poor clinical outcome after treatment compared to the other grade 4 growth pat-
terns. Retrospective analysis of men in the ERSPC Rotterdam first screening round showed 
a comparable 15-year cancer-specific survival of men with biopsy Gleason 3+3 disease 
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(99%) and men with biopsy Gleason 3+4 disease without cribriform/intraductal growth 
(96%), while a significantly poorer 15-year cancer-specific survival of 85% was observed 
in men with Gleason 3+4 disease and cribriform/intraductal growth (124). In chapter 6, 
the percentage of cribriform/intraductal growth was significantly higher in the Gleason 
score reclassified men (after pathological revision) in the ERSPC Rotterdam first screening 
who died of the disease (63%) as compared to those who did not die of the disease (13%). 
Moreover, the median percentage of Grade 4 disease in the Gleason score reclassified 
men who died of the disease was also higher (16%) compared to those who did not die 
of the disease (8%). Therefore, biopsy Gleason 3+4 prostate cancer without cribriform/
intraductal growth and a low percentage of grade 4 disease (≤10%) could be considered 
favorable Gleason 3+4 prostate cancer, and hence suitable for active surveillance. As of 
2012, the PRIAS study allows for the inclusion of men with minimal Gleason 3+4 disease 
(≤10% core involvement) if aged ≥70 years.
In conclusion, it seems that we have taken some steps in improving patient selection for 
active surveillance by the use of baseline MRI and identification of favorable Gleason grade 
4 growth patterns. Hopefully, long-term follow-up data will confirm this improved patient 
selection by showing lower disease reclassification rates or even higher disease-specific 
survival rates as compared to current TRUS-biopsy based data.  
do men on active surveillance comply with current strict follow-up protocols, 
including repeated biopsies, and if not, what are the reasons for non-
compliance?  
Most guidelines and protocols on active surveillance recommend repeated PSA measure-
ments every 3 – 6 months during follow-up, a confirmatory TRUS-biopsy within the first 
year after diagnosis and a surveillance biopsy every 1 – 3 years afterwards (103). Triggers 
for disease reclassification in most protocols are a PSA-DT <3 years, >2 positive biopsy 
cores and/or Gleason score ≥3+4 prostate cancer (103). In Chapter 7, the compliance with 
the follow-up protocol of the PRIAS study was analyzed. The compliance with PSA testing 
was persistently high (>90%) during follow-up, presumably due to the non-invasive char-
acteristics of the PSA test. In contrast, a drastic decline of the compliance with protocol-
based follow-up biopsies was observed over time, from 81% at confirmatory biopsy to 
only 33% at surveillance biopsy 10 years after diagnosis. The low biopsy compliance is 
probably due to the invasive features of the prostate biopsy and could be either driven 
by patient, doctor or both. Complaints caused by a previous biopsy, such as hematuria, 
hematospermia and pain, certainly effect the compliance at follow-up biopsy (125). An 
analysis from the PRIAS study showed that men who have experienced complaints at 
diagnostic or first repeat biopsy more often do not comply with a follow-up biopsy (21%) 
compared to men without complaints at prior biopsy (12%) (125). Reassuring PSA-values 
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and pathological outcome at prior biopsy can also trigger both the patient and doctor not 
to comply with a protocol-based follow-up biopsy. Anyhow, the low biopsy compliance 
during follow-up seems to indicate that repeat biopsies are considered burdening for 
patients and that strategies are needed to safely reduce the number of follow-up biopsies 
in order to increase adherence to the protocol.  That being said, the long-term cancer-
specific survival in PRIAS (>99% at 10-yr of follow-up) can already be regarded as excellent 
despite the low biopsy compliance, questioning the importance of follow-up biopsies in 
general. Follow-up biopsies may even be of less importance after improved patient selec-
tion for surveillance by the performance of a baseline MRI (± targeted biopsy).     
Similar to the low compliance with follow-up biopsies, the compliance with the recom-
mendation to discontinue surveillance based on a PSA-DT <3 years in the PRIAS study 
was poor (29%), although these men were at higher risk of disease reclassification. The 
compliance with the recommendation to discontinue surveillance based on >2 positive 
biopsy cores was substantially higher (76%). Together, the PSA-DT <3 years and >2 posi-
tive cores recommendations comprised more than 50% of all recommendations to switch 
to active treatment in the PRIAS study. Nevertheless, approximately 50% of these men still 
harbor “true Gleason 3+3 disease” on radical prostatectomy (102), indicating that these 
recommendations to trigger active treatment are far from perfect. Therefore, the PRIAS 
protocol was adapted stating that these recommendations (i.e. PSA-DT <3 years and >2 
positive cores) should trigger an MRI ± targeted biopsy (inclusion in the MRI side study) 
instead of immediate active treatment with curative intent. The number of biopsy cores 
positive for Gleason 3+3 disease is no longer restricted in men on surveillance as long as 
an MRI ± targeted biopsy has been performed. 
Can we selectively identify those men who need a follow-up biopsy using 
magnetic resonance imaging, avoiding unnecessary biopsies in men at low risk 
of reclassification? 
As previously indicated, strategies are needed to safely reduce the number of follow-up 
biopsies, thereby increasing protocol adherence. Ideally, we should only perform a follow-
up biopsy in men with an elevated risk of disease reclassification and refrain from follow-
up biopsies in men at low-risk. The multi-parametric MRI can help to identify men with 
an elevated risk of disease reclassification by detecting lesions suspicious for high-grade 
prostate cancer. A strategy with the performance of only MRI ± targeted biopsy, omitting 
follow-up TRUS-biopsies, could avoid follow-up biopsy procedures in the approximately 
33% of men on active surveillance who do not harbor a cancer-suspicious lesion on MRI 
(109). However, an MRI ± targeted biopsy strategy is known to miss approximately 10% of 
high-grade prostate cancers detected by TRUS-biopsy and therefore does not seem to be 
sufficient (126-133). A better strategy would be to risk-stratify based on both MRI and clini-
cal parameters and to perform only a follow-up biopsy (i.e. TRUS-biopsy + MRI-targeted 
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biopsy) in case of an elevated risk of disease reclassification. In Chapter 8, a total of 210 
men on active surveillance who received a first multi-parametric MRI at different time 
points during follow-up were retrospectively stratified based on the PI-RADS score and 
PSA-density. In accordance with a prior study of Washino et al. in biopsy naïve men (134), 
no Gleason score upgrading in TRUS-biopsy ± MRI-targeted biopsy was observed in men 
with PI-RADS 1 – 3 and a PSA-density <0.15 ng/mL2. This risk-based approach could safely 
avoid up to 50% of follow-up biopsy procedures in men with PI-RADS 1 – 3.
In men on active surveillance who have received consecutive (two or more) multi-
parametric MRI-scans, the decision to perform a follow-up biopsy could be based on the 
presence of cancer-suspicious alterations on the present scan in comparison with a prior 
MRI (126, 135). Unfortunately, published data on men on active surveillance who have 
received consecutive MRI-scans are currently still lacking. A specialized task force has 
recently developed the Prostate Cancer Radiological Estimation of Change in Sequential 
Evaluation (PRECISE) recommendations for reporting of prostate MRI in men on active 
surveillance. These PRECISE recommendations will facilitate data collection in order to 
define “radiologic progression” in men who have received sequential MRI’s (136).
Thus, (repeated) MRI can be used to select men for follow-up biopsy and avoid unneces-
sary biopsies in men at low-risk of disease reclassification. However, multi-parametric MRI 
is costly and not yet widely available. Furthermore, the importance of follow-biopsies in 
general is questionable, given the excellent long-term disease-specific survival in the ab-
sence of compliance with follow-up biopsies. Therefore, one could argue not to intensify 
the follow-up of most men on active surveillance with (repeated) MRI-scans, but rather to 
minimize the follow-up (i.e. less to zero biopsies and MRI’s), especially if a baseline MRI has 
been performed at diagnosis.
Conclusion
A high percentage of men is not considered suitable for active surveillance at diagnosis 
or reclassifies at short-term follow-up. This indicates the need for more accurate eligibility 
criteria. A baseline MRI after diagnosis of low-risk prostate cancer helps to early identify 
men who harbor higher-grade disease, and on the other hand, helps to safely include men 
on active surveillance with higher-volume low-grade disease. In addition, the histologi-
cal growth pattern of grade 4 disease could be helpful to identify men with low-volume 
Gleason 3+4 prostate cancer who are suitable for active surveillance. The low biopsy 
compliance during follow-up on active surveillance indicates the need for strategies to 
reduce unnecessary follow-up biopsies in those men selected for surveillance based on 
the traditional diagnostic TRUS-biopsy. The multi-parametric MRI, together with clinical 
parameters such as the PSA-density, can help to identify those men who need a follow-up 
biopsy and safely avoid a biopsy in those with a low-risk of disease reclassification. 
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Future perspectives
Recently, two prediction models for disease reclassification at follow-up TRUS biopsy 
have been developed based on large datasets (137, 138). In the near future, follow-up 
of men on active surveillance will be personalized using dynamic risk prediction models 
that incorporate both repeated measurements of clinical and radiological parameters, as 
perhaps newly validated biomarkers and assays, such as Prolaris (139) and Oncotype DX 
(140). These dynamic prediction models should certainly also take into account the pa-
tient comorbidity and life expectancy, as the individual on active surveillance for prostate 
cancer still has a 10 fold higher risk of dying from other causes (100). The Movember-GAP3 
project can provide the necessary data having the availability of approximately 40% of all 
men on active surveillance globally (141). The increasing performance of sequential multi-
parametric MRI-scans in men on active surveillance could provide the evidence for follow-
up with MRI only, omitting repeat biopsies in the absence of radiological progression. 
Finally, recent level-I evidence for the effectiveness of vascular-targeted photodynamic 
therapy in delaying disease progression could trigger an increasing use of focal therapy 
instead of active surveillance in specific cases (142).
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SUMMARY
Chapter 1 (General Introduction) gives an overview of the pathophysiology, epidemiol-
ogy, diagnosis and grading of prostate cancer. The history of PSA-based prostate cancer 
screening is discussed, as well as its benefits (i.e. cancer-specific morbidity and mortal-
ity reduction) and its harms (i.e. unnecessary testing and overdiagnosis of insignificant 
prostate cancer). The concepts of prediction models, multi-parametric MRI and active 
surveillance for low-risk prostate cancer are introduced. Several research questions are 
formulated, which are answered in Chapter 9 (General Discussion).
Part I  Screening
A comprehensive overview of the history of PSA-based prostate cancer screening is given 
in Chapter 2. All prostate cancer screening studies are discussed, including the two largest 
trials: the European Randomized study of Screening for Prostate cancer (ERSPC) and the 
Prostate, Lung, Colorectal and Ovarian (PLCO) trial. Subsequently, an overview is given of 
the recommendations of current guidelines on prostate cancer screening. The major draw-
backs of screening (i.e. unnecessary biopsies and overdiagnosis of insignificant cancer) are 
discussed. It is emphasized that these drawbacks may be overcome (partially) in the future 
by the combined implementation of magnetic resonance imaging, new biomarkers and 
multivariable risk-stratification.
The harms of population-based prostate cancer screening generally outweigh the ben-
efit of a mortality reduction, particularly in men aged ≥70 years with a relatively limited 
life expectancy. The benefit-to-harm ratio of screening in these men can be improved by 
the implementation of multivariable risk-stratification and MRI. In Chapter 3 it is shown 
that a significant proportion (13%) of the 337 men biopsied in the fifth screening round 
of the ERSPC Rotterdam (age between 71 – 75 years) harbored high-grade (Gleason score 
≥3+4) prostate cancer. Given the fact that these men have a median life expectancy of 
approximately 13 years, some of them may still benefit from the early detection and 
subsequent treatment of prostate cancer. A screening strategy with upfront multivariable 
risk-stratification using the ERSPC-risk calculator and the combined performance of MRI 
(+/- targeted biopsy) and transrectal ultrasound-guided systematic biopsy (TRUS-biopsy) 
seems to be the optimal strategy, as it would have avoided two-thirds of biopsy proce-
dures and insignificant prostate cancer diagnoses in our cohort, while maintaining the 
high-grade prostate cancer detection rate of a TRUS-biopsy all men approach.
According to the European Association of Urology prostate cancer guidelines a pre-
biopsy MRI is only indicated in case of a sustained suspicion of prostate cancer, usually 
based on PSA(-kinetics), after a negative TRUS-biopsy. However, not all men with a sus-
tained clinical suspicion of prostate cancer after a negative TRUS-biopsy harbor (high-
grade) prostate cancer. Multivariable risk-based patient selection for multi-parametric MRI 
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could help to avoid the performance of unnecessary, costly MRI-scans. In Chapter 4 it is 
shown that risk-stratification based on the ERSPC-risk calculator(4) would have avoided 
the performance of 50% of MRI-scans in a clinical cohort of 122 men, missing 10% of high-
grade prostate cancers. It is concluded that further improvement could be achieved by 
adjusting the ERSPC-risk calculator(4), which is constructed based on 6-core TRUS-biopsy 
data from a screening cohort, to the clinical setting with 10 – 12 core TRUS-biopsy and MRI 
(+/-targeted biopsy).
Multivariable risk-stratification is to be preferred before the performance of a multi-
parametric MRI in order to avoid unnecessary MRI-scans. Nevertheless, the discriminative 
ability of prediction models with clinical parameters can be improved by the incorporation 
of MRI parameters such as the PI-RADS score, thereby helping to avoid unnecessary biopsy 
procedures after the performance of an MRI-scan. In Chapter 5, the ERSPC-risk calculator 
3 and 4 are adjusted for the prediction of any-grade and high-grade prostate cancer in 
12-core TRUS-biopsy +/- MRI-targeted biopsy using data from a multi-institutional cohort 
of 961 men. Application of the improved MRI-ERSPC risk calculators in our cohort would 
have avoided 25% of biopsy procedures, missing 4% of high-grade prostate cancers.
Part II Active surveillance
Men with localized high-grade (Gleason score ≥3+4) prostate cancer are usually treated 
with curative intent (i.e. radical prostatectomy or radiotherapy), as their cancer has the 
potential to metastasize and cause disease-related morbidity and mortality. In contrast, 
men with localized low-grade (Gleason score 3+3) prostate cancer are often followed-up 
on active surveillance as “true Gleason 3+3 disease” does not metastasize. Nevertheless, in 
the Rotterdam section of the ERSPC study a total of 15 men diagnosed in the first screen-
ing round with biopsy cT1/2 Gleason score 3+3 prostate cancer eventually died of the 
disease. In Chapter 6, pathological revision of the biopsy specimens revealed a higher-
grade tumor component according to the contemporary Gleason score in half of these 
men. Furthermore, it was shown that the cribriform Gleason grade 4 growth pattern and 
intraductal carcinoma are associated with prostate cancer death and may therefore be 
used for patient selection for active surveillance. 
Men on active surveillance are usually followed-up according to a strict protocol with 
repeated measurements of the PSA-level and follow-up biopsies. A strict follow-up 
scheme and repeated biopsies in particular could be burdening for patients on surveil-
lance. In Chapter 7 the compliance with PSA measurements and follow-up biopsies is 
assessed in the largest active surveillance study worldwide: the Prostate cancer Research: 
International Active Surveillance (PRIAS) study. While the compliance with PSA testing 
was persistently high (>90%) during follow-up, a drastic decline of the compliance with 
follow-up biopsies was observed over time, from 81% at confirmatory biopsy to only 33% 
at surveillance biopsy 10 years after diagnosis. This seems to indicate that repeat biopsies 
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are considered burdening for patients and that strategies are needed to safely reduce the 
number of follow-up biopsies in order to increase adherence to the protocol.  
Multi-parametric MRI is increasingly used in men on active surveillance. MRI at diagnosis 
could help to improve the selection of men with low-risk prostate cancer who are suitable 
for surveillance. Furthermore, MRI could be helpful to safely reduce the number of follow-
up biopsy procedures. In Chapter 8, a similar disease reclassification rate (Gleason score 
≥3+4) of approximately 25% was observed at diagnosis, at first repeat biopsy (1 year after 
diagnosis) and at surveillance biopsy (4 years after diagnosis) in a cohort of 210 men on 
active surveillance who received a first MRI +/- targeted biopsy. No disease reclassification 
occurred in men with a PI-RADS score 1 – 3 and a low PSA-density (<0.15 ng/mL2). Thus, 
risk-stratification based on the PI-RADS score and PSA-density could help to safely reduce 
the number of follow-up biopsies in men on active surveillance. 
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SAMEnVATTInG
In Hoofdstuk 1 (Algemene Introductie) wordt een overzicht gegeven van de patho-
fysiologie, epidemiologie, diagnose en gradering van prostaatkanker. De geschiedenis 
van prostaatkanker screening met behulp van PSA wordt bediscussieerd, evenals de 
voordelen (i.e. reductie van kanker-specifieke morbiditeit en mortaliteit) en nadelen (i.e. 
onnodige onderzoeken en overdiagnose van insignificante tumoren) van screening. De 
begrippen “predictiemodellen, multi-parametrische MRI en active surveillance voor laag-
risico prostaatkanker’ worden geïntroduceerd. Er worden meerdere onderzoeksvragen 
geformuleerd, dewelke worden beantwoord in Hoofdstuk 9 (Algemene Discussie).
deel I Screening
In Hoofdstuk 2 wordt een uitgebreid overzicht gegeven van de geschiedenis van pros-
taatkanker screening met behulp van PSA. Alle prostaatkanker screening studies worden 
bediscussieerd, waaronder de twee grootste studies: de “European Randomized study 
of Screening for Prostate Cancer (ERSPC)” en de “Prostate, Lung, Colorectal and Ovarian 
(PLCO)” studie. Vervolgens wordt er een overzicht gegeven van de aanbevelingen uit de 
huidige richtlijnen voor prostaatkanker screening. De nadelen van screening (i.e. onnodige 
biopten en overdiagnose van insignificante tumoren) worden bediscussieerd. Er wordt 
benadrukt dat deze nadelen in de toekomst (gedeeltelijk) kunnen worden overwonnen 
door de gecombineerde implementatie van MRI, nieuwe biomarkers en multivariabele 
risico-stratificatie. 
Over het algemeen weegt het voordeel van een mortaliteitsreductie niet op tegen de 
nadelen van prostaatkanker screening op populatieniveau, met name niet bij mannen 
met een leeftijd ≥70 jaar en dus een relatief beperkte levensverwachting. De verhouding 
tussen de voordelen en nadelen van screening bij deze mannen kan worden verbeterd 
door multivariabele risico-stratificatie en MRI te implementeren. In Hoofdstuk 3 wordt 
aangetoond dat een significant percentage (13%) van de 337 gebiopteerde mannen in 
de vijfde screening ronde van de ERSPC Rotterdam (leeftijd tussen de 71 – 75 jaar) hoog-
gradig (Gleason score ≥3+4) prostaatkanker heeft. Gezien het feit dat deze mannen een 
mediane levensverwachting van ongeveer 13 jaar hebben, hebben sommigen nog baat 
bij de vroege detectie en daaropvolgende behandeling van prostaatkanker. Een screen-
ing strategie met op voorhand multivariabele risico-stratificatie gebruikmakende van de 
ERSPC-risico calculator en het gecombineerd verrichten van zowel MRI (+/- gerichte bi-
opsie) als transrectale echogeleide systematische biopsie (TRUS-biopsie) lijkt de optimale 
screening strategie te zijn. Met deze strategie zou namelijk twee derde van de bioptproce-
dures en diagnoses van insignificant prostaatkanker in ons cohort zijn voorkomen, terwijl 
de detectie van hooggradig prostaatkanker gelijk zou blijven aan wanneer alle mannen 
een TRUS-biopsie zouden krijgen. 
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Volgens de prostaatkanker richtlijn van de Europese Vereniging voor Urologie (EAU) is 
een MRI vóór het verrichten van een biopsie alleen geïndiceerd bij een blijvende verdenk-
ing op prostaatkanker, meestal gebaseerd op PSA(-kinetiek), na een negatieve TRUS-
biopsie. Echter, niet alle mannen met een blijvende verdenking op prostaatkanker na een 
negatieve TRUS-biopsie hebben (hooggradig) prostaatkanker. Selectie van patiënten voor 
multi-parametrische MRI op basis van multivariabele risico-stratificatie kan het verrichten 
van onnodige, dure MRI-scans voorkomen. In Hoofdstuk 4 wordt aangetoond dat risico-
stratificatie met behulp van de ERSPC-risico calculator(4) het verrichten van 50% van de 
MRI-scans zou voorkomen in een klinisch cohort van 122 mannen, waarbij 10% van de 
hooggradige prostaatkankers zou worden gemist. Er wordt geconcludeerd dat verdere 
verbetering kan worden bewerkstelligd door de ERSPC-risico calculator(4), die gecon-
strueerd is op basis van sextant TRUS-biopsie gegevens in een screening cohort, aan te 
passen aan de klinische setting met 10 – 12 TRUS-biopten en MRI (+/- gerichte biopsie).
Multivariabele risico-stratificatie is te prefereren vóór het verrichten van een multi-
parametrische MRI om zo onnodige MRI-scans te voorkomen. Echter, het onderscheidend 
vermogen van predictiemodellen met alleen klinische parameters kan worden verbeterd 
door MRI parameters zoals de PI-RADS score te incorporeren, om zo onnodige bioptpro-
cedures te voorkomen na het verrichten van een MRI-scan. In Hoofdstuk 5 worden de 
ERSPC-risico calculator 3 en 4 aangepast voor het voorspellen van prostaatkanker en 
hooggradig prostaatkanker in 12 TRUS-biopten +/- MRI-gerichte biopten, gebruikmak-
ende van gegevens van een multi-institutioneel cohort van 961 mannen. Gebruik van 
deze verbeterde MRI-ERSPC risico calculators zou 25% van de bioptprocedures hebben 
voorkomen, waarbij 4% van de hooggradige prostaatkankers zou zijn gemist. 
deel II  Active surveillance
Mannen met gelokaliseerd hooggradig (Gleason score ≥3+4) prostaatkanker worden 
meestal behandeld met als doel te genezen (i.e. radicale prostatectomie of radiothera-
pie), gezien de tumor in potentie kan metastaseren en ziekte-specifieke morbiditeit en 
mortaliteit kan veroorzaken. Daarentegen worden mannen met gelokaliseerd laaggradig 
(Gleason score 3+3) prostaatkanker vaak actief opgevolgd (active surveillance) gezien er 
geen metastasering optreedt indien er daadwerkelijk alleen sprake is van Gleason 3+3 
prostaatkanker. Desalniettemin zijn in totaal 15 mannen die in de eerste screening ronde 
van de ERSPC Rotterdam gediagnosticeerd werden met cT1/2 Gleason score 3+3 prostaat-
kanker uiteindelijk aan de ziekte overleden. In Hoofdstuk 6 toonde pathologische revisie 
van de biopten bij de helft van deze mannen een hooggradige tumor component volgens 
de hedendaagse Gleason score. Bovendien werd aangetoond dat het cribriforme Gleason 
graad 4 groeipatroon en intraductaal carcinoom geassocieerd zijn met prostaatkanker 
dood en daarom gebruikt zouden kunnen worden bij de patiënten selectie voor active 
surveillance.  
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Mannen op active surveillance worden meestal opgevolgd volgens een strikt protocol 
met herhaalde metingen van de PSA-waarde en biopsieën. Een strikt opvolgschema en 
met name herhaalde biopsieën zouden belastend kunnen zijn voor patiënten op active 
surveillance. In Hoofdstuk 7 wordt de naleving van de PSA metingen en opvolg biopsieën 
geëvalueerd binnen de grootste active surveillance studie wereldwijd: de ‘Prostate cancer 
Research: International Active Surveillance (PRIAS)’ studie. Alhoewel de naleving van PSA 
metingen persisterend hoog (>90%) was gedurende opvolging, werd er een drastische 
vermindering van de naleving van opvolg biopsieën geobserveerd, van 81% bij het con-
firmatie biopt 1 jaar na diagnose tot slechts 33% bij de biopsie 10 jaar na diagnose. Dit lijkt 
erop te wijzen dat herhaalbiopsieën als belastend worden ervaren door patiënten en dat 
er behoefte is aan strategieën om het aantal herhaalbiopsieën veilig te reduceren en zo de 
naleving van het opvolgprotocol te verbeteren. 
Multiparametrische MRI wordt in toenemende mate gebruikt bij mannen op active 
surveillance. Een MRI-scan bij diagnose zou de selectie van mannen met laag-risico 
prostaatkanker die geschikt zijn voor active surveillance kunnen verbeteren. Bovendien 
zou MRI gebruikt kunnen worden om het aantal opvolg biopsieën veilig te reduceren. 
In Hoofdstuk 8 wordt een vergelijkbaar percentage (ongeveer 25%) geobserveerd van 
mannen die reclassificeren (Gleason score ≥3+4) bij diagnose, bij het eerste herhaalbiopt 
(1 jaar na diagnose) en bij surveillance biopsie (4 jaar na diagnose) in een cohort van 210 
mannen op active surveillance die een eerste MRI +/- gerichte biopsie krijgen. Ziekte 
reclassificatie werd niet geobserveerd bij mannen met een PI-RADS score 1 – 3 en een 
lage PSA-densiteit (<0.15 ng/mL2). Risico-stratificatie op basis van de PI-RADS score en 
PSA-densiteit zou dus kunnen helpen om het aantal herhaal biopsieën bij mannen op 
active surveillance veilig te reduceren. 
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Isabelle, Bodine, Lisanne, Kai, Peter, Nuno, Anssi en natuurlijk mijn jaargenootje Kim!
Leonard, ik kijk met veel plezier terug op onze uitvoerige discussies over het prostaat-
kanker onderzoek en de wetenschap in zijn algemeenheid. Frank-Jan, ik heb bewonde-
ring voor jouw immer positieve insteek, je bent een topgozer! Jan, dank voor jouw hulp 
wanneer het een en ander mijn statistische pet weer te boven ging. Lieve Lionne, ik heb 
veel respect voor wat jij allemaal hebt weten te bereiken de afgelopen jaren. Jouw vrijwel 
dagelijkse hulp en advies waren van onschatbare waarde voor mij! Met jullie als kamerge-
nootjes ging ik iedere dag met plezier naar mijn werk. 
Lieve Conja, Marlies en Sophie, heel veel dank voor jullie ongelooflijke inzet voor ons 
team. Ik nam altijd graag een pauzemomentje om even bij te kletsen bij jullie op de kamer. 
Lieve Lisette, jij bent een uniek mens met een groot hart, ik ken niemand anders met zo’n 
ongekende drive en passie voor ons vak en tegelijkertijd zo’n enorm talent om te feesten. 
Lieve Diederick en Christine, superveel dank dat ik tijdelijk in jullie tweede appartementje 
heb mogen vertoeven.
Beste prof. Schröder, hartelijk dank voor uw ongelooflijke inzet voor de ERSPC studie 
en de Urologie in zijn algemeenheid. Ik vind het geweldig dat ik in de nadagen van uw 
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carrière nog met u heb mogen samenwerken. Beste meneer Knol, hartelijk dank voor uw 
trouwe inzet voor de Stichting Wetenschappelijk Onderzoek Prostaatkanker (SWOP). Veel 
dank aan de leden van de CODC commissie, dr. Hoekstra, dr. Merkelbach, en dr. Kirkels, 
onze discussies betreffende prostaatkanker casuïstiek waren voor mij zeer leerzaam. 
Marianne, Chris, Andrea en Tineke, dank voor de fijne samenwerking, we hebben wat 
afgelachen in ons bioptenkamertje! Martijn, veel dank voor jouw begeleiding bij ‘ons’ 
multidisciplinaire overleg. Ik vind het geweldig leuk dat jij ook tijdens mijn opleiding mijn 
mentor bent! 
Dank aan alle collega’s van het Rotterdams Urologisch Assistenten Genootschap (RUAG) 
voor de gezelligheid tijdens onze vele borrels. Hartelijk dank aan dr. van der Laan en de rest 
van de vakgroep en arts-assistenten van de afdeling Chirurgie in het Amphia ziekenhuis, ik 
heb mijn start binnen jullie team als zeer prettig ervaren.
Beste prof. Bangma, ik wil u hartelijk danken voor uw begeleiding tijdens mijn promotie-
traject. Ondanks uw drukke bestaan als wetenschapper en afdelingshoofd Urologie wist 
u toch altijd de tijd vrij te maken om mijn presentaties en artikelen kritisch te beoordelen. 
De door u voorgezeten journal club en ontbijtsessies met de Sunrise Group waren voor mij 
erg leerzaam en belangrijk voor mijn wetenschappelijke vorming. 
Beste dr. Schoots, beste Ivo, hartelijk dank voor de geweldige manier waarop jij mij als 
copromotor hebt begeleid. Jouw ongekende enthousiasme is erg aanstekelijk en was 
motiverend voor mij als promovendus. Ondanks jouw drukke werk als clinicus liet jouw 
immer nuttige feedback op mijn werk nooit lang op zich wachten. Jouw wetenschappe-
lijke invalshoek was hierbij altijd origineel en inventief. 
Beste prof. Roobol, lieve Monique, als ik iemand dank verschuldigd ben voor dit proef-
schrift dan ben jij het. Ik kan mij oprecht geen betere begeleider voorstellen dan jij. Ik 
ben supertrots en vereerd dat ik de eerste promovendus mag zijn onder jouw hoogleraar-
schap. Ik heb enorm veel respect voor de eigengereide manier waarop jij leiding geeft aan 
ons team en alle wetenschappelijke projecten weet te coördineren.
Lieve Tahlita, wat ben ik trots dat jij als paranimf naast mij staat tijdens de verdediging. 
Jij bent voor mij een voorbeeld, niet alleen binnen de Urologie en de wetenschap, maar 
ook als mens. Tahlita en Hedy, jullie zijn geweldige vriendinnen van wie ik de afgelopen 
jaren veel steun heb ervaren.
Lieve Nathalie, uiteraard sta jij naast mij tijdens de verdediging. Zonder jouw onvoor-
waardelijke steun had ik dit promotietraject nooit op deze manier af kunnen leggen. 
Misschien voelt het daarom dan ook niet zozeer als mijn, als wel onze promotie. Ik ben je 
ongelooflijk dankbaar en prijs mezelf gelukkig met zo’n fantastische vriendin als jij. Ik kijk 
uit naar al het moois wat ons in de toekomst nog te wachten staat. 
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